{"meta":{"query_hash":"7c55eea1011c","filters":{"venue":"Cancer Chemotherapy and Pharmacology"},"cohort_total":186,"direct_labels_cover":0,"predictions_cover":186,"exported":186,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7c55eea1011c","api":"https://metacan.xera.ac/api/v1/cohort?venue=Cancer+Chemotherapy+and+Pharmacology"},"results":[{"id":"W1269875034","doi":"10.1007/s00280-015-2859-8","title":"Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates - Health Solutions","keywords":"Gefitinib; Erlotinib; Lapatinib; Pharmacology; Tyrosine-kinase inhibitor; Chemistry; Sunitinib; Dasatinib; Tyrosine kinase; Sorafenib; IC50; Vandetanib; Imatinib; Biochemistry; Medicine; Internal medicine; Cancer; In vitro; Epidermal growth factor receptor; Receptor","score_opus":0.012817044680818861,"score_gpt":0.2725603903060015,"score_spread":0.25974334562518264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1269875034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97894156,0.019603422,0.00021285246,0.0005162404,0.00025432848,0.00017825754,0.00007881806,0.0000119467795,0.00020257368],"genre_scores_gemma":[0.99297774,0.004754998,0.0000494694,0.0012849825,0.00042031414,0.00003795783,0.000063377935,0.000025233867,0.0003859288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991198,0.0000478851,0.00020890015,0.0003102242,0.00011231858,0.00020083859],"domain_scores_gemma":[0.99958885,0.000011017481,0.00010972166,0.00008688161,0.000052220366,0.00015130622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001473146,0.00018309805,0.00021314435,0.000041078314,0.00005292304,0.000007783384,0.00005778473,0.00016230116,0.000112705966],"category_scores_gemma":[0.0000023960722,0.00017799198,0.00004242029,0.000050264585,0.00017859395,0.000012920062,0.000030207093,0.000107250395,3.6009095e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008748494,0.0001122877,0.0033321816,0.000057900666,0.00009006464,0.000007367965,0.000421707,0.000015828835,0.9667366,0.00000942287,0.026269564,0.002072189],"study_design_scores_gemma":[0.0037277609,0.00032767563,0.00012562341,0.000014879178,0.00005410448,0.000016167296,0.00022632084,0.000024986475,0.97215825,0.000040180323,0.023088016,0.00019603726],"about_ca_topic_score_codex":0.00011871161,"about_ca_topic_score_gemma":0.000009672518,"teacher_disagreement_score":0.014848423,"about_ca_system_score_codex":0.000020042069,"about_ca_system_score_gemma":0.00009058875,"threshold_uncertainty_score":0.72583026},"labels":[],"label_agreement":null},{"id":"W1485463859","doi":"10.1007/s00280-003-0600-5","title":"Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Erasmus+","keywords":"Ketotifen; Doxorubicin; Pharmacology; Cardiotoxicity; In vivo; Medicine; P-glycoprotein; Multiple drug resistance; Toxicity; Biology; Chemotherapy; Drug resistance; Internal medicine","score_opus":0.011156783804032152,"score_gpt":0.28719737719788846,"score_spread":0.2760405933938563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1485463859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917747,0.00779931,0.0000035247099,0.0013922069,0.0002729882,0.00076342653,0.00019108615,0.000025581807,0.00037442506],"genre_scores_gemma":[0.9816761,0.014849708,0.00007212746,0.0023957703,0.000077205215,0.00019990724,0.000013284358,0.000040219948,0.00067570026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982402,0.0001506266,0.00042068277,0.0005474611,0.00014139153,0.0004996637],"domain_scores_gemma":[0.9994938,0.000074119576,0.00010621434,0.00012359876,0.00003846407,0.00016381506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003276548,0.00030672486,0.000724629,0.0002047563,0.00005940236,0.000009510172,0.00008380309,0.00024460696,0.00058489485],"category_scores_gemma":[0.0000040365812,0.0002852904,0.00005022069,0.00037930056,0.00015374071,0.00009072715,0.000009675909,0.00045683252,5.9192513e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016614434,0.00021838206,0.023439087,0.00025291223,0.00007120424,0.000077986035,0.0014300895,0.0000058946434,0.9713673,0.000008509508,0.0010713579,0.00039584667],"study_design_scores_gemma":[0.011337671,0.000038258473,0.018681005,0.00022128894,0.00004377525,0.000004872385,0.00020571165,0.000028903105,0.96170586,0.000050316896,0.007378212,0.00030409585],"about_ca_topic_score_codex":0.001293431,"about_ca_topic_score_gemma":0.0040304437,"teacher_disagreement_score":0.009676227,"about_ca_system_score_codex":0.00025993763,"about_ca_system_score_gemma":0.0001423749,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W1549234286","doi":"10.1007/s00280-003-0609-9","title":"Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Berberine and alkaloids research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Sanguinarine; Cytotoxicity; Glutathione; Apoptosis; Programmed cell death; Cancer cell; Cell culture; DNA fragmentation; Molecular biology; Biology; Biochemistry; Chemistry; Pharmacology; In vitro; Alkaloid; Cancer; Enzyme","score_opus":0.028932101287650988,"score_gpt":0.33180703909973247,"score_spread":0.30287493781208147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549234286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963676,0.00090032653,0.000023354089,0.0015537374,0.00006170303,0.00032390348,0.000008454302,0.00003637318,0.0007245868],"genre_scores_gemma":[0.99266887,0.001566905,0.000102718936,0.0041262233,0.00012352354,0.000057828587,0.000012751407,0.000031300784,0.0013098756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907964,0.0000886301,0.00011801165,0.000304586,0.000129228,0.0002799053],"domain_scores_gemma":[0.9995201,0.000034492234,0.000048632613,0.00009450853,0.0000964669,0.00020579404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013625747,0.00015508677,0.00026357808,0.00006379853,0.00010751163,0.00001628605,0.000037984973,0.0001282454,0.0018415893],"category_scores_gemma":[0.0000073453048,0.00012730666,0.00002459767,0.00018518702,0.000093314586,0.00008112248,0.0000102780705,0.00024992885,0.0000021403619],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093843706,0.00021494571,0.03357117,0.00006953658,0.00036035906,0.00002604603,0.00095413724,5.78881e-7,0.9443906,0.000031324023,0.0012562332,0.018186668],"study_design_scores_gemma":[0.01025134,0.0021011066,0.01972509,0.000043906024,0.00018430376,0.0000494071,0.00011292193,0.00011937634,0.95195997,0.0001018965,0.015073434,0.00027727554],"about_ca_topic_score_codex":0.00014187941,"about_ca_topic_score_gemma":0.000015474669,"teacher_disagreement_score":0.017909393,"about_ca_system_score_codex":0.000053569802,"about_ca_system_score_gemma":0.00009465457,"threshold_uncertainty_score":0.9990709},"labels":[],"label_agreement":null},{"id":"W1594902063","doi":"10.1007/s00280-002-0566-8","title":"Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Refractory (planetary science); Medicine; Solid tumor; Maximum tolerated dose; Internal medicine; Oncology; Pharmacology; Cancer; Biology","score_opus":0.1627209557731493,"score_gpt":0.5160638178940202,"score_spread":0.35334286212087096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1594902063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802923,0.00021452659,0.00032142788,0.00005205526,0.0002731475,0.000896668,0.000038821094,0.000017161577,0.00015694812],"genre_scores_gemma":[0.9925454,0.00027339047,0.00644717,0.0004868675,0.00007926589,0.00009265683,6.2413176e-7,0.00003393119,0.000040662333],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980295,0.0006034466,0.0005946413,0.0003632787,0.00015757454,0.00025161417],"domain_scores_gemma":[0.9955466,0.0038466912,0.000281981,0.00012634866,0.00007739487,0.00012100307],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006526996,0.00021036662,0.0006903749,0.00008945717,0.00003640992,0.0000058135347,0.00009010993,0.0000811807,0.00094959186],"category_scores_gemma":[0.0005203472,0.00016853932,0.000021848446,0.0001784402,0.00022564543,0.00005046762,0.000022675842,0.00026788822,3.3393474e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046779983,0.08101133,0.4288191,0.0025519102,0.0029196115,0.00016080675,0.011026638,0.000084809435,0.09619059,0.0012583118,0.0062841848,0.32291272],"study_design_scores_gemma":[0.5611614,0.048391413,0.076582566,0.00059192476,0.0019992138,0.000016200402,0.0010780508,0.0011105682,0.22525224,0.0754693,0.005862656,0.0024844818],"about_ca_topic_score_codex":0.000011985294,"about_ca_topic_score_gemma":0.000006024393,"teacher_disagreement_score":0.5143814,"about_ca_system_score_codex":0.000035041507,"about_ca_system_score_gemma":0.000054805136,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W1935124198","doi":"10.1007/s00280-002-0561-0","title":"All-trans-retinoic acid increases cytotoxicity of 1-β-d-arabinofuranosylcytosine in NB4 cells","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Cytotoxicity; Nucleoside; Retinoic acid; Acute promyelocytic leukemia; Pharmacology; Nucleoside transporter; MTT assay; Apoptosis; Transporter; Potency; Biology; Chemistry; In vitro; Molecular biology; Biochemistry","score_opus":0.009958186782329457,"score_gpt":0.2814055794228455,"score_spread":0.27144739264051604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1935124198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98808277,0.010004363,0.000273363,0.000162939,0.00018451842,0.00022663346,0.000022904718,0.000008611898,0.0010339267],"genre_scores_gemma":[0.9823134,0.015127165,0.00020510894,0.0019574845,0.0001318392,0.0000663408,0.000015671518,0.000025021076,0.00015799781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988465,0.00014723757,0.00027442395,0.00036414855,0.00007891148,0.00028881364],"domain_scores_gemma":[0.9995892,0.000024763975,0.00010602661,0.00014123398,0.000055344564,0.00008339812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019026651,0.00020438805,0.00027954092,0.000053547836,0.000036715894,0.000006304902,0.00015373837,0.00021359875,0.0005405193],"category_scores_gemma":[0.000012346472,0.00019725272,0.00006759368,0.00012692265,0.00024173065,0.000006001783,0.000019296489,0.00013692498,9.249903e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040659914,0.00014980229,0.005866829,0.00013974168,0.00008467877,0.000004839308,0.00010449727,0.000042361913,0.99147904,0.00003601866,0.0009850977,0.00070051994],"study_design_scores_gemma":[0.0027672134,0.00017864323,0.00049281196,0.000016255299,0.000029923913,0.000013370517,0.000029917912,0.000015775588,0.969392,0.000106111045,0.026750917,0.00020703133],"about_ca_topic_score_codex":0.000049481503,"about_ca_topic_score_gemma":0.000014807396,"teacher_disagreement_score":0.02576582,"about_ca_system_score_codex":0.000022339049,"about_ca_system_score_gemma":0.00014804471,"threshold_uncertainty_score":0.80437326},"labels":[],"label_agreement":null},{"id":"W1940434397","doi":"10.1007/s00280-015-2852-2","title":"Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"Lombardi Comprehensive Cancer Center, Georgetown University; American Cancer Society","keywords":"Medicine; Sorafenib; Tolerability; Internal medicine; Clinical endpoint; Nausea; Hepatocellular carcinoma; Temozolomide; Phases of clinical research; Regimen; Veliparib; Gastroenterology; Surgery; Progressive disease; Vomiting; Oncology; Clinical trial; Adverse effect; Chemotherapy","score_opus":0.09353586075040868,"score_gpt":0.3560939212492875,"score_spread":0.26255806049887886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1940434397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836072,0.012548099,0.000039341354,0.00087321526,0.0002672371,0.0025592314,0.000025240997,0.00003284173,0.00004763727],"genre_scores_gemma":[0.9957257,0.0023208167,0.00014837141,0.0007539113,0.00015044677,0.0006376281,0.000039151888,0.000035989735,0.00018799701],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893004,0.00007887145,0.0002864153,0.00034841042,0.00012623883,0.0002300009],"domain_scores_gemma":[0.99924105,0.00007905685,0.00015283095,0.00013067917,0.00019104818,0.00020531162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021459938,0.00022428269,0.0005034352,0.0001047073,0.00011257552,0.000006654562,0.00005865648,0.000116218376,0.00008890665],"category_scores_gemma":[0.000007250097,0.00019374117,0.000060829552,0.000117288844,0.000115572606,0.00008708504,0.000021705806,0.00011487904,4.012411e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019172203,0.008531049,0.45552316,0.00016903486,0.00068899273,0.00003174739,0.008122237,9.719433e-7,0.32751465,0.000025512687,0.0012807178,0.17893972],"study_design_scores_gemma":[0.2407892,0.068798706,0.0067801923,0.000032947995,0.00069676084,0.000023492334,0.0011114166,0.006547794,0.6336796,0.00021623615,0.040885556,0.000438074],"about_ca_topic_score_codex":0.00008129532,"about_ca_topic_score_gemma":0.0000042212614,"teacher_disagreement_score":0.448743,"about_ca_system_score_codex":0.000067728346,"about_ca_system_score_gemma":0.0001467094,"threshold_uncertainty_score":0.79005355},"labels":[],"label_agreement":null},{"id":"W1941265576","doi":"10.1007/s00280-015-2761-4","title":"A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"Symphogen; Merck KGaA","keywords":"Medicine; Tolerability; Cetuximab; Internal medicine; Epidermal growth factor receptor; Adverse effect; Oncology; Head and neck cancer; Antibody; Head and neck squamous-cell carcinoma; Monoclonal antibody; Gastroenterology; Cancer; Immunology","score_opus":0.0269664643091963,"score_gpt":0.35541487793565163,"score_spread":0.3284484136264553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1941265576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371374,0.0026298582,0.0000020322107,0.0013952091,0.0003013877,0.001680512,0.00004788715,0.0000026418263,0.00022675001],"genre_scores_gemma":[0.99899703,0.000120801444,0.000016899892,0.0005931526,0.00010508345,0.000037806025,0.0000025303943,0.00001832025,0.00010838378],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887896,0.00016460152,0.00027490853,0.00020066039,0.000277701,0.0002031803],"domain_scores_gemma":[0.99925566,0.00006484044,0.00019871899,0.0002008663,0.00019797779,0.00008196826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019733739,0.0001304272,0.00043384178,0.000047059875,0.000023633096,0.0000021633089,0.00015838165,0.00010728709,0.000085856074],"category_scores_gemma":[0.000015107636,0.000071354254,0.000045041183,0.00027449682,0.0006045526,0.000028873677,0.00005065517,0.00026430745,4.219146e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031375274,0.0008332707,0.9132078,0.0006345057,0.000067276946,0.0000024635003,0.003968159,0.000031817613,0.044370253,0.0000056634576,0.0019464882,0.0035570222],"study_design_scores_gemma":[0.13394783,0.0031297011,0.20912224,0.00013603824,0.000083647676,0.0000030284714,0.00010563892,0.00006483083,0.6512954,0.00001921222,0.0019971216,0.00009530587],"about_ca_topic_score_codex":0.00036550494,"about_ca_topic_score_gemma":0.000035614365,"teacher_disagreement_score":0.7040856,"about_ca_system_score_codex":0.00006779959,"about_ca_system_score_gemma":0.0005816299,"threshold_uncertainty_score":0.2909742},"labels":[],"label_agreement":null},{"id":"W1963733180","doi":"10.1007/s00280-005-0035-2","title":"Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Neutropenia; Pharmacodynamics; Population; Pharmacokinetics; Nadir; Internal medicine; Dosing; Body surface area; Pemetrexed; Incidence (geometry); Pharmacology; Oncology; Chemotherapy","score_opus":0.05261056602320502,"score_gpt":0.42377558807928983,"score_spread":0.3711650220560848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963733180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779818,0.0015415858,0.017182613,0.0016295316,0.00031956768,0.0011612313,0.000023477813,0.000050776678,0.00010943077],"genre_scores_gemma":[0.9873115,0.0035427632,0.0023038883,0.0052802837,0.00069606875,0.0005407275,0.000032818807,0.000027355696,0.00026461243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990339,0.000041409185,0.00035336256,0.00031379447,0.00007027912,0.00018723939],"domain_scores_gemma":[0.9994507,0.0000914127,0.0001645916,0.00012718665,0.00008007855,0.000086049746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018238848,0.00014500662,0.0004161677,0.000058377114,0.000094400886,0.000004935911,0.000066876164,0.00012880177,0.00015021308],"category_scores_gemma":[0.0000046447717,0.00012385081,0.00018084874,0.00012241837,0.00005443725,0.00006496167,0.00001094638,0.00013691226,0.0000014678214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023455322,0.00029432253,0.013618808,0.00006766543,0.00029014522,3.6269515e-7,0.0001382009,0.00075519545,0.786845,0.00030106737,0.0015761271,0.19376755],"study_design_scores_gemma":[0.04091412,0.0025705937,0.046205398,0.000080556936,0.0011182358,0.000018724579,0.000049788036,0.38544938,0.44173303,0.0031540466,0.077954225,0.0007518845],"about_ca_topic_score_codex":0.000037518173,"about_ca_topic_score_gemma":0.000014493672,"teacher_disagreement_score":0.3846942,"about_ca_system_score_codex":0.00006350923,"about_ca_system_score_gemma":0.000076663775,"threshold_uncertainty_score":0.50504893},"labels":[],"label_agreement":null},{"id":"W1964182986","doi":"10.1007/s00280-002-0524-5","title":"The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Regional Health Centre; Health Canada; Royal Victoria Hospital","funders":"","keywords":"Autophosphorylation; Comet assay; DNA damage; Epidermal growth factor receptor; Chemistry; Sulforhodamine B; A431 cells; Tyrosine kinase; Epidermal growth factor; Tyrosine-kinase inhibitor; Molecular biology; Kinase; Biochemistry; Cancer research; Biology; Signal transduction; Cell; DNA; In vitro; Receptor; Protein kinase A; Cytotoxicity; Cell cycle; Cancer","score_opus":0.01769426798458933,"score_gpt":0.2683996772569544,"score_spread":0.25070540927236507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964182986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93865424,0.05257685,0.0006334754,0.004934458,0.0009825014,0.0010729462,0.000020209172,0.000112115296,0.0010131798],"genre_scores_gemma":[0.98925626,0.003216484,0.00025066387,0.006024689,0.00035870037,0.0002187013,0.000010575523,0.000057330726,0.0006066135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988072,0.00006859937,0.00023200721,0.0003320531,0.0001582375,0.0004018816],"domain_scores_gemma":[0.9993596,0.000053378426,0.00011948117,0.0001561487,0.00014660496,0.000164763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016342901,0.00024826778,0.00031073528,0.00004270483,0.00031756386,0.000025291141,0.00008075854,0.00012850607,0.00025615652],"category_scores_gemma":[0.000019268233,0.00015978685,0.00005673923,0.00020827618,0.000639186,0.00005591338,0.000014919166,0.00040589366,0.0000029520997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00172099,0.00015575184,0.0005126839,0.000073906835,0.000337806,0.000030159636,0.00093127415,0.00009361644,0.98587,0.00022882072,0.0073799933,0.002664993],"study_design_scores_gemma":[0.009885374,0.00030877237,0.00015134954,0.00009896879,0.0001600562,0.00010505365,0.00015321036,0.0002000138,0.771332,0.000012540327,0.21738674,0.00020587795],"about_ca_topic_score_codex":0.00005001792,"about_ca_topic_score_gemma":0.000020244333,"teacher_disagreement_score":0.21453796,"about_ca_system_score_codex":0.00015297793,"about_ca_system_score_gemma":0.00038941886,"threshold_uncertainty_score":0.6515919},"labels":[],"label_agreement":null},{"id":"W1967553796","doi":"10.1007/s00280-005-0011-x","title":"Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia; University of British Columbia","funders":"","keywords":"Nephrotoxicity; Creatinine; Amphotericin B; Triglyceride; Internal medicine; Lipoprotein; Cholesterol; High-density lipoprotein; Chemistry; Potassium; Medicine; Endocrinology; Toxicity; Antifungal","score_opus":0.013240641704968551,"score_gpt":0.3142373012587358,"score_spread":0.30099665955376725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967553796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971365,0.0012301549,0.0000017654226,0.0005433286,0.00008799554,0.00066869764,0.0000083224,0.000012273448,0.00031100155],"genre_scores_gemma":[0.9940314,0.004146454,0.00012614205,0.0012563963,0.00031885685,0.00007647307,0.0000026932987,0.000013154854,0.000028404791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989217,0.00008074736,0.00035502226,0.00029290083,0.00009076728,0.00025885648],"domain_scores_gemma":[0.9995791,0.0000891572,0.000117079384,0.00007927293,0.000041311763,0.000094120885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022011573,0.00013895739,0.00042094736,0.00013911571,0.00002836018,0.000002627896,0.00005034316,0.00018391464,0.00018561694],"category_scores_gemma":[0.00001889723,0.00012974063,0.000036248304,0.00021571998,0.00009357389,0.00007266524,0.000025383506,0.00028398505,5.849308e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015899775,0.00035948874,0.6700474,0.00012000259,0.000018268276,0.0000023865537,0.0012973559,0.000004239142,0.24633093,0.0000017240486,0.000039297618,0.08018892],"study_design_scores_gemma":[0.0090107005,0.0007135963,0.81428003,0.000034571214,0.000040283732,0.000002631727,0.00012205511,0.0009339947,0.17305501,0.000022485625,0.0016718704,0.000112785136],"about_ca_topic_score_codex":0.00030755505,"about_ca_topic_score_gemma":0.0010779448,"teacher_disagreement_score":0.1442326,"about_ca_system_score_codex":0.00017700606,"about_ca_system_score_gemma":0.00015345708,"threshold_uncertainty_score":0.5290669},"labels":[],"label_agreement":null},{"id":"W1967669588","doi":"10.1007/s00280-005-0145-x","title":"Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Extravasation; Vincristine; Liposome; Pharmacology; Medicine; Cancer research; Chemotherapy; Chemistry; Pathology; Internal medicine; Cyclophosphamide; Biochemistry","score_opus":0.05915090412979619,"score_gpt":0.41597934344471604,"score_spread":0.35682843931491987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967669588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615234,0.0012566613,0.00011420414,0.0014825696,0.00022687805,0.0005130105,0.000013691174,0.000018077948,0.00022253704],"genre_scores_gemma":[0.99702775,0.0011074014,0.00027708782,0.0008319914,0.00053122663,0.0000687991,0.000010408901,0.000011965899,0.00013339259],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926114,0.000044528148,0.00019947636,0.00023756915,0.000070938644,0.0001863296],"domain_scores_gemma":[0.99967855,0.000048750546,0.000090911875,0.00004927089,0.000037692356,0.000094843774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008548128,0.00013554048,0.00033601685,0.00011966356,0.00003932595,0.000005811994,0.00003583497,0.000052743388,0.00087326096],"category_scores_gemma":[0.0000025879413,0.00013156547,0.00001983428,0.00011846517,0.0000766528,0.000114649425,0.000021448921,0.00011847441,0.0000015082469],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003351588,0.00025404498,0.057429407,0.000114784685,0.00007212449,0.000003425462,0.0007206148,0.000088314584,0.8773043,0.000008134254,0.00034449453,0.060308773],"study_design_scores_gemma":[0.00515635,0.00042143092,0.20410062,0.000031454125,0.00009078658,0.000015044918,0.000008428508,0.0016612618,0.78353846,0.0000055290016,0.004873365,0.00009725729],"about_ca_topic_score_codex":0.00031194798,"about_ca_topic_score_gemma":0.00045211733,"teacher_disagreement_score":0.1466712,"about_ca_system_score_codex":0.00008282922,"about_ca_system_score_gemma":0.000064554326,"threshold_uncertainty_score":0.95615953},"labels":[],"label_agreement":null},{"id":"W1967866035","doi":"10.1007/s00280-002-0538-z","title":"The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Chemistry; Doxorubicin; Pharmacology; Calcein; Pharmacokinetics; Chelation; In vivo; Medicine; Biochemistry; Internal medicine; Chemotherapy; Biology; Organic chemistry","score_opus":0.024255580567516703,"score_gpt":0.30753484986844787,"score_spread":0.28327926930093117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967866035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520516,0.012250858,0.00016794179,0.030686228,0.0007231535,0.001736393,0.000010001578,0.000045149663,0.0023286943],"genre_scores_gemma":[0.9738276,0.006546047,0.00008071229,0.017051803,0.0010476012,0.0005032967,0.0000025666384,0.00003429097,0.00090605876],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984576,0.00016812414,0.0003040869,0.00037870475,0.00024977577,0.00044167106],"domain_scores_gemma":[0.99911547,0.00035315083,0.00010713802,0.00020762894,0.00009487276,0.0001217467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064618705,0.00026571908,0.0004457449,0.000097525306,0.00036976938,0.00003992897,0.00018639895,0.00013724012,0.00035765677],"category_scores_gemma":[0.000031351075,0.00016612011,0.00016187016,0.00045294006,0.00014146291,0.000129186,0.000027777261,0.0005407427,0.000010564631],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000451928,0.000085979365,0.00008669675,0.000042581385,0.00039844273,0.0000098937635,0.012221428,0.000053373875,0.9432953,0.00031309662,0.0021683725,0.040872924],"study_design_scores_gemma":[0.0045023267,0.00010648375,0.0009982005,0.000040906343,0.00018602372,0.00009022058,0.0010085015,0.0004893452,0.905067,0.0003300785,0.086971834,0.00020905652],"about_ca_topic_score_codex":0.00007674427,"about_ca_topic_score_gemma":0.00008765814,"teacher_disagreement_score":0.08480346,"about_ca_system_score_codex":0.00015020369,"about_ca_system_score_gemma":0.00005383758,"threshold_uncertainty_score":0.6774181},"labels":[],"label_agreement":null},{"id":"W1969320029","doi":"10.1007/s00280-010-1530-7","title":"A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Jewish General Hospital","funders":"Novartis Pharmaceuticals Canada","keywords":"Chlorambucil; Imatinib; Medicine; Fludarabine; Imatinib mesylate; Chronic lymphocytic leukemia; Tyrosine-kinase inhibitor; Pharmacology; Internal medicine; Chemotherapy; Leukemia; Gastroenterology; Oncology; Cancer; Cyclophosphamide","score_opus":0.015285900770481496,"score_gpt":0.3521121000178381,"score_spread":0.33682619924735663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969320029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702454,0.00043075625,0.000001873615,0.000077610384,0.0001126393,0.0021907298,0.0000053622034,0.000022787159,0.00013369272],"genre_scores_gemma":[0.9984285,0.0007186971,0.000019550407,0.00023259193,0.000060873994,0.00038112505,0.000016460177,0.00003333136,0.000108827844],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985341,0.00008649789,0.0003987347,0.00036987296,0.00022993951,0.00038084565],"domain_scores_gemma":[0.99932414,0.00009722581,0.00014446616,0.00018877884,0.00012671357,0.00011864615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002619245,0.00020200765,0.00051322137,0.00025270382,0.000029690265,0.0000074835393,0.00011178557,0.00013115356,0.00044902504],"category_scores_gemma":[0.000014679577,0.0001639806,0.000025785639,0.00048809164,0.00018664583,0.00008653557,0.000027216623,0.00035716285,0.000001763241],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.056289755,0.017584672,0.27969337,0.0027045528,0.0011296333,0.00059852836,0.030108836,0.0009466295,0.3539368,0.00003176192,0.0006601376,0.25631532],"study_design_scores_gemma":[0.7494672,0.013309968,0.025307318,0.00023975887,0.00017232381,0.00004325757,0.00020544644,0.06675045,0.14351393,0.00002588942,0.00063301966,0.0003314131],"about_ca_topic_score_codex":0.003286286,"about_ca_topic_score_gemma":0.0015645202,"teacher_disagreement_score":0.69317746,"about_ca_system_score_codex":0.015654573,"about_ca_system_score_gemma":0.0072019496,"threshold_uncertainty_score":0.9984263},"labels":[],"label_agreement":null},{"id":"W1970715182","doi":"10.1007/s00280-005-1023-2","title":"Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Ifosfamide; Chemistry; In vivo; Mass spectrometry; Glutathione; Metabolite; Magnetic resonance imaging; Pharmacology; Drug metabolism; Chromatography; Metabolism; Biochemistry; Medicine; Internal medicine; Biology; Chemotherapy; Enzyme; Radiology","score_opus":0.015397605053791973,"score_gpt":0.32209756980289733,"score_spread":0.3066999647491054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970715182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.956541,0.040666394,0.00038885904,0.0018448718,0.0001093696,0.0003421845,0.000024311259,0.00001988329,0.00006314118],"genre_scores_gemma":[0.97466606,0.016977137,0.006764032,0.0010686512,0.0003476243,0.0000114004515,0.0000032634798,0.00002955895,0.00013227915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989315,0.000049491187,0.00040532634,0.00028965008,0.00013333301,0.00019069495],"domain_scores_gemma":[0.9993959,0.000071668226,0.00022290126,0.00014542074,0.000085121734,0.00007896512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019998327,0.00015546147,0.0004070649,0.00017330259,0.000035668996,0.0000055748396,0.000062045576,0.000109998786,0.0006281615],"category_scores_gemma":[0.000012173531,0.00015516311,0.00004844112,0.0002991945,0.00028645725,0.00009501811,0.000011626683,0.00014920937,6.948307e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039137865,0.00009199436,0.01204118,0.00018847446,0.00006820322,9.760607e-7,0.00047320966,0.0000046544214,0.9712971,0.00003454529,0.000106652275,0.015301663],"study_design_scores_gemma":[0.0027325882,0.00014969298,0.020010533,0.00004429573,0.00016276892,0.000021679665,0.000048312704,0.0018112707,0.97342235,0.0002816975,0.0012001977,0.00011462258],"about_ca_topic_score_codex":0.000026661015,"about_ca_topic_score_gemma":0.0000029884432,"teacher_disagreement_score":0.023689257,"about_ca_system_score_codex":0.00009568588,"about_ca_system_score_gemma":0.00009989367,"threshold_uncertainty_score":0.6877928},"labels":[],"label_agreement":null},{"id":"W1973588440","doi":"10.1007/s00280-013-2224-8","title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Panobinostat; Medicine; Prostate cancer; Tolerability; Internal medicine; Oncology; Cancer; Clinical endpoint; Prostate-specific antigen; Phases of clinical research; Urology; Adverse effect; Chemotherapy; Clinical trial; Histone deacetylase","score_opus":0.008602750773293795,"score_gpt":0.31324066361341824,"score_spread":0.3046379128401244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973588440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977581,0.00066471595,0.0000026797984,0.00016961711,0.00008224276,0.0012376114,0.00005231536,0.0000040937284,0.000028660179],"genre_scores_gemma":[0.99842656,0.00050432165,0.000016666849,0.00024124747,0.00007358576,0.0005495962,0.000025397489,0.000021745029,0.00014088028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906194,0.00007887097,0.00020733806,0.00029539992,0.00011522513,0.00024121841],"domain_scores_gemma":[0.9995598,0.0000100966,0.00008745772,0.000111476584,0.00015482317,0.000076353885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060427465,0.00013970812,0.00018782455,0.00006188092,0.000044254273,0.000009202691,0.00008557704,0.00006582644,0.00030947133],"category_scores_gemma":[0.0000024894084,0.000117528856,0.000015622285,0.000121207835,0.00012674682,0.000008338941,0.000022205606,0.000109151144,9.1669665e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030754812,0.0023428488,0.033027813,0.00005075385,0.00014668619,0.0000040596005,0.0021217852,0.00005460544,0.9385572,4.803585e-7,0.0015569935,0.01906128],"study_design_scores_gemma":[0.034354758,0.008250311,0.039726518,0.0000254571,0.000032463886,0.0000013521077,0.0004435044,0.000044457996,0.913573,0.0000044185167,0.0032634328,0.00028032347],"about_ca_topic_score_codex":0.0011080641,"about_ca_topic_score_gemma":0.0005474536,"teacher_disagreement_score":0.031279277,"about_ca_system_score_codex":0.000044954533,"about_ca_system_score_gemma":0.00015341483,"threshold_uncertainty_score":0.47926876},"labels":[],"label_agreement":null},{"id":"W1975048166","doi":"10.1007/s00280-005-0077-5","title":"A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Pharmacodynamics; Neutropenia; Population; Pharmacology; Pharmacokinetics; Homocysteine; Internal medicine; Oncology; Chemotherapy","score_opus":0.03385451318269302,"score_gpt":0.3721025579256311,"score_spread":0.3382480447429381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975048166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853761,0.003397863,0.0040948265,0.0042023035,0.0007953013,0.0016266059,0.00005600637,0.00016692147,0.00028405926],"genre_scores_gemma":[0.97081655,0.0076607107,0.0014815349,0.016520778,0.0011532741,0.00095599063,0.0000566311,0.00006910038,0.0012854185],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998579,0.000048029546,0.00031271193,0.0004995918,0.00012012603,0.00044050915],"domain_scores_gemma":[0.9993966,0.00007216818,0.00012440232,0.00013355615,0.00008384596,0.00018942688],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013274862,0.00030830287,0.00047916386,0.00012616935,0.00024579914,0.00002096539,0.00010993165,0.00012632918,0.0010966277],"category_scores_gemma":[0.0000030968904,0.00027191173,0.00022437428,0.00019930565,0.000056886864,0.00014269674,0.000021604128,0.00024177626,0.0000059278536],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002192662,0.00020269066,0.0010797117,0.00006966119,0.0004040622,0.000003302776,0.00019193256,0.0028150948,0.9029083,0.00008794333,0.004015403,0.08602921],"study_design_scores_gemma":[0.030177452,0.00074979686,0.0029365015,0.000050834307,0.00091181434,0.00004365983,0.000023457213,0.46949363,0.42716017,0.0006142679,0.06715035,0.0006880766],"about_ca_topic_score_codex":0.000033357457,"about_ca_topic_score_gemma":0.000010206635,"teacher_disagreement_score":0.47574815,"about_ca_system_score_codex":0.00018694726,"about_ca_system_score_gemma":0.00010617601,"threshold_uncertainty_score":0.9999733},"labels":[],"label_agreement":null},{"id":"W1975417822","doi":"10.1007/s00280-007-0429-4","title":"Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Thallium and Germanium Studies","field":"Environmental Science","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Prostate cancer; Medicine; Prostate; Creatinine; Cancer; Oral administration; Endocrinology; Urology; Internal medicine; Chemistry","score_opus":0.021874364354830745,"score_gpt":0.362844966164183,"score_spread":0.34097060180935224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975417822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931867,0.0019507745,0.00014111536,0.0034561737,0.00057598914,0.00048028727,0.0000020368734,0.000020128255,0.00018676964],"genre_scores_gemma":[0.9930807,0.0019543867,0.00009097598,0.00434485,0.00018255995,0.00010809991,4.6322722e-7,0.000012568183,0.0002254232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990614,0.00004995294,0.00018165878,0.0002776203,0.0001177341,0.0003116439],"domain_scores_gemma":[0.99948376,0.00027183065,0.00008760295,0.00006207242,0.000008227882,0.0000865029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029443274,0.00015689943,0.00020594428,0.000021934127,0.00025909411,0.000029701358,0.00011049964,0.0000680994,0.00020151993],"category_scores_gemma":[0.000005416872,0.00010127575,0.000035374786,0.00016233936,0.00019581748,0.00013847082,0.00007213972,0.00012701873,0.0000013480179],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005924911,0.000069196896,0.046179246,0.00008510057,0.000115340445,0.000017487915,0.0045568543,0.00004963511,0.9104665,0.0000070993583,0.00026005594,0.037601016],"study_design_scores_gemma":[0.0010980894,0.00027691512,0.23798402,0.000029015793,0.00009775909,0.0000066503685,0.0002736732,0.000050894112,0.7529288,0.000052133597,0.007024237,0.00017785117],"about_ca_topic_score_codex":0.000189305,"about_ca_topic_score_gemma":0.00039988314,"teacher_disagreement_score":0.19180477,"about_ca_system_score_codex":0.000086035965,"about_ca_system_score_gemma":0.000023031793,"threshold_uncertainty_score":0.41299054},"labels":[],"label_agreement":null},{"id":"W1976060118","doi":"10.1007/s00280-011-1556-5","title":"Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Medicine; Single-nucleotide polymorphism; Oncology; Internal medicine; Toxicity; Cisplatin; Radiation therapy; Esophageal cancer; Gastroenterology; Chemotherapy; Genotype; Cancer; Biology; Genetics","score_opus":0.018628931616632486,"score_gpt":0.27345161612749896,"score_spread":0.2548226845108665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976060118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938032,0.0028225468,0.00019569446,0.00046430324,0.000046450492,0.0023204202,0.00025831268,0.000023609411,0.00006544597],"genre_scores_gemma":[0.9957755,0.0010199449,0.00056191284,0.0018063167,0.00012373846,0.0004296476,0.00022665718,0.000033590295,0.000022655406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823046,0.00034446424,0.00032994885,0.00056079595,0.00020523652,0.00032912183],"domain_scores_gemma":[0.99916506,0.00023884019,0.00019127261,0.00014993676,0.00010186001,0.00015301582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015341284,0.00029516342,0.00043075846,0.00011572448,0.00010460765,0.00001880485,0.00007727578,0.00016654642,0.00015084044],"category_scores_gemma":[0.000008827291,0.00019142624,0.000021676266,0.00029173397,0.00019010283,0.00014786636,0.000012959869,0.00031651524,8.1173073e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04281451,0.0005905327,0.9159822,0.000020690833,0.00049348554,0.00010401228,0.0125442995,0.0001551185,0.0007574472,0.0000042800316,0.000058696263,0.026474737],"study_design_scores_gemma":[0.05912429,0.007090813,0.91752905,0.00006195283,0.00016696348,0.000007198611,0.000067580535,0.006371458,0.009377392,0.000016660631,0.000018220557,0.00016842622],"about_ca_topic_score_codex":0.0012784887,"about_ca_topic_score_gemma":0.0007388839,"teacher_disagreement_score":0.02630631,"about_ca_system_score_codex":0.00046714587,"about_ca_system_score_gemma":0.0003990091,"threshold_uncertainty_score":0.78061354},"labels":[],"label_agreement":null},{"id":"W1976191662","doi":"10.1007/s00280-004-0762-9","title":"A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Docetaxel; Medicine; Debulking; Neutropenia; Ovarian cancer; Cisplatin; Progressive disease; Chemotherapy; Phases of clinical research; Internal medicine; Oncology; Surgery; Cancer; Tumor Debulking","score_opus":0.03240721167240346,"score_gpt":0.3838513191967099,"score_spread":0.35144410752430644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976191662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98553425,0.0056264605,0.000004470339,0.005410615,0.00016211244,0.0031756845,0.000053086835,0.000009007188,0.000024298208],"genre_scores_gemma":[0.98750013,0.009896912,0.00006443683,0.001052846,0.00012292957,0.0013150305,0.00000379363,0.000019492005,0.000024452174],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988375,0.000048183345,0.0004004368,0.00037028824,0.00012984854,0.0002137591],"domain_scores_gemma":[0.99941766,0.000078876976,0.00018460202,0.00019257594,0.000053513497,0.000072796014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107266904,0.00024361785,0.0006315833,0.00010038992,0.00008083026,0.000005180593,0.00007098327,0.000052156607,0.00026627403],"category_scores_gemma":[0.0000022090478,0.00015894647,0.000052957985,0.00020205336,0.00009116781,0.000046265734,0.000019379328,0.00009378654,1.6664956e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020420209,0.10416668,0.37821624,0.00032594678,0.0031528652,0.0002521424,0.09958049,0.00066242827,0.014359541,0.000018539315,0.00010992742,0.37873498],"study_design_scores_gemma":[0.5109944,0.09537109,0.3210844,0.00026380425,0.0022008312,0.000027499389,0.005536553,0.00026465708,0.05686472,0.000050028197,0.006957004,0.0003850355],"about_ca_topic_score_codex":0.0023702178,"about_ca_topic_score_gemma":0.0022294598,"teacher_disagreement_score":0.49057415,"about_ca_system_score_codex":0.00017408625,"about_ca_system_score_gemma":0.000098896126,"threshold_uncertainty_score":0.64816487},"labels":[],"label_agreement":null},{"id":"W1976238224","doi":"10.1007/s00280-004-0817-y","title":"Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Apoptosis; In vivo; In vitro; Camptothecin; DAPI; Mammary tumor; Molecular biology; Chemistry; Pharmacology; Transfection; Biochemistry; Biology; Medicine; Internal medicine","score_opus":0.015310234798929694,"score_gpt":0.2888894467009151,"score_spread":0.2735792119019854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976238224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833917,0.012087966,0.0013083066,0.0023072383,0.00019823304,0.00043227294,0.00017683065,0.000022531436,0.00007491633],"genre_scores_gemma":[0.9638767,0.021734143,0.0012365481,0.011928564,0.0005351148,0.0001769267,0.0000554627,0.000060852417,0.00039565982],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998606,0.0000461151,0.00024377301,0.00063369033,0.000093122304,0.00037730183],"domain_scores_gemma":[0.99923,0.000019840856,0.0001216823,0.00021286319,0.000057999117,0.00035760095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014047527,0.00033128465,0.0003459777,0.000075134565,0.00013851532,0.00005380018,0.00015086289,0.0001729582,0.00011966922],"category_scores_gemma":[0.0000070980564,0.00032501496,0.000067651024,0.00009327158,0.00020780686,0.000015610729,0.00011805075,0.00014505725,0.0000013913478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006808893,0.00007794192,0.00007038534,0.000064059604,0.0003764755,0.000014386805,0.00020873552,0.0000111789695,0.9824673,0.0002511303,0.00012839833,0.015649134],"study_design_scores_gemma":[0.0066586793,0.00071447046,0.0001041332,0.000021575252,0.00014691966,0.0002164226,0.00007062603,0.000027515713,0.9466562,0.00040341966,0.044586472,0.00039352503],"about_ca_topic_score_codex":0.0002185346,"about_ca_topic_score_gemma":0.000090398644,"teacher_disagreement_score":0.044458073,"about_ca_system_score_codex":0.000040302304,"about_ca_system_score_gemma":0.0002769775,"threshold_uncertainty_score":0.9999202},"labels":[],"label_agreement":null},{"id":"W1976269797","doi":"10.1007/s00280-013-2372-x","title":"Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"","keywords":"Tolerability; Monoclonal antibody; Medicine; Oncology; Internal medicine; Solid tumor; Pharmacology; Antibody; Immunology; Adverse effect; Cancer","score_opus":0.011441081278847342,"score_gpt":0.33948244511454867,"score_spread":0.3280413638357013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976269797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975668,0.00014400619,0.00008867508,0.00042430163,0.000061528095,0.0016408034,0.000028621103,0.000009411917,0.00003583819],"genre_scores_gemma":[0.9989902,0.00020355676,0.00022868945,0.00045075984,0.000018153196,0.000068646965,0.000016870528,0.000017659295,0.000005491245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871683,0.00012543693,0.00043608726,0.00033570587,0.00015941993,0.00022653802],"domain_scores_gemma":[0.99920166,0.00018023634,0.00019651915,0.00012281544,0.0001913786,0.00010738679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024055055,0.00018302092,0.00074336404,0.00017899428,0.000031848147,0.0000024013289,0.000057202655,0.00008265494,0.000027048638],"category_scores_gemma":[0.000024165145,0.00014188704,0.000017976032,0.00027523938,0.0001774562,0.00007699971,0.0000232833,0.00016841778,8.5852214e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0587697,0.008926642,0.8478065,0.00013856485,0.000122037214,0.0000047959934,0.0062280935,0.00007722606,0.052524015,0.000006532235,0.000025783429,0.025370099],"study_design_scores_gemma":[0.14905062,0.03522347,0.7703984,0.00009370548,0.00006863675,0.0000015714412,0.000341052,0.00016885578,0.04403068,0.000010285905,0.00046772364,0.00014501216],"about_ca_topic_score_codex":0.00014541313,"about_ca_topic_score_gemma":0.00019698642,"teacher_disagreement_score":0.09028093,"about_ca_system_score_codex":0.00012609613,"about_ca_system_score_gemma":0.00013517927,"threshold_uncertainty_score":0.57859856},"labels":[],"label_agreement":null},{"id":"W1978070269","doi":"10.1007/s00280-008-0916-2","title":"The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Tubulin; GTP'; Microtubule; Chemistry; Depolymerization; Paclitaxel; Intracellular; Biochemistry; Biophysics; Biology; Cell biology; Enzyme","score_opus":0.016665978335506784,"score_gpt":0.2766505347709534,"score_spread":0.25998455643544666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978070269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686841,0.026114734,0.000120433615,0.0038820659,0.0004820815,0.00043425796,0.000048826085,0.00001959446,0.00021392839],"genre_scores_gemma":[0.9528654,0.03408632,0.000111067435,0.011129585,0.00048268985,0.000066985325,0.000028536675,0.000027158094,0.0012022136],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988377,0.00008350254,0.00020770518,0.00043249968,0.00006505573,0.00037353297],"domain_scores_gemma":[0.9995175,0.000022493512,0.00010286686,0.00018083678,0.000068422145,0.000107867214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012405716,0.0002591751,0.00022971157,0.000026270325,0.00044946471,0.0000754361,0.00018182892,0.00015025306,0.00004398582],"category_scores_gemma":[0.0000042893407,0.00019203484,0.000059941853,0.000055619264,0.00051624567,0.000009532806,0.00005585535,0.00017555524,0.0000016781768],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007960115,0.00006923626,0.00043468934,0.000029292924,0.00015846887,0.0000043402606,0.00030348392,0.0000037157365,0.96516573,0.00002296017,0.017725654,0.015286405],"study_design_scores_gemma":[0.0016495199,0.0003644587,0.0013589421,0.000014616258,0.000046768255,0.000053223015,0.000091776485,0.00011193821,0.48059478,0.000055955752,0.51540333,0.00025469353],"about_ca_topic_score_codex":0.00005955599,"about_ca_topic_score_gemma":0.0000735175,"teacher_disagreement_score":0.49767768,"about_ca_system_score_codex":0.000026556774,"about_ca_system_score_gemma":0.0001140825,"threshold_uncertainty_score":0.78309536},"labels":[],"label_agreement":null},{"id":"W1983318447","doi":"10.1007/s00280-004-0942-7","title":"Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Vinorelbine; Multiple drug resistance; Solid tumor; Medicine; Pharmacology; Internal medicine; Chemotherapy; Oncology; Drug resistance; Cancer research; Cancer; Biology; Cisplatin; Genetics","score_opus":0.008023811078206176,"score_gpt":0.30108309324845184,"score_spread":0.2930592821702457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983318447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667346,0.00033396273,0.000010116329,0.0013038563,0.00011674532,0.001475146,0.000012914412,0.000011879021,0.000061907194],"genre_scores_gemma":[0.9986033,0.00013603852,0.00016185598,0.00065128645,0.00004574237,0.000134919,0.000008012405,0.0000244414,0.0002344018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998992,0.00004912082,0.00029269702,0.00027042616,0.00018753101,0.00020819358],"domain_scores_gemma":[0.99955267,0.000020075307,0.00015561999,0.00013167439,0.00008118098,0.000058765836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094689996,0.00017020389,0.00036347998,0.000093220566,0.000041814437,0.0000029433709,0.00008222267,0.00005219688,0.00006261284],"category_scores_gemma":[0.0000015062064,0.00010643109,0.000020909903,0.00028622773,0.000118466014,0.000077861994,0.000007356422,0.00019480256,1.516715e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08383356,0.023389563,0.7720024,0.00038015746,0.00022399814,0.00004470507,0.01284427,0.0002542482,0.08727638,0.000023589082,0.00016950053,0.019557618],"study_design_scores_gemma":[0.2179068,0.0057914015,0.5166831,0.00045125384,0.00014791226,0.0000015714021,0.00086089683,0.00013435441,0.25610265,0.000011482412,0.001622811,0.00028574403],"about_ca_topic_score_codex":0.0000160847,"about_ca_topic_score_gemma":0.0014158376,"teacher_disagreement_score":0.2553193,"about_ca_system_score_codex":0.00010287467,"about_ca_system_score_gemma":0.000096857926,"threshold_uncertainty_score":0.4340134},"labels":[],"label_agreement":null},{"id":"W1984547199","doi":"10.1007/s00280-006-0347-x","title":"A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Celecoxib; Cyclophosphamide; Clinical endpoint; Renal cell carcinoma; Internal medicine; Progressive disease; Toxicity; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Chemotherapy; Urology; Oncology","score_opus":0.0051715397907841345,"score_gpt":0.2636782597352365,"score_spread":0.2585067199444524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984547199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973547,0.0011049552,0.000002914943,0.000117734446,0.0002688712,0.0009701312,0.000017402182,0.000011361682,0.0001519352],"genre_scores_gemma":[0.99856716,0.00019623552,0.00004243733,0.0006433528,0.00027979552,0.00007980837,0.0000156181,0.000021518206,0.00015406065],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991187,0.000049093593,0.00025149796,0.00022993865,0.000103142236,0.00024763934],"domain_scores_gemma":[0.9996061,0.000041901996,0.00012702541,0.000073066694,0.00005498253,0.000096921925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119050404,0.00016813078,0.00044193937,0.000081371974,0.000043314376,0.0000031687161,0.00003485796,0.000100615805,0.00018112015],"category_scores_gemma":[0.000002138312,0.00013327891,0.000030803796,0.00010892429,0.00015222002,0.000040889932,0.000013050247,0.00015687893,3.1718753e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35141948,0.006129577,0.36937198,0.0005760871,0.0001118698,0.00013144141,0.0010282922,0.000008418783,0.23363753,0.000009012689,0.0037656773,0.03381064],"study_design_scores_gemma":[0.52358675,0.010091663,0.08221164,0.00004538804,0.00012030176,0.0000036766564,0.000011444485,0.0000802073,0.38046893,0.000013438707,0.0031731876,0.00019334188],"about_ca_topic_score_codex":0.00017221305,"about_ca_topic_score_gemma":0.000025295853,"teacher_disagreement_score":0.28716034,"about_ca_system_score_codex":0.000041938074,"about_ca_system_score_gemma":0.00011325472,"threshold_uncertainty_score":0.54349566},"labels":[],"label_agreement":null},{"id":"W1985535018","doi":"10.1007/s00280-004-0955-2","title":"Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM)","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Cancer Research Society","keywords":"Doxycycline; Chorioallantoic membrane; Angiogenesis; Matrix metalloproteinase; In vivo; Pharmacology; Matrix metalloproteinase inhibitor; Chemistry; Medicine; Biology; Cancer research; Internal medicine; Antibiotics; Biochemistry","score_opus":0.010230482127430553,"score_gpt":0.2954464021296871,"score_spread":0.28521592000225654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985535018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97233295,0.024120368,0.000076315846,0.002785017,0.00011225499,0.0001948636,0.000055537224,0.000004477788,0.00031821188],"genre_scores_gemma":[0.9617615,0.030627254,0.00007049644,0.0064861984,0.0007087255,0.000089943,0.00005325548,0.000016378439,0.00018629506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992305,0.00007117982,0.00020036614,0.00023952994,0.0000723854,0.00018600943],"domain_scores_gemma":[0.9997177,0.00001872867,0.00008423434,0.000114360315,0.000029247884,0.000035727007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018479882,0.00013269039,0.00016502454,0.000033666125,0.000042347096,0.000005409329,0.00012003329,0.0001278781,0.0003214765],"category_scores_gemma":[0.0000020994485,0.00010158876,0.000071146285,0.00010648924,0.000115556264,0.0000047759104,0.000019584679,0.000059678427,0.0000010401109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024288603,0.000089189714,0.003623474,0.000023438228,0.00006810672,5.0221627e-7,0.00020538151,0.000046392528,0.9619549,0.00000729798,0.015510285,0.018228153],"study_design_scores_gemma":[0.0013790455,0.000097316835,0.00127693,0.000006993193,0.000024452876,0.000006179474,0.00003600977,0.000051551244,0.7933444,0.000008721989,0.20365883,0.00010957383],"about_ca_topic_score_codex":0.00006647148,"about_ca_topic_score_gemma":0.0000967307,"teacher_disagreement_score":0.18814854,"about_ca_system_score_codex":0.000015268197,"about_ca_system_score_gemma":0.000037941234,"threshold_uncertainty_score":0.41426694},"labels":[],"label_agreement":null},{"id":"W1985543168","doi":"10.1007/s00280-009-0968-y","title":"A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Pharmacokinetics; Tolerability; Medicine; Adverse effect; Maximum tolerated dose; Vomiting; Pharmacology; Nausea; Response Evaluation Criteria in Solid Tumors; Drug; Internal medicine; Phases of clinical research; Oncology; Toxicity","score_opus":0.013180397049429405,"score_gpt":0.3435477192316031,"score_spread":0.3303673221821737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985543168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985166,0.00029401324,0.000015723737,0.000106636115,0.000072597686,0.0009467069,0.00003966376,0.0000046561686,0.0000034088594],"genre_scores_gemma":[0.999415,0.00014865307,0.00010046231,0.00022306143,0.00004222514,0.000033163753,0.000016664631,0.000015312096,0.0000055038627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988584,0.00018839625,0.0002727882,0.00033636484,0.00013405425,0.0002100131],"domain_scores_gemma":[0.99944896,0.000014665105,0.00014606204,0.00014679259,0.00016345813,0.0000800565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001331484,0.00016667321,0.0002591949,0.000050476392,0.000042939177,0.000005281246,0.00013561544,0.00008300912,0.00002308891],"category_scores_gemma":[0.0000104344745,0.00012487585,0.000024523162,0.00016942412,0.00019206814,0.000016278605,0.00003954006,0.00014890083,3.063567e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045008413,0.0029963376,0.23369308,0.00003548012,0.000046958718,4.1797801e-7,0.000703352,0.000096552445,0.7490833,4.3359964e-7,0.000020742742,0.0088225035],"study_design_scores_gemma":[0.021554764,0.004804064,0.37609157,0.000010958152,0.000022907747,3.8036347e-7,0.000064313426,0.00035437875,0.59695685,0.00000580153,0.000026980571,0.00010706784],"about_ca_topic_score_codex":0.000038657883,"about_ca_topic_score_gemma":0.000055828976,"teacher_disagreement_score":0.15212648,"about_ca_system_score_codex":0.000021636488,"about_ca_system_score_gemma":0.00006246535,"threshold_uncertainty_score":0.50922894},"labels":[],"label_agreement":null},{"id":"W1990086381","doi":"10.1007/s00280-010-1389-7","title":"A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Docetaxel; Prostate cancer; Prednisone; Medicine; Internal medicine; Oncology; Cancer research; Castration; Cancer; Pharmacology; Hormone","score_opus":0.030365239443130243,"score_gpt":0.3928297857683229,"score_spread":0.36246454632519265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990086381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863021,0.004466484,2.1038514e-7,0.006117945,0.00030969537,0.00258437,0.00010762405,0.00001640597,0.00009518484],"genre_scores_gemma":[0.9796113,0.01743707,0.000016427697,0.00046722,0.00017356519,0.00065760664,0.000006904546,0.000026074937,0.0016038251],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879146,0.000059122787,0.00029708626,0.00037713174,0.00015663571,0.00031858403],"domain_scores_gemma":[0.999404,0.000057551566,0.00012355142,0.00018130009,0.00008598363,0.00014760866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011493021,0.00023305987,0.00043937025,0.000091600465,0.0002068153,0.000013359686,0.000072753,0.00008460546,0.0004528956],"category_scores_gemma":[0.0000054672237,0.00014686017,0.000046994104,0.0002285841,0.00029942582,0.000063724845,0.000041499123,0.00025274267,4.6190252e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015789844,0.005829423,0.03828064,0.00022683958,0.0007152381,0.00013843806,0.01784338,0.000049137823,0.8735339,0.000010456218,0.00036005964,0.047222633],"study_design_scores_gemma":[0.1859258,0.018278163,0.04386543,0.00017360317,0.00068609783,0.0000753716,0.0011368915,0.0010160983,0.7318024,0.00008580155,0.016570518,0.00038381296],"about_ca_topic_score_codex":0.0033570048,"about_ca_topic_score_gemma":0.0056912075,"teacher_disagreement_score":0.17013596,"about_ca_system_score_codex":0.00016935296,"about_ca_system_score_gemma":0.0004899649,"threshold_uncertainty_score":0.59887844},"labels":[],"label_agreement":null},{"id":"W1990206652","doi":"10.1007/s00280-001-0403-5","title":"Comparison of apoptotic, necrotic and clonogenic cell death and inhibition of cell growth following camptothecin and X-radiation treatment in a human melanoma and a human fibroblast cell line","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"National Cancer Institute","keywords":"Camptothecin; Programmed cell death; Propidium iodide; Clonogenic assay; Apoptosis; Cell culture; Cell growth; Biology; Cell; Cancer research; Necrosis; Acridine orange; Molecular biology; Biochemistry","score_opus":0.014444432437030906,"score_gpt":0.3073200835033996,"score_spread":0.2928756510663687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990206652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99263525,0.006729663,0.000121313176,0.00003617473,0.000031288368,0.0003446505,0.000010093732,0.0000031951995,0.00008838738],"genre_scores_gemma":[0.9914279,0.008112206,0.00014174085,0.00005731249,0.000064323256,0.000022069995,0.000036767902,0.000015553233,0.00012215045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992611,0.00004975315,0.00023534488,0.00027759164,0.0000393429,0.0001369017],"domain_scores_gemma":[0.99970394,0.00001768674,0.00014031114,0.00005671696,0.000019648787,0.00006171418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007381863,0.00015572892,0.00027231718,0.00007078645,0.00007094873,0.000008587731,0.000020984273,0.00012133477,0.000017195965],"category_scores_gemma":[6.5030264e-7,0.00014616858,0.000029238496,0.00004658568,0.00007490288,0.000008747027,0.000023188712,0.000048673006,2.5288884e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015913148,0.00015671624,0.04641348,0.00015550885,0.000032568874,0.0000014150235,0.0006367503,0.000018902614,0.9499296,0.00002035734,0.000008102721,0.0024674814],"study_design_scores_gemma":[0.0051534935,0.0013541692,0.01614462,0.00002442921,0.0000782113,0.000004288756,0.00009176319,0.00037177757,0.976333,0.000094522344,0.0002140935,0.00013558529],"about_ca_topic_score_codex":0.0001670781,"about_ca_topic_score_gemma":0.00006170376,"teacher_disagreement_score":0.030268861,"about_ca_system_score_codex":0.000018080571,"about_ca_system_score_gemma":0.000017082559,"threshold_uncertainty_score":0.5960582},"labels":[],"label_agreement":null},{"id":"W1990365798","doi":"10.1007/s002800000222","title":"TNF-α further augments natural killer cells when co-administered with an interferon inducer to irradiated, leukemic, bone-marrow-transplanted mice","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tumor necrosis factor alpha; Bone marrow; Cytokine; Haematopoiesis; Immunology; Natural killer cell; Interferon; Cancer research; Biology; Stem cell; Cytotoxic T cell; In vitro; Cell biology","score_opus":0.016780088308106653,"score_gpt":0.2906677799964995,"score_spread":0.27388769168839283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990365798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675615,0.0019035216,0.00007853837,0.0015111762,0.00823071,0.00048580297,0.000014027692,0.000097734766,0.00092237187],"genre_scores_gemma":[0.9565842,0.001871332,0.000037374917,0.014166925,0.00016783526,0.00010657644,0.00015929184,0.000051284525,0.026855139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984943,0.00020104632,0.00029703823,0.0004992056,0.00004139722,0.00046695737],"domain_scores_gemma":[0.99949354,0.00004979277,0.00012764595,0.00016599693,0.000078306155,0.000084724066],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010541782,0.00033067726,0.00035422138,0.0001570756,0.0001692575,0.000026295154,0.00018259586,0.00027754542,0.014396995],"category_scores_gemma":[0.0000012262996,0.0002776047,0.000056946592,0.00011200273,0.00015692059,0.00022227321,0.000018348825,0.0005056531,0.00022245279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014621228,0.00017426195,0.00053069246,0.000022977873,0.0004446511,0.000013858982,0.003158079,0.000008311903,0.92862177,0.0000017286059,0.04041915,0.011983316],"study_design_scores_gemma":[0.0057265875,0.0009901439,0.0008307194,0.000044078093,0.00007838673,0.00017739706,0.0002767598,0.000021127382,0.5473607,0.0000029273415,0.44417095,0.00032021693],"about_ca_topic_score_codex":0.0002845127,"about_ca_topic_score_gemma":0.00009831205,"teacher_disagreement_score":0.4037518,"about_ca_system_score_codex":0.00015210493,"about_ca_system_score_gemma":0.00007248057,"threshold_uncertainty_score":0.99996763},"labels":[],"label_agreement":null},{"id":"W1991404956","doi":"10.1007/s00280-010-1342-9","title":"Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Calicheamicin; Immunoconjugate; CD22; Chemotherapy; CHOP; Cancer research; Medicine; Monoclonal antibody; Antibody; Internal medicine; Immunology","score_opus":0.017626628089461523,"score_gpt":0.3344375505906821,"score_spread":0.31681092250122056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991404956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366724,0.0009605626,0.00023442588,0.0021880544,0.00025535596,0.0023739473,0.00010414691,0.000081450955,0.00013480162],"genre_scores_gemma":[0.99073505,0.005086237,0.0012064453,0.002221798,0.00020273906,0.00024028734,0.00007970523,0.00012693302,0.000100815785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973229,0.00011875654,0.0006823275,0.000851692,0.00042147472,0.00060284405],"domain_scores_gemma":[0.9976062,0.00027150186,0.0008134986,0.00054120476,0.0004986918,0.0002689108],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027411006,0.0006787116,0.0017432516,0.00021317386,0.00014641916,0.000022851005,0.00023620421,0.00027906595,0.0013991689],"category_scores_gemma":[0.000005431643,0.0004315304,0.00014734457,0.00057288865,0.0010273379,0.00018183613,0.000023124836,0.00053423777,0.0000021121587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04719944,0.003857173,0.11283406,0.00037917294,0.0021486972,0.000063043015,0.0013412612,0.000017980958,0.821379,0.000013640061,0.00057491567,0.010191602],"study_design_scores_gemma":[0.059913427,0.0045729047,0.25443324,0.000255125,0.00034316635,0.0001398958,0.00008264979,0.00065448676,0.6769153,0.000007965986,0.0022822276,0.00039965584],"about_ca_topic_score_codex":0.0006348733,"about_ca_topic_score_gemma":0.0001331677,"teacher_disagreement_score":0.14446376,"about_ca_system_score_codex":0.00018446178,"about_ca_system_score_gemma":0.0007330073,"threshold_uncertainty_score":0.9998137},"labels":[],"label_agreement":null},{"id":"W1992013332","doi":"10.1007/s00280-002-0525-4","title":"Differential responses of EGFR-/AGT-expressing cells to the \"combi-triazene\" SMA41","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemical Reactions and Mechanisms","field":"Chemistry","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; McGill University; Health Canada; Royal Victoria Hospital","funders":"","keywords":"Triazene; Cancer research; Differential (mechanical device); Biology; Chemistry; Pharmacology; Cell biology","score_opus":0.021054060810524248,"score_gpt":0.3148057642350206,"score_spread":0.29375170342449636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992013332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950482,0.0007816231,0.00039942248,0.00087240053,0.00058997195,0.0001104441,0.000037331334,0.00002521933,0.0021353841],"genre_scores_gemma":[0.9942985,0.0013876877,0.00017233149,0.0013952103,0.00027273674,0.000071093076,0.0000022519523,0.000022400141,0.002377756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992002,0.000041529616,0.00019209688,0.00023793781,0.000090726,0.0002374671],"domain_scores_gemma":[0.9993885,0.00021579352,0.00008752713,0.00015802393,0.000040111827,0.00011005185],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000773088,0.00014783246,0.00021554259,0.000030990457,0.00010588937,0.0000145654585,0.0001462923,0.00010966467,0.00787719],"category_scores_gemma":[0.000014475547,0.00011065339,0.000072240655,0.00009376166,0.00008277741,0.000026877278,0.000026117548,0.00017841194,0.0000031224004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041804582,0.00007917854,0.000041682517,0.000044791264,0.00007057951,0.0000011680811,0.00032393725,0.000007741826,0.9831705,0.00015328958,0.0033790006,0.012310097],"study_design_scores_gemma":[0.0011162879,0.000020355203,0.000009855365,0.000017232522,0.000041105108,0.0000038680832,0.0000661799,0.000027523036,0.7801488,0.00016377965,0.2182853,0.00009971156],"about_ca_topic_score_codex":0.000030836258,"about_ca_topic_score_gemma":0.000003505387,"teacher_disagreement_score":0.2149063,"about_ca_system_score_codex":0.000047990135,"about_ca_system_score_gemma":0.000066229586,"threshold_uncertainty_score":0.9930298},"labels":[],"label_agreement":null},{"id":"W1992368913","doi":"10.1007/s00280-012-2038-0","title":"Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Juravinski Cancer Centre; McGill University; Ontario Institute for Cancer Research; BC Cancer Agency; Jewish General Hospital","funders":"Cancer Research UK","keywords":"Ketoconazole; Pharmacokinetics; Medicine; Rifampicin; Pharmacology; Drug interaction; Internal medicine; Gastroenterology; Pathology; Dermatology","score_opus":0.027445500362463033,"score_gpt":0.4104649299551251,"score_spread":0.3830194295926621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992368913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996315,0.0015625472,0.0000041165686,0.00036036427,0.00017237179,0.0013416966,0.000008480843,0.0000029852392,0.00023244161],"genre_scores_gemma":[0.9979526,0.00082558434,0.000027225027,0.0009436199,0.000093157265,0.00011166101,0.000002663726,0.0000103280945,0.00003318142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913985,0.00016384317,0.00016713429,0.00011444922,0.00022490945,0.00018981525],"domain_scores_gemma":[0.999427,0.00019034227,0.00010648801,0.000076901124,0.00012070391,0.00007853689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035607687,0.000098507706,0.00032078265,0.00006496401,0.000025548465,9.155561e-7,0.00004305992,0.00006145649,0.00020107535],"category_scores_gemma":[0.000024510111,0.00006177115,0.000019286394,0.000113953414,0.00024130906,0.000029531153,0.000013257388,0.00015407598,2.3115615e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003352707,0.0014013997,0.8953958,0.00029852364,0.00016191234,5.021936e-7,0.0010974278,0.000004449353,0.08131351,0.000012213096,0.000294508,0.01666701],"study_design_scores_gemma":[0.047975976,0.0016807048,0.68763083,0.0001233562,0.00049639604,0.0000016555482,0.000025159687,0.00051821204,0.26126617,0.000021347554,0.00019892237,0.0000612774],"about_ca_topic_score_codex":0.000018724202,"about_ca_topic_score_gemma":0.0000023406976,"teacher_disagreement_score":0.207765,"about_ca_system_score_codex":0.000055192275,"about_ca_system_score_gemma":0.00012506361,"threshold_uncertainty_score":0.25189546},"labels":[],"label_agreement":null},{"id":"W1992550766","doi":"10.1007/s00280-013-2226-6","title":"Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institutes of Health; Public Health Agency of Canada","keywords":"Gemcitabine; Pharmacodynamics; Apoptosis; Adenocarcinoma; Pancreatic cancer; Cell cycle; Cancer research; Internal medicine; Pharmacology; Chemistry; Oncology; Medicine; Biology; Chemotherapy; Pharmacokinetics; Cancer; Biochemistry","score_opus":0.013173311332558186,"score_gpt":0.31446018496275263,"score_spread":0.30128687363019446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992550766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99183434,0.005544907,0.00016001966,0.0005047681,0.00013947618,0.0009440944,0.0000064922538,0.000014330761,0.0008515774],"genre_scores_gemma":[0.98700047,0.010903595,0.00038126597,0.0010695806,0.000105675295,0.0001422761,0.0000026101397,0.000024943209,0.00036961245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894726,0.00009057948,0.00029056668,0.0002593142,0.00012827686,0.00028398092],"domain_scores_gemma":[0.9991655,0.00033772722,0.000109919325,0.000118389566,0.0000968958,0.00017157823],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012160316,0.0001753765,0.00066311884,0.00012337255,0.00004249308,0.0000031845675,0.00007110176,0.00011724961,0.0009543039],"category_scores_gemma":[0.0000072488597,0.00014454433,0.000052364532,0.00011142846,0.00025459775,0.000044584944,0.000026844114,0.00021250753,0.000005201318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007015475,0.00030150983,0.01820179,0.0020651475,0.00029533377,0.000008244999,0.00061956217,0.000103632534,0.9740208,0.000013174665,0.00027227914,0.0033970072],"study_design_scores_gemma":[0.011299022,0.001458022,0.018642752,0.00017961652,0.00060083246,0.000013860823,0.000080056125,0.16648377,0.8008283,0.00021066824,0.000037597252,0.0001655052],"about_ca_topic_score_codex":0.00018876776,"about_ca_topic_score_gemma":7.924603e-7,"teacher_disagreement_score":0.17319247,"about_ca_system_score_codex":0.000044905777,"about_ca_system_score_gemma":0.00010315694,"threshold_uncertainty_score":0.99995893},"labels":[],"label_agreement":null},{"id":"W1993531901","doi":"10.1007/s00280-007-0483-y","title":"Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thompson Rivers University; University of British Columbia","funders":"National Cancer Institute","keywords":"G2-M DNA damage checkpoint; CHEK1; Cell cycle checkpoint; Nuclear export signal; Mitosis; Kinase; DNA damage; Cancer research; Biology; Cell biology; Cell cycle; DNA repair; Chemistry; Biochemistry; DNA; Cell; Cell nucleus","score_opus":0.009639481280983724,"score_gpt":0.28341223120258374,"score_spread":0.2737727499216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993531901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969103,0.0021028295,0.00034971215,0.00019330162,0.0001379272,0.00017581937,0.0000115612265,0.000007916569,0.00011063817],"genre_scores_gemma":[0.9961973,0.0027661503,0.00030211173,0.00053196977,0.00012483307,0.000011146726,0.00002560714,0.000016455517,0.000024462699],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999408,0.00002291782,0.00020840843,0.0001864999,0.00005602728,0.00011814536],"domain_scores_gemma":[0.99966484,0.000011249533,0.00015806236,0.000065758024,0.000052855616,0.000047214377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000185608,0.00009214188,0.00013505004,0.0000354871,0.000034160217,0.0000027521296,0.00003451069,0.00012729857,0.00008998102],"category_scores_gemma":[0.000004091293,0.00009754082,0.000030379217,0.00005047907,0.00007672263,0.0000069914054,0.000018998171,0.000048099548,1.7799272e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024862948,0.00003998684,0.0007320837,0.00004647686,0.00005951595,4.4602862e-7,0.00028099323,0.00000156387,0.98379403,0.00007398586,0.0005780042,0.014144268],"study_design_scores_gemma":[0.001354511,0.0002604145,0.0015831534,0.000010207024,0.000021114804,0.0000033502831,0.000092706985,0.000050082657,0.99163985,0.00008387773,0.0048112627,0.0000894956],"about_ca_topic_score_codex":0.000022624272,"about_ca_topic_score_gemma":0.0000035612788,"teacher_disagreement_score":0.014054772,"about_ca_system_score_codex":0.000014218568,"about_ca_system_score_gemma":0.000027393471,"threshold_uncertainty_score":0.3977599},"labels":[],"label_agreement":null},{"id":"W1993832391","doi":"10.1007/s00280-012-1916-9","title":"Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; QT interval; Medicine; Prednisone; Prostate cancer; Pharmacokinetics; Adverse effect; Internal medicine; Pharmacology; Abiraterone; Urology; Cancer; Cardiology; Androgen deprivation therapy","score_opus":0.022724383275859676,"score_gpt":0.355739936494965,"score_spread":0.3330155532191053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993832391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924278,0.0035481285,0.000001540535,0.002060743,0.00017673797,0.0016315219,0.000066184744,0.00001040201,0.000076931676],"genre_scores_gemma":[0.9962884,0.0017816932,0.000014621012,0.00073083775,0.00008075798,0.0006636942,0.000017396242,0.000025268491,0.00039733798],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888694,0.0001825477,0.0001991466,0.00019294414,0.00018001578,0.0003584068],"domain_scores_gemma":[0.9994798,0.00014171514,0.000103120954,0.000103706334,0.00006550315,0.00010617177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028996222,0.00019062495,0.00037671672,0.000072901574,0.000054459186,0.00000768032,0.00006038862,0.00003864183,0.0005742797],"category_scores_gemma":[0.000004010256,0.00009795981,0.00003468672,0.00016905145,0.00021880449,0.000084854575,0.000014761316,0.0001994276,0.000001839887],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16012926,0.001250244,0.5920661,0.0018121367,0.0022299555,0.00003273758,0.010435802,0.00015527006,0.16305833,0.00003220851,0.0020576243,0.06674032],"study_design_scores_gemma":[0.050319027,0.007269897,0.2027492,0.00037183735,0.00043909944,0.000003766164,0.00010631169,0.00016596189,0.7367201,0.000009031542,0.0016152923,0.00023051574],"about_ca_topic_score_codex":0.00015536946,"about_ca_topic_score_gemma":0.000034210945,"teacher_disagreement_score":0.57366174,"about_ca_system_score_codex":0.00021188421,"about_ca_system_score_gemma":0.00013781228,"threshold_uncertainty_score":0.62879604},"labels":[],"label_agreement":null},{"id":"W1994441302","doi":"10.1007/s00280-013-2346-z","title":"Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Breast Cancer Society of Canada","keywords":"Chromatography; Mass spectrometry; Liquid chromatography–mass spectrometry; Chemistry; Tandem mass spectrometry; Extraction (chemistry); Tamoxifen; High-performance liquid chromatography; Selected reaction monitoring; Medicine; Cancer; Internal medicine; Breast cancer","score_opus":0.015796257930327576,"score_gpt":0.3556537983517138,"score_spread":0.3398575404213862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994441302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96655387,0.02254078,0.0103855925,0.00008092086,0.00016051049,0.0002112783,0.00001948522,0.000012209441,0.000035333684],"genre_scores_gemma":[0.97857237,0.009499889,0.011207764,0.0003767234,0.00024805326,0.000018901117,0.000046054847,0.000022104077,0.0000081713215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990316,0.00019750812,0.00020734058,0.00032624337,0.00006141877,0.00017590572],"domain_scores_gemma":[0.9995006,0.000061500315,0.00018656082,0.00007735711,0.000092776594,0.000081219325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024733003,0.00017687034,0.00027712746,0.00009920843,0.00007962969,0.00001356091,0.000055693738,0.00022861047,0.00003249654],"category_scores_gemma":[0.000010007812,0.00016333956,0.000031525025,0.00018988561,0.000103063365,0.000027999386,0.000020126921,0.00012311529,1.6041251e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006174037,0.00004119565,0.0009147404,0.00004257825,0.0003327049,7.6263086e-7,0.00044742908,0.00002503463,0.9943465,0.0001648716,0.00001951964,0.0030472495],"study_design_scores_gemma":[0.0018146813,0.0007229045,0.00083525555,0.000014745007,0.000120563025,0.0000142094295,0.00006400482,0.0034082916,0.99167067,0.00020696339,0.0009461206,0.0001815938],"about_ca_topic_score_codex":0.00004322847,"about_ca_topic_score_gemma":0.0000021595336,"teacher_disagreement_score":0.01304089,"about_ca_system_score_codex":0.0000072177645,"about_ca_system_score_gemma":0.000031466698,"threshold_uncertainty_score":0.66607934},"labels":[],"label_agreement":null},{"id":"W1994673341","doi":"10.1007/s00280-004-0939-2","title":"In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Geldanamycin; In vivo; Pharmacology; Derivative (finance); Chemistry; Hydrochloride; Medicine; Hsp90; Biochemistry; Biology; Heat shock protein","score_opus":0.015349046276918412,"score_gpt":0.31225544703291863,"score_spread":0.2969064007560002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994673341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880882,0.0067041335,0.00077407947,0.0023494351,0.00059422187,0.00053740246,0.00004117835,0.000018386036,0.00089295226],"genre_scores_gemma":[0.9738034,0.008319644,0.0008601285,0.009880979,0.0010076291,0.00016262758,0.000030713847,0.000068294394,0.0058666007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799067,0.00011082768,0.0004867015,0.0006541663,0.00015454795,0.00060305954],"domain_scores_gemma":[0.999264,0.000054004784,0.00016472001,0.0002797054,0.00009227814,0.0001452987],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003986567,0.00037053242,0.0005200423,0.00014923984,0.00008682558,0.000016149132,0.0003117037,0.00027727414,0.0016093075],"category_scores_gemma":[0.000006990603,0.00033446337,0.00013596949,0.00018136973,0.00022322062,0.000020639542,0.000113022135,0.00024496493,0.000002568181],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010767617,0.0002264973,0.00017617209,0.000041202016,0.00024821408,0.00000722655,0.0007934219,0.0003380749,0.97453713,0.00005003687,0.010295099,0.012210153],"study_design_scores_gemma":[0.003987168,0.00034151957,0.00016045675,0.000016747366,0.000047453475,0.000009982014,0.000043503085,0.00023026104,0.7116151,0.000105655694,0.28315485,0.00028732474],"about_ca_topic_score_codex":0.00019308906,"about_ca_topic_score_gemma":0.00032165193,"teacher_disagreement_score":0.27285975,"about_ca_system_score_codex":0.00007574702,"about_ca_system_score_gemma":0.00013974463,"threshold_uncertainty_score":0.9999107},"labels":[],"label_agreement":null},{"id":"W1995170617","doi":"10.1007/s00280-014-2481-1","title":"Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carboplatin; Medicine; Neutropenia; Etoposide; Topotecan; Internal medicine; Leukopenia; Pharmacology; Lung cancer; Docetaxel; Chemotherapy; Febrile neutropenia; Oncology; Gastroenterology; Cisplatin","score_opus":0.00965616637976602,"score_gpt":0.37579528785663024,"score_spread":0.3661391214768642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995170617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962011,0.0010799661,0.000045096986,0.0010683194,0.00007269747,0.0013405198,0.00002679206,0.000015222085,0.00015026599],"genre_scores_gemma":[0.9967143,0.001348495,0.00013553856,0.00088009366,0.000044461307,0.00075535243,0.000011633282,0.00002314253,0.000086969085],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991527,0.000058238933,0.00022268691,0.00026126014,0.00012366532,0.00018144403],"domain_scores_gemma":[0.99955094,0.000052565887,0.00014263399,0.00008512608,0.00011347875,0.000055253444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000078827296,0.00015997305,0.0004214112,0.00012730589,0.000036620633,0.000004093669,0.000041959047,0.000038274113,0.00016863881],"category_scores_gemma":[0.0000019655124,0.000111571775,0.00001361901,0.00025649584,0.000103795035,0.00008022543,0.0000053747904,0.00012781167,1.1837972e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06494449,0.014380892,0.4093632,0.0005466541,0.0013183,0.00006889826,0.110760085,0.00131343,0.019089157,0.000087514934,0.00028075866,0.3778466],"study_design_scores_gemma":[0.69546574,0.05215355,0.1456111,0.0016147044,0.00057212776,0.000015719548,0.012208731,0.0019407826,0.086627,0.00017522593,0.0030016645,0.00061365706],"about_ca_topic_score_codex":0.00081065204,"about_ca_topic_score_gemma":0.002493313,"teacher_disagreement_score":0.63052124,"about_ca_system_score_codex":0.00015483686,"about_ca_system_score_gemma":0.00018646824,"threshold_uncertainty_score":0.4549765},"labels":[],"label_agreement":null},{"id":"W1995389617","doi":"10.1007/s00280-002-0443-5","title":"Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute on Aging","keywords":"Fludarabine; Medicine; Toxicity; Creatinine; Internal medicine; Renal function; Gastroenterology; Chronic lymphocytic leukemia; Anemia; Neutropenia; Clinical endpoint; Interquartile range; Leukemia; Surgery; Cyclophosphamide; Chemotherapy; Clinical trial","score_opus":0.030700621468147726,"score_gpt":0.3453199439162757,"score_spread":0.31461932244812796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995389617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498564,0.0024812985,0.000013652905,0.00005326027,0.00006302207,0.002262051,0.00006524308,0.000033566863,0.000042255673],"genre_scores_gemma":[0.996933,0.0021883207,0.000061253995,0.00016204262,0.000017157508,0.0004001979,0.00004762402,0.000028664146,0.00016178392],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981207,0.0001294644,0.0006307546,0.0005280233,0.00019539004,0.0003956398],"domain_scores_gemma":[0.99889797,0.00031326036,0.00025698356,0.0002175351,0.00015956521,0.00015466429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018291379,0.00029243156,0.0012467336,0.00041654627,0.00004278144,0.000006358735,0.00011371808,0.00017783217,0.00045801152],"category_scores_gemma":[0.000058750393,0.00024086822,0.00011643263,0.0009529841,0.00041462784,0.000052553216,0.000043969216,0.0001435322,5.5240065e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021943603,0.003133655,0.91313297,0.0016827383,0.013504593,0.00015760052,0.0052606924,0.003989515,0.023885818,0.0000044554,0.00057507487,0.0127292955],"study_design_scores_gemma":[0.17516059,0.015281492,0.20447797,0.00032975405,0.0047912123,0.00002225296,0.00016587332,0.45783213,0.14150451,0.000009578984,0.000039461167,0.00038520072],"about_ca_topic_score_codex":0.002237302,"about_ca_topic_score_gemma":0.00015493932,"teacher_disagreement_score":0.708655,"about_ca_system_score_codex":0.011123573,"about_ca_system_score_gemma":0.0008504903,"threshold_uncertainty_score":0.99267256},"labels":[],"label_agreement":null},{"id":"W1995811281","doi":"10.1007/s00280-006-0362-y","title":"Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Neutropenia; Taxane; Internal medicine; Refractory (planetary science); Paclitaxel; Adverse effect; Toxicity; Pharmacology; Oncology; Chemotherapy; Gastroenterology; Cancer; Breast cancer","score_opus":0.01851690814974668,"score_gpt":0.37115694981906044,"score_spread":0.3526400416693138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995811281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932709,0.0026265795,0.000012882799,0.0016093956,0.0004171612,0.0011304581,0.000035309193,0.000029166757,0.00086816953],"genre_scores_gemma":[0.9941293,0.002438118,0.00016533748,0.0018305451,0.00037398844,0.00032152835,0.000030815416,0.000032362826,0.0006780299],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878424,0.000060481972,0.00034815044,0.00033556682,0.00011170511,0.00035987707],"domain_scores_gemma":[0.9995279,0.00005714828,0.00016178763,0.000097493285,0.000056503377,0.000099216275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010887034,0.00023023282,0.00064764713,0.00014688767,0.000035952155,0.0000038724274,0.00006264727,0.000097799064,0.0013736713],"category_scores_gemma":[0.0000012700667,0.00018210012,0.00006376583,0.00025743604,0.00022242007,0.000059664537,0.00001174051,0.00017707734,0.0000013400553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30043536,0.0039739036,0.006155975,0.00018467456,0.00030950148,0.00025255702,0.0003982103,0.00006760702,0.6464825,0.000049423234,0.00344119,0.03824908],"study_design_scores_gemma":[0.38800737,0.0070152213,0.0013897326,0.00006266072,0.00024216494,0.000048611724,0.00003147229,0.00013634123,0.5870528,0.00008162834,0.015736196,0.00019578627],"about_ca_topic_score_codex":0.00039035984,"about_ca_topic_score_gemma":0.00020586417,"teacher_disagreement_score":0.08757202,"about_ca_system_score_codex":0.00011817521,"about_ca_system_score_gemma":0.00026461948,"threshold_uncertainty_score":0.9995392},"labels":[],"label_agreement":null},{"id":"W1996081258","doi":"10.1007/s00280-008-0730-x","title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; BC Children's Hospital; Izaak Walton Killam Health Centre","funders":"","keywords":"Imatinib; Imatinib mesylate; Medicine; Pharmacokinetics; NONMEM; Tyrosine-kinase inhibitor; Pharmacology; Population; Myeloid leukemia; Internal medicine; Dosing; Metabolite; Oncology; Cancer","score_opus":0.01325244747741804,"score_gpt":0.30946617371609253,"score_spread":0.2962137262386745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996081258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97014207,0.028817927,0.0000015076596,0.0003141288,0.000105573985,0.00051332475,0.000035515317,0.000014315441,0.000055629265],"genre_scores_gemma":[0.9160732,0.082915045,0.00012154945,0.0006059517,0.00011360369,0.00003307601,0.000025944624,0.000016923646,0.00009469658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924475,0.000037022328,0.00022700844,0.00024061199,0.00007634031,0.00017427835],"domain_scores_gemma":[0.9996983,0.00002596359,0.000095915064,0.000054560347,0.000033928274,0.00009134495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006436807,0.00014735946,0.0003556052,0.00008713787,0.000036278805,0.0000019774582,0.000027456439,0.00007579589,0.00019651788],"category_scores_gemma":[0.000003826494,0.00013275184,0.000021239784,0.00010484841,0.00008748236,0.00006008479,0.000018505634,0.00012491693,3.819279e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001341229,0.00012275961,0.86044705,0.00018422873,0.00035338633,0.000015856262,0.0017876066,0.000007717843,0.10022319,0.000014349968,0.00018975548,0.035312884],"study_design_scores_gemma":[0.019075487,0.00012484717,0.8705437,0.000042658765,0.00016998503,0.00024787695,0.000008660484,0.0015615693,0.107788436,0.000016748438,0.00030391672,0.000116069525],"about_ca_topic_score_codex":0.0003577214,"about_ca_topic_score_gemma":0.000008901336,"teacher_disagreement_score":0.054097116,"about_ca_system_score_codex":0.00006782956,"about_ca_system_score_gemma":0.000051053372,"threshold_uncertainty_score":0.5413463},"labels":[],"label_agreement":null},{"id":"W1996145189","doi":"10.1007/s00280-008-0704-z","title":"Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acadia University; University of Alberta","funders":"","keywords":"Resveratrol; Cell cycle; Chemistry; Apoptosis; Tubulin; Cell cycle checkpoint; Cell culture; Viability assay; Western blot; MTT assay; Cell growth; Cell; Microtubule; Biochemistry; Cancer research; Biology; Cell biology; Gene; Genetics","score_opus":0.019522603895097933,"score_gpt":0.30264128342149405,"score_spread":0.28311867952639613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996145189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97679764,0.015298736,0.0022022456,0.0028216224,0.0016702304,0.00093505153,0.000094444404,0.00008077949,0.00009922182],"genre_scores_gemma":[0.96281886,0.02686707,0.00045050113,0.008075214,0.0013809206,0.00013507566,0.000049952814,0.000071410104,0.00015098223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975975,0.00023654579,0.00052352354,0.0006600296,0.0004214231,0.00056094077],"domain_scores_gemma":[0.9983753,0.0005367739,0.00023930747,0.00031221338,0.00012522716,0.00041116905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021174272,0.00049094605,0.001366028,0.00022258969,0.00018489482,0.0000080497275,0.00019424054,0.00029992685,0.0019571774],"category_scores_gemma":[0.000017371702,0.00036167222,0.0002481521,0.00024143166,0.0005026094,0.000077434845,0.000029510044,0.0006058686,0.0000025760585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022874586,0.00040846586,0.024242645,0.00032365794,0.0013486459,0.00036676388,0.0011799317,0.000011232966,0.9619311,0.000024012092,0.002638211,0.0052378867],"study_design_scores_gemma":[0.017550632,0.001326991,0.048816863,0.00017398236,0.0009848877,0.00015221866,0.000052356318,0.0015597063,0.9263748,0.00038872924,0.002263726,0.00035513152],"about_ca_topic_score_codex":0.00029777622,"about_ca_topic_score_gemma":0.000015575934,"teacher_disagreement_score":0.035556313,"about_ca_system_score_codex":0.00008924249,"about_ca_system_score_gemma":0.00015968853,"threshold_uncertainty_score":0.99988353},"labels":[],"label_agreement":null},{"id":"W1996697383","doi":"10.1007/s00280-006-0245-2","title":"A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Paclitaxel; Pharmacokinetics; Pharmacology; Medicine; Chemotherapy; Internal medicine","score_opus":0.0242078547080019,"score_gpt":0.3711345531872951,"score_spread":0.3469266984792932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996697383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915877,0.0030996385,0.001398433,0.0013493836,0.00017658134,0.002182192,0.000062111096,0.00002831503,0.000115626186],"genre_scores_gemma":[0.9960136,0.0010046335,0.00027939523,0.0012577577,0.00036056322,0.00072442624,0.000041803643,0.000022740693,0.00029511435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991786,0.000023314007,0.0002664954,0.0002760093,0.00006725169,0.00018835849],"domain_scores_gemma":[0.9995755,0.0000886194,0.00013728785,0.00006588481,0.00006691286,0.000065797736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088058725,0.00015763335,0.0003428139,0.000084730025,0.00007447029,0.0000036651816,0.000034019195,0.000066636654,0.00017277335],"category_scores_gemma":[9.298156e-7,0.00014206114,0.000041931613,0.00014335944,0.00006268979,0.000047479258,0.000012028669,0.00007262635,1.9111005e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065836934,0.0023420735,0.030315252,0.00022283132,0.0004142456,0.0000012599904,0.00076036446,0.00005205281,0.8920815,0.00012903148,0.0015868059,0.065510914],"study_design_scores_gemma":[0.20963706,0.008389143,0.16949408,0.00004680016,0.0037509347,0.000081486425,0.00038117584,0.02996518,0.4600111,0.00031743976,0.11720818,0.0007174171],"about_ca_topic_score_codex":0.0004254873,"about_ca_topic_score_gemma":0.00005474703,"teacher_disagreement_score":0.43207037,"about_ca_system_score_codex":0.000058631733,"about_ca_system_score_gemma":0.000049323746,"threshold_uncertainty_score":0.5793085},"labels":[],"label_agreement":null},{"id":"W1998295128","doi":"10.1007/s00280-009-0965-1","title":"Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ginseng Biological Effects and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; University of British Columbia Hospital; Vancouver General Hospital","funders":"Health Canada","keywords":"Biodistribution; Pharmacokinetics; Prostate cancer; In vivo; Medicine; Cancer; Prostate; Pharmacology; Distribution (mathematics); Oncology; Internal medicine; Biology; Mathematics","score_opus":0.04347664029488311,"score_gpt":0.4315106341974881,"score_spread":0.38803399390260496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998295128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944833,0.0027258233,0.00059130875,0.0008901396,0.00004967994,0.0010963149,0.00014209756,0.000005134944,0.000016235495],"genre_scores_gemma":[0.9925088,0.0061908658,0.00008502636,0.0006996351,0.00011124477,0.00030087002,0.00006692931,0.0000065953404,0.000030026758],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99910253,0.00007853052,0.0003010818,0.0002977465,0.0000541736,0.00016594087],"domain_scores_gemma":[0.99963605,0.00003084092,0.00011316509,0.00006778625,0.00010482313,0.00004735842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047041732,0.00011477018,0.00018730588,0.000037766564,0.000043429387,0.000005415592,0.00005861019,0.00014232285,0.000034730067],"category_scores_gemma":[0.000014284728,0.00010296762,0.000035855715,0.00007929859,0.000092696835,0.0000053395484,0.000012674254,0.000079886086,3.6858616e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005109787,0.00021418829,0.010198276,0.000028084534,0.000026942584,6.276497e-8,0.000122018195,0.003979396,0.9080779,0.000038317274,0.00047740413,0.076326415],"study_design_scores_gemma":[0.015161466,0.00079358625,0.13086174,0.00003931785,0.000109926674,8.608385e-7,0.000009988001,0.22935322,0.6177586,0.0012887142,0.0043376884,0.00028493826],"about_ca_topic_score_codex":0.000031869567,"about_ca_topic_score_gemma":0.000067073386,"teacher_disagreement_score":0.29031935,"about_ca_system_score_codex":0.000024634937,"about_ca_system_score_gemma":0.000063375264,"threshold_uncertainty_score":0.41988978},"labels":[],"label_agreement":null},{"id":"W1998502989","doi":"10.1007/s00280-009-1128-0","title":"N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Natural Science Foundation of Chongqing; National Natural Science Foundation of China","keywords":"Hepatocellular carcinoma; Metabolite; In vivo; Prodrug; Chemistry; Cell growth; Pharmacokinetics; Pharmacology; Microsome; In vitro; High-performance liquid chromatography; Fluorouracil; SN-38; Cell culture; Biochemistry; Cancer research; Medicine; Biology; Internal medicine; Chemotherapy; Chromatography; Cancer","score_opus":0.014703945578934166,"score_gpt":0.2976487523657712,"score_spread":0.28294480678683703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998502989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97751564,0.016639443,0.000028248198,0.0025974985,0.00012988763,0.0005764231,0.000016354728,0.000040714396,0.0024557698],"genre_scores_gemma":[0.9900585,0.004903374,0.00005576108,0.0035951436,0.00028947135,0.00006669991,0.00001434219,0.000022479859,0.0009942533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886143,0.00004422384,0.00028756156,0.0003413556,0.00013383999,0.0003315977],"domain_scores_gemma":[0.9993689,0.00003249185,0.00013500729,0.000119006356,0.00018036428,0.0001642249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007696468,0.00025161155,0.0005321403,0.00008873263,0.00014050264,0.0000055610326,0.00006740454,0.000109563654,0.00070280855],"category_scores_gemma":[0.0000029246182,0.00021424265,0.00010896698,0.00018135655,0.00015133333,0.00005338921,0.000020995041,0.00017343792,0.0000016348405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034077468,0.0008242298,0.074046806,0.00048859796,0.00033216912,0.00024368087,0.0021329408,0.0000018295021,0.87282175,0.00011510199,0.006789587,0.038795553],"study_design_scores_gemma":[0.010800761,0.002387348,0.02739198,0.00003165483,0.00037695648,0.000026808117,0.00012271231,0.0003413324,0.9528361,0.00029587478,0.005131997,0.00025648472],"about_ca_topic_score_codex":0.000294343,"about_ca_topic_score_gemma":0.000012975058,"teacher_disagreement_score":0.08001433,"about_ca_system_score_codex":0.00015970445,"about_ca_system_score_gemma":0.00011953201,"threshold_uncertainty_score":0.87365615},"labels":[],"label_agreement":null},{"id":"W1998912113","doi":"10.1007/s00280-015-2682-2","title":"Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; EMD Serono; National Institutes of Health","keywords":"Medicine; FOLFIRI; Cetuximab; Irinotecan; Colorectal cancer; Gastroenterology; Folinic acid; Neutropenia; Internal medicine; Adverse effect; Phases of clinical research; Chemotherapy; Pharmacology; Cancer","score_opus":0.04090778995048399,"score_gpt":0.3827514266994293,"score_spread":0.3418436367489453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998912113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867404,0.0047821603,0.00007175078,0.00042480035,0.00057817216,0.0052952603,0.00012254906,0.000027827346,0.000023446555],"genre_scores_gemma":[0.99496317,0.00044271504,0.00011944239,0.0007473579,0.000038242044,0.0029439696,0.00011012506,0.000059272003,0.00057569245],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99808156,0.00029713055,0.0005254671,0.0005172452,0.000086543216,0.0004920331],"domain_scores_gemma":[0.9989724,0.0001804783,0.0003685743,0.00017874145,0.00021080842,0.00008898966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034742794,0.00035913923,0.0008791726,0.00015782613,0.00014683271,0.00002587279,0.0003596565,0.00011010878,0.0002570889],"category_scores_gemma":[0.000026000833,0.00027510352,0.00005391911,0.00023969008,0.0001789327,0.000354758,0.000069450725,0.00020307949,0.0000012292019],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6641867,0.016512582,0.023145288,0.000358045,0.004482962,0.00004591086,0.019882701,0.00031136296,0.15354818,0.000016922746,0.0050145704,0.112494774],"study_design_scores_gemma":[0.7048811,0.014070245,0.0054213027,0.00021194643,0.00068528124,0.0000034168365,0.0018620825,0.00090332754,0.25936463,0.00005159717,0.011766044,0.0007790152],"about_ca_topic_score_codex":0.00019870173,"about_ca_topic_score_gemma":0.00022123143,"teacher_disagreement_score":0.111715764,"about_ca_system_score_codex":0.00029103944,"about_ca_system_score_gemma":0.00086832594,"threshold_uncertainty_score":0.99997014},"labels":[],"label_agreement":null},{"id":"W1998957272","doi":"10.1007/s00280-007-0557-x","title":"The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"PLGA; Conjugated system; Paclitaxel; Chemistry; Biophysics; Materials science; Cancer research; Pharmacology; In vitro; Medicine; Chemotherapy; Biochemistry; Surgery; Polymer; Biology; Organic chemistry","score_opus":0.01471589924344024,"score_gpt":0.31121599045389714,"score_spread":0.2965000912104569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998957272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612373,0.0020235388,0.00020200803,0.00030963199,0.0002776828,0.0009752895,0.00006703256,0.00001758212,0.0000034901036],"genre_scores_gemma":[0.9983507,0.0010006338,0.00004850964,0.00028636027,0.00011311836,0.000095765114,0.0000067640653,0.000014420008,0.00008374804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990146,0.00008665759,0.00040839324,0.0001905563,0.00007872573,0.00022105023],"domain_scores_gemma":[0.9989673,0.00038412688,0.00038978196,0.00008826274,0.00013573587,0.000034791738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008236816,0.00011157365,0.00021060927,0.000018242428,0.0002566097,0.000026101512,0.00011314738,0.000049978516,0.00007874536],"category_scores_gemma":[0.00001170424,0.000066509005,0.000024489244,0.00009060867,0.00035258484,0.000093930495,0.000020061309,0.000048871705,3.6617465e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018518432,0.000028511813,0.0013174227,0.00020033418,0.000034463817,6.007598e-7,0.0018691462,0.000020490956,0.9934628,0.000047599,0.00015293792,0.0010138515],"study_design_scores_gemma":[0.0016935195,0.0002115744,0.0010952564,0.000043826043,0.00004163899,0.0000048452953,0.00031689586,0.00036731156,0.99546593,0.000026041149,0.0006524102,0.00008075778],"about_ca_topic_score_codex":0.00005214596,"about_ca_topic_score_gemma":0.000016385127,"teacher_disagreement_score":0.0022269366,"about_ca_system_score_codex":0.000026517548,"about_ca_system_score_gemma":0.00006568271,"threshold_uncertainty_score":0.27121586},"labels":[],"label_agreement":null},{"id":"W2000578400","doi":"10.1007/s00280-004-0888-9","title":"Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer","year":2004,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Irinotecan; Oxaliplatin; Medicine; Capecitabine; Colorectal cancer; Oncology; Internal medicine; Chemotherapy; Fluorouracil; Clinical trial; Cancer","score_opus":0.11949839204300174,"score_gpt":0.4833830811872288,"score_spread":0.36388468914422706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000578400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009176742,0.98144716,0.000018726236,0.0016726966,0.0007716191,0.0057176165,0.001031143,0.000039269038,0.00012504235],"genre_scores_gemma":[0.0004828854,0.99252033,0.00025453212,0.0010762285,0.0005972677,0.0043822327,0.000117674754,0.000108161155,0.0004607007],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707633,0.00019947333,0.0013009068,0.00074705656,0.00019541694,0.0004807941],"domain_scores_gemma":[0.9976146,0.0007186471,0.0010627046,0.00015099614,0.00021667698,0.00023635008],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057010964,0.00075638725,0.00519493,0.0002026832,0.00015628648,0.000018152135,0.00011556408,0.0003063838,0.002566636],"category_scores_gemma":[0.000046967052,0.00054346526,0.00057022186,0.0002865484,0.0003645463,0.000053376563,0.000039089562,0.00032367336,9.703225e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070081945,0.0006027353,0.000006163775,0.012997086,0.007070833,0.00001884268,0.00078010117,8.0663773e-7,0.00096074,0.000021770942,0.0021069827,0.96842575],"study_design_scores_gemma":[0.038613442,0.0029154473,0.0000060906727,0.0031325677,0.0081323115,0.0000935914,0.00005229425,0.000010636675,0.008141601,0.000101335245,0.93835056,0.00045009682],"about_ca_topic_score_codex":0.00029046304,"about_ca_topic_score_gemma":0.00005483932,"teacher_disagreement_score":0.9679756,"about_ca_system_score_codex":0.00054816913,"about_ca_system_score_gemma":0.00146794,"threshold_uncertainty_score":0.9997017},"labels":[],"label_agreement":null},{"id":"W2002175782","doi":"10.1007/s00280-012-2001-0","title":"Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; European Commission","keywords":"Abiraterone acetate; Pharmacokinetics; Prednisone; Theophylline; Pharmacology; Medicine; Dextromethorphan; Prostate cancer; Bioequivalence; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.020446399794246364,"score_gpt":0.35373694292767893,"score_spread":0.3332905431334326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002175782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989307,0.00787573,0.0000042330416,0.001025096,0.00009425608,0.0015496227,0.000107006585,0.0000059400236,0.00003114098],"genre_scores_gemma":[0.9923405,0.006720202,0.0000646901,0.00032085337,0.000057068533,0.00032155827,0.000013249053,0.000024184565,0.0001376957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887425,0.00022014535,0.00024041375,0.00018548273,0.00018358382,0.00029612108],"domain_scores_gemma":[0.9993161,0.00024547122,0.00015067881,0.00009451381,0.00008786053,0.00010537332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038743607,0.00019218026,0.00043916976,0.00009501199,0.000041339976,0.0000047182707,0.00005216627,0.00003761063,0.00027620597],"category_scores_gemma":[0.0000052915193,0.00010209157,0.000027475688,0.00020997711,0.00032257772,0.000061277744,0.000016125137,0.00016856976,2.6331202e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075762376,0.0007347281,0.30625474,0.0017549649,0.0013153821,0.000008294079,0.0043410077,0.00011942245,0.5571453,0.000026695398,0.0002050628,0.05233203],"study_design_scores_gemma":[0.031245314,0.004344021,0.117303945,0.00018081514,0.00044626652,0.0000020726836,0.000048792346,0.00019715876,0.84576786,0.000011574688,0.00032218485,0.00013000103],"about_ca_topic_score_codex":0.000090144255,"about_ca_topic_score_gemma":0.00000987574,"teacher_disagreement_score":0.28862256,"about_ca_system_score_codex":0.00008121643,"about_ca_system_score_gemma":0.000097780605,"threshold_uncertainty_score":0.41631734},"labels":[],"label_agreement":null},{"id":"W2002606479","doi":"10.1007/s00280-012-2008-6","title":"Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Pemetrexed; Medicine; Sunitinib; Tolerability; Cisplatin; Lung cancer; Pharmacokinetics; Internal medicine; Mesothelioma; Oncology; Response Evaluation Criteria in Solid Tumors; Dosing; Pharmacology; Chemotherapy; Phases of clinical research; Cancer; Adverse effect; Pathology","score_opus":0.011945402496927991,"score_gpt":0.3474005889607801,"score_spread":0.3354551864638521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002606479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475807,0.0021393476,0.0000110521105,0.00012673788,0.000059070888,0.002737433,0.000081598984,0.0000127171825,0.00007397322],"genre_scores_gemma":[0.9971526,0.0015137666,0.00027339012,0.0003403189,0.000046451347,0.00053664343,0.00005079279,0.00003662674,0.000049364455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988368,0.000067574285,0.00028755766,0.00034577155,0.00013693262,0.0003253215],"domain_scores_gemma":[0.99933034,0.00006753194,0.00019277738,0.00009932302,0.000104231585,0.00020581325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015001485,0.0002612701,0.00049111753,0.00018602105,0.000060787126,0.000010124895,0.000031410615,0.000058308146,0.000036963866],"category_scores_gemma":[0.0000019146437,0.00018364082,0.000008739072,0.00029501322,0.0001521982,0.00021988743,0.0000139268095,0.00013389428,2.5159279e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028591279,0.0023682455,0.9383358,0.00022824803,0.0003508756,0.000009896334,0.009638016,0.00002850255,0.010027896,8.0352277e-7,0.000020465437,0.010399998],"study_design_scores_gemma":[0.14181995,0.0057389424,0.83607763,0.00018905681,0.0006761335,0.0000061642945,0.00064642663,0.0004902335,0.014094499,8.9990544e-7,0.00004418141,0.00021587129],"about_ca_topic_score_codex":0.0004186341,"about_ca_topic_score_gemma":0.00043504458,"teacher_disagreement_score":0.11322867,"about_ca_system_score_codex":0.00009134585,"about_ca_system_score_gemma":0.00011280746,"threshold_uncertainty_score":0.74886554},"labels":[],"label_agreement":null},{"id":"W2004891108","doi":"10.1007/s00280-012-1843-9","title":"A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Occupational Cancer Research Centre; BC Cancer Agency","funders":"","keywords":"Irinotecan; Capecitabine; Medicine; Bevacizumab; Internal medicine; Neutropenia; Clinical endpoint; Colorectal cancer; Adverse effect; Phases of clinical research; Gastroenterology; Oncology; Oxaliplatin; Surgery; Chemotherapy; Cancer; Clinical trial","score_opus":0.01766081404963258,"score_gpt":0.33735710684214626,"score_spread":0.31969629279251366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004891108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849195,0.009338519,7.416677e-7,0.00026668847,0.00013364053,0.0016195136,0.00004753042,0.000015468795,0.00008592654],"genre_scores_gemma":[0.9964969,0.002353578,0.000026719648,0.00035639308,0.00006847002,0.0005938541,0.000007946638,0.000022923145,0.00007318799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989936,0.000053701435,0.000238128,0.00025845226,0.00012557057,0.0003305948],"domain_scores_gemma":[0.99954766,0.000043472315,0.000114648945,0.00006636371,0.00009226005,0.00013558692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006885182,0.00022632205,0.0005850179,0.000101813624,0.000086509855,0.0000034422185,0.0000343496,0.00004069874,0.00040425683],"category_scores_gemma":[0.0000030168376,0.00015898072,0.000023681245,0.00022488789,0.00014080753,0.00008052081,0.000032180178,0.00012187412,1.7071775e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019084075,0.011590595,0.8338701,0.00016007159,0.0015590342,0.0000110305045,0.015332235,0.0000039380097,0.002924877,0.0000018708143,0.0001944229,0.115267746],"study_design_scores_gemma":[0.14021532,0.03509246,0.80734307,0.00009123639,0.0014014124,0.000009667937,0.00083339674,0.000055524357,0.012586788,0.0000037260575,0.0020571705,0.00031023502],"about_ca_topic_score_codex":0.00095500593,"about_ca_topic_score_gemma":0.0008088941,"teacher_disagreement_score":0.12113124,"about_ca_system_score_codex":0.000162759,"about_ca_system_score_gemma":0.000084310705,"threshold_uncertainty_score":0.6483045},"labels":[],"label_agreement":null},{"id":"W2005326402","doi":"10.1007/s00280-006-0201-1","title":"A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; University Health Network; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Rash; Nausea; Pharmacokinetics; Tolerability; Vomiting; Internal medicine; Toxicity; Refractory (planetary science); Cancer; Adverse effect; Neutropenia; Gastroenterology","score_opus":0.052890369095027284,"score_gpt":0.4238264113722936,"score_spread":0.3709360422772663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005326402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524325,0.00062397186,1.2686482e-7,0.0006319956,0.00028662928,0.0030973197,0.000072646464,0.0000027031529,0.00004138285],"genre_scores_gemma":[0.9988856,0.00012355113,0.000016669199,0.00035358235,0.0000973515,0.00046912412,0.000004638799,0.000009847039,0.000039642775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812204,0.00022650235,0.00091052003,0.00022805254,0.00037401123,0.00013888086],"domain_scores_gemma":[0.9987688,0.00018363028,0.0007125027,0.00009578802,0.00019546962,0.000043779488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037397523,0.000153738,0.00077321037,0.00006417129,0.000048324568,0.0000014524383,0.0001158029,0.000038809405,0.000056046425],"category_scores_gemma":[0.000045470744,0.0000877408,0.000052401392,0.00035105064,0.00026734205,0.000047708167,0.000036481604,0.00017791546,5.3840488e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082628755,0.014736522,0.9601232,0.00010098639,0.0005605746,0.0000017252403,0.003467135,0.00039040923,0.0004888366,0.0000034604327,0.0011308143,0.010733494],"study_design_scores_gemma":[0.061483,0.0040603494,0.930432,0.00017898128,0.00016743656,2.6726664e-7,0.00049767987,0.000031853815,0.0021999355,0.00002307558,0.00084692216,0.00007850629],"about_ca_topic_score_codex":0.103297606,"about_ca_topic_score_gemma":0.5461568,"teacher_disagreement_score":0.4428592,"about_ca_system_score_codex":0.00025561094,"about_ca_system_score_gemma":0.0014098142,"threshold_uncertainty_score":0.9026736},"labels":[],"label_agreement":null},{"id":"W2007098763","doi":"10.1007/s00280-008-0865-9","title":"Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Temsirolimus; Pharmacology; Desipramine; Pharmacokinetics; CYP2D6; Medicine; Drug interaction; CYP3A4; Metabolite; Internal medicine; Cytochrome P450; Chemistry; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Metabolism","score_opus":0.016624250316955975,"score_gpt":0.276635116532381,"score_spread":0.260010866215425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007098763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961328,0.0017822857,0.0009369135,0.00030250865,0.00012781657,0.00033346677,0.00008614784,0.00001636503,0.00028171984],"genre_scores_gemma":[0.99460804,0.0024907063,0.00042088956,0.001645951,0.00041674552,0.000086996304,0.00005671195,0.000038577135,0.00023540715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895453,0.00006513824,0.00021611723,0.00038621988,0.000100996294,0.00027701526],"domain_scores_gemma":[0.9994204,0.00002343314,0.00016454942,0.00015172607,0.00013609735,0.00010380819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007336233,0.00022289738,0.00029150367,0.00004421256,0.000094468545,0.000006421825,0.00011175236,0.000177223,0.00012997442],"category_scores_gemma":[0.0000023011398,0.00020278977,0.000050190243,0.00008248192,0.00055370154,0.000007700465,0.000022210259,0.00012321887,9.985907e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025637373,0.00009194271,0.0016268012,0.00005962449,0.00031467268,0.00003957808,0.0006777638,0.000056724402,0.9922478,0.000007699053,0.0008822801,0.001431382],"study_design_scores_gemma":[0.0031079904,0.001449536,0.008406306,0.000028012953,0.00006982927,0.00026863645,0.00004354958,0.00005029145,0.9820171,0.000023576065,0.0042785727,0.00025659037],"about_ca_topic_score_codex":0.00006648693,"about_ca_topic_score_gemma":0.00002879123,"teacher_disagreement_score":0.010230685,"about_ca_system_score_codex":0.000039477094,"about_ca_system_score_gemma":0.00022711439,"threshold_uncertainty_score":0.82695264},"labels":[],"label_agreement":null},{"id":"W2010348633","doi":"10.1007/s00280-003-0619-7","title":"Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Pharmacology; Pharmacokinetics; Etoposide; Chemistry; Medicine; Chemotherapy; Cancer; Internal medicine; Breast cancer","score_opus":0.01904655638343964,"score_gpt":0.31370586718684657,"score_spread":0.2946593108034069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010348633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510324,0.0025447586,0.000007440848,0.00082819356,0.00023207522,0.0008977928,0.000029522616,0.000028019922,0.00032896438],"genre_scores_gemma":[0.9883179,0.0065083,0.00009012189,0.0043031387,0.00013056108,0.00024193437,0.000020409729,0.000043285483,0.00034434506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986737,0.00012480908,0.00031437416,0.0003755457,0.00019447914,0.00031712168],"domain_scores_gemma":[0.99939394,0.000049287675,0.00013260807,0.00014566739,0.00012701703,0.00015148232],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014409791,0.00025055508,0.0006059285,0.00015173096,0.000047427722,0.0000065026684,0.000062885294,0.00018321443,0.0009917594],"category_scores_gemma":[0.00000807015,0.00020824996,0.00007485352,0.00036913934,0.00015730839,0.00007695379,0.000007595432,0.0002451785,0.0000014969505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027902494,0.0004955731,0.045821175,0.00013519038,0.0005097821,0.0000215223,0.0014528963,0.00005867594,0.94164103,0.00009492299,0.00031810038,0.0066608507],"study_design_scores_gemma":[0.020514268,0.00042323503,0.041038748,0.000102780665,0.00023692954,0.000013914819,0.00004994261,0.00001855283,0.93000656,0.000058213354,0.007335264,0.00020156686],"about_ca_topic_score_codex":0.0014987835,"about_ca_topic_score_gemma":0.0002516652,"teacher_disagreement_score":0.017724019,"about_ca_system_score_codex":0.00019130323,"about_ca_system_score_gemma":0.00026705736,"threshold_uncertainty_score":0.99992144},"labels":[],"label_agreement":null},{"id":"W2010805828","doi":"10.1007/s00280-010-1532-5","title":"Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Breast cancer; Regimen; Internal medicine; Odds ratio; Oncology; Logistic regression; Confidence interval; Chemotherapy; Hormonal therapy; Stage (stratigraphy); Univariate analysis; Multivariate analysis; Chemotherapy regimen; Adjuvant therapy; Cancer; Surgery","score_opus":0.006683265854655013,"score_gpt":0.2763086582364524,"score_spread":0.2696253923817974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010805828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896895,0.0074798046,0.0000035647565,0.0018463058,0.00039894076,0.00027033975,0.00022927429,0.000008224914,0.0000740165],"genre_scores_gemma":[0.95721525,0.038492214,0.00007284194,0.0036722058,0.00023807355,0.00022353075,0.000019936564,0.000026317917,0.000039630362],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909985,0.000033314627,0.00021522386,0.00035766754,0.00007827936,0.00021566515],"domain_scores_gemma":[0.9995497,0.000014504847,0.00016154387,0.00012864922,0.00006536073,0.000080267084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053769036,0.00021371184,0.00030965777,0.00004457674,0.00005249758,0.000005097587,0.00008089913,0.00012020739,0.0001007831],"category_scores_gemma":[0.0000020912098,0.0001708591,0.00003584849,0.000057909914,0.0002488215,0.000007490304,0.000059116464,0.00015099492,1.6558491e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021485907,0.0001672199,0.11377357,0.00004696931,0.00016590736,0.0000039959173,0.00071272027,0.0000088760935,0.8282781,0.0000052468213,0.0014738841,0.05321488],"study_design_scores_gemma":[0.0075674434,0.00035569552,0.30641672,0.00009322731,0.00007143484,0.000072694354,0.00008369874,0.0003290654,0.6705979,0.000079232515,0.013909713,0.00042313628],"about_ca_topic_score_codex":0.00013531427,"about_ca_topic_score_gemma":0.000035439694,"teacher_disagreement_score":0.19264315,"about_ca_system_score_codex":0.000027983247,"about_ca_system_score_gemma":0.00016367219,"threshold_uncertainty_score":0.6967432},"labels":[],"label_agreement":null},{"id":"W2010993787","doi":"10.1007/s00280-012-1867-1","title":"The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Temozolomide; Bevacizumab; Glioma; Medicine; U87; Glioblastoma; Oncology; Internal medicine; Cancer research; Pharmacology; Chemotherapy","score_opus":0.020777456025469033,"score_gpt":0.3745197170617356,"score_spread":0.35374226103626655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010993787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107546,0.0051535536,0.0000016323379,0.002650375,0.00025054105,0.00036268652,0.000016588612,0.000007916542,0.00048125448],"genre_scores_gemma":[0.9942696,0.0046338225,0.000015336675,0.00067107764,0.00027374658,0.00010482673,0.0000036802985,0.000009759522,0.000018126553],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993933,0.000042507163,0.00016044191,0.000101710204,0.000058523092,0.00024356047],"domain_scores_gemma":[0.9995704,0.00016640691,0.000061643186,0.000076597666,0.00002717871,0.000097728785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097227145,0.00010539751,0.00019927254,0.000045881177,0.00005992156,0.0000044156086,0.000036648387,0.000057758552,0.00049215526],"category_scores_gemma":[0.0000058562705,0.000062757375,0.00006522459,0.0001189436,0.00011517935,0.00003624224,0.000005877529,0.00010105448,0.0000027775382],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035072486,0.0013570213,0.5913208,0.000023993416,0.0006457501,0.000025341385,0.0014107715,0.00004860179,0.31992465,0.0005489056,0.0055637467,0.07562316],"study_design_scores_gemma":[0.015815021,0.0010471599,0.45841897,0.000043463544,0.00014218672,0.00006261172,0.000082304156,0.0003872939,0.5174892,0.00012043065,0.006252532,0.00013885272],"about_ca_topic_score_codex":0.0001766333,"about_ca_topic_score_gemma":0.000022159,"teacher_disagreement_score":0.19756453,"about_ca_system_score_codex":0.00013606218,"about_ca_system_score_gemma":0.00007880346,"threshold_uncertainty_score":0.5388755},"labels":[],"label_agreement":null},{"id":"W2011760818","doi":"10.1007/s00280-013-2126-9","title":"A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Carboplatin; Pharmacokinetics; Neutropenia; Pharmacodynamics; Rash; Febrile neutropenia; Adverse effect; Internal medicine; Nausea; Lung cancer; Gastroenterology; Mucositis; Pharmacology; Chemotherapy","score_opus":0.02949049664627675,"score_gpt":0.38000288019242273,"score_spread":0.350512383546146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011760818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98596174,0.0023817632,0.000098917924,0.0070984317,0.0004565202,0.0037519063,0.00009727211,0.000034578294,0.000118869764],"genre_scores_gemma":[0.9813123,0.008472497,0.00048831775,0.007647658,0.00023566069,0.0011670551,0.000021441792,0.000053449985,0.00060162426],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99811405,0.00016261986,0.00061118667,0.00046829728,0.00015928554,0.0004845791],"domain_scores_gemma":[0.9988238,0.00038619986,0.00022694595,0.00015398582,0.0001472213,0.00026185313],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021845305,0.00038956525,0.00084621366,0.00019901746,0.00007661087,0.000017054386,0.00014006102,0.00008263737,0.002958257],"category_scores_gemma":[0.00001206394,0.00024224349,0.00006754841,0.0004247466,0.00038572733,0.00012139835,0.000059312104,0.0003177695,0.000002841583],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20693201,0.0014452836,0.0008815503,0.00029962885,0.000949154,0.00008607486,0.0027745927,0.000081060294,0.626162,0.000006524559,0.0021165053,0.15826562],"study_design_scores_gemma":[0.53620195,0.017413348,0.0014585461,0.0002920993,0.0017511038,0.0002290285,0.0005350644,0.014352481,0.40668562,0.00008279611,0.020318987,0.0006789877],"about_ca_topic_score_codex":0.00020044533,"about_ca_topic_score_gemma":0.00015332772,"teacher_disagreement_score":0.32926995,"about_ca_system_score_codex":0.00012675031,"about_ca_system_score_gemma":0.00021109545,"threshold_uncertainty_score":0.9979532},"labels":[],"label_agreement":null},{"id":"W2014514137","doi":"10.1007/s00280-005-0155-8","title":"Antiproliferative and Antiproteolytic activity of Pentoxifylline in cultures of B16F10 Melanoma cells","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pentoxifylline; Chemistry; Matrix metalloproteinase; Pharmacology; Zymography; Extracellular matrix; MTT assay; Cell adhesion; Cell growth; In vitro; Cytotoxicity; Cell culture; Molecular biology; Cell; Biochemistry; Biology","score_opus":0.008637095251625556,"score_gpt":0.2991862646148014,"score_spread":0.2905491693631759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014514137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448586,0.004517229,0.00012490035,0.00039118627,0.000068989495,0.00027754236,0.000029098017,0.0000025486293,0.00010266613],"genre_scores_gemma":[0.9923203,0.006480115,0.00025412094,0.0006182565,0.00019532422,0.000030266097,0.0000035559133,0.000009316629,0.00008876698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99940896,0.000051729767,0.00015092039,0.00021112897,0.000045000048,0.00013225635],"domain_scores_gemma":[0.99974,0.000008610432,0.00010311378,0.00006890425,0.000037162303,0.000042230546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009529293,0.00011529408,0.00021353652,0.000035718847,0.000020086152,0.0000025181614,0.00005937714,0.000116833864,0.00009154],"category_scores_gemma":[0.0000026065113,0.00010106798,0.000030680087,0.00005098447,0.00012408642,0.000007516675,0.000030542116,0.00007776754,1.7833163e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059039413,0.000107283806,0.0013051349,0.00006399752,0.000056836823,7.53302e-7,0.0002035457,0.00001571389,0.991289,0.00001944696,0.00039700427,0.0059508984],"study_design_scores_gemma":[0.0019160989,0.00031807786,0.0006219948,0.000016056234,0.000014356717,0.0000031711922,0.000015216465,0.00021919663,0.9929401,0.000042350406,0.0037922084,0.000101158235],"about_ca_topic_score_codex":0.000027906359,"about_ca_topic_score_gemma":0.000020565209,"teacher_disagreement_score":0.0058497405,"about_ca_system_score_codex":0.000007359062,"about_ca_system_score_gemma":0.000043399163,"threshold_uncertainty_score":0.41214323},"labels":[],"label_agreement":null},{"id":"W2014573616","doi":"10.1007/s00280-004-0947-2","title":"Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Geldanamycin; Hsp90; Heat shock protein; Hsp90 inhibitor; Cancer research; Clonogenic assay; Melanoma; Chemistry; In vitro; Biology; Biochemistry","score_opus":0.028818357196587374,"score_gpt":0.3692101097795229,"score_spread":0.3403917525829355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014573616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754456,0.019406045,0.0006682864,0.0016606073,0.00009780348,0.0018568092,0.000035603567,0.000017224933,0.0008119624],"genre_scores_gemma":[0.98744774,0.005607067,0.0030452514,0.0019670546,0.00031550153,0.00059950934,0.000033116616,0.00006636816,0.000918411],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964458,0.0006907285,0.0007316305,0.0010486203,0.0002762869,0.0008069298],"domain_scores_gemma":[0.99882853,0.00025699995,0.00019449767,0.0003552357,0.0000916652,0.0002730782],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010995719,0.00050883007,0.00091520423,0.00037943633,0.00010125395,0.00002556546,0.00029306186,0.00057549786,0.000098123535],"category_scores_gemma":[0.000055550754,0.00050068676,0.00008523405,0.000315034,0.0003748718,0.00003036383,0.00020864178,0.0006927829,8.5777384e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015173028,0.00035628994,0.005791257,0.00026187842,0.00012854177,0.000014607893,0.0008633287,0.0006627151,0.8690757,0.000025204956,0.0012999489,0.120003186],"study_design_scores_gemma":[0.006294478,0.0012278386,0.0072495197,0.000087076245,0.000035248355,0.000010714959,0.00008108285,0.0070250174,0.9655852,0.00014527449,0.0117819095,0.00047668058],"about_ca_topic_score_codex":0.00029115324,"about_ca_topic_score_gemma":0.00055777724,"teacher_disagreement_score":0.119526505,"about_ca_system_score_codex":0.0001307637,"about_ca_system_score_gemma":0.00018495288,"threshold_uncertainty_score":0.9997445},"labels":[],"label_agreement":null},{"id":"W2015268376","doi":"10.1007/s00280-011-1679-8","title":"Hematologic adverse events associated with temozolomide","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pancytopenia; Medicine; Aplastic anemia; Internal medicine; Adverse effect; Myelodysplastic syndromes; Temozolomide; Bone marrow suppression; Bone marrow failure; Bone Marrow Aplasia; Pediatrics; Surgery; Bone marrow; Chemotherapy","score_opus":0.04505727237691332,"score_gpt":0.3367991244967081,"score_spread":0.2917418521197948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015268376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397427,0.0005966411,0.00004090991,0.0015302727,0.00012786391,0.00046264593,0.000009140301,0.000075490585,0.0031827693],"genre_scores_gemma":[0.98821145,0.0016076519,0.0003321323,0.007707133,0.00010393457,0.0001295887,0.000009264375,0.00003092448,0.001867901],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990463,0.00006731513,0.00014485828,0.0002775349,0.00011230941,0.00035168338],"domain_scores_gemma":[0.9994866,0.000063335705,0.00007814155,0.00010876489,0.00008506885,0.00017805281],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001475893,0.00015968172,0.00032526292,0.00007200646,0.000069147085,0.0000011402755,0.000091240705,0.00014217455,0.004272687],"category_scores_gemma":[0.0000118544385,0.00011593175,0.000040719304,0.00017886514,0.00020335653,0.000052699193,0.000024966088,0.000294448,0.000016586073],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015983934,0.0011842354,0.6831054,0.00032398658,0.003527963,0.00095264416,0.0046907905,0.000004272806,0.23741141,0.00016310379,0.03670296,0.015949314],"study_design_scores_gemma":[0.042560056,0.002463751,0.2502774,0.00020974311,0.0006864476,0.00052212685,0.0003752033,0.00065450586,0.6783331,0.0005569374,0.022641065,0.00071968074],"about_ca_topic_score_codex":0.00006589649,"about_ca_topic_score_gemma":0.0000128850315,"teacher_disagreement_score":0.4409217,"about_ca_system_score_codex":0.00020197242,"about_ca_system_score_gemma":0.00022535463,"threshold_uncertainty_score":0.9966375},"labels":[],"label_agreement":null},{"id":"W2016501792","doi":"10.1007/s002800050037","title":"Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G 2 arrest","year":2000,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Camptothecin; Cytotoxicity; Cancer research; Pharmacology; Breast cancer; Chemistry; Medicine; Cancer; Internal medicine; In vitro; Biochemistry","score_opus":0.009885625366621123,"score_gpt":0.28713966258694773,"score_spread":0.2772540372203266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016501792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974724,0.0013113667,0.0001063046,0.00036804748,0.00017591604,0.00029364828,0.00008335934,0.0000035811415,0.00018538756],"genre_scores_gemma":[0.98162556,0.016689476,0.000078171135,0.0011272049,0.00017024014,0.00011102133,0.000009425133,0.000020960264,0.00016796796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991671,0.000039738738,0.00022528284,0.00027877736,0.000085748856,0.00020334971],"domain_scores_gemma":[0.9996265,0.000008251473,0.00013062458,0.00012491389,0.000055317574,0.000054388962],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000089365494,0.0001572527,0.00024185634,0.00004072364,0.00002645445,0.0000032695157,0.00010460367,0.000113186514,0.0018357177],"category_scores_gemma":[2.2274808e-7,0.00014024576,0.000039263206,0.00011063175,0.00009825035,0.0000051930656,0.0000123766695,0.00008038632,4.0801305e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018166295,0.00015392368,0.00092777435,0.00006420042,0.00013688076,7.6784596e-7,0.0002643237,0.00014688708,0.9666252,0.000009183863,0.00012362211,0.029730564],"study_design_scores_gemma":[0.0029423814,0.00034489483,0.001403012,0.000041916777,0.000034892142,0.0000030042875,0.00003166551,0.000083954015,0.99027723,0.0000251043,0.0046582553,0.00015368211],"about_ca_topic_score_codex":0.00044644973,"about_ca_topic_score_gemma":0.00029934084,"teacher_disagreement_score":0.029576883,"about_ca_system_score_codex":0.000037381753,"about_ca_system_score_gemma":0.00013833283,"threshold_uncertainty_score":0.9990767},"labels":[],"label_agreement":null},{"id":"W2016651596","doi":"10.1007/s00280-010-1499-2","title":"The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Docetaxel; Paclitaxel; Ex vivo; In vivo; Micelle; Pharmacology; Chemistry; Pharmacokinetics; Cancer research; Chemotherapy; Medicine; Internal medicine; Biology; Biotechnology","score_opus":0.01197922883307866,"score_gpt":0.3274978254427914,"score_spread":0.3155185966097127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016651596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744426,0.01714009,0.00005798685,0.006154137,0.0006145563,0.00042468848,0.000070462025,0.000021474698,0.0010739792],"genre_scores_gemma":[0.98520947,0.00903765,0.00052360696,0.0029149326,0.000562302,0.00007379906,0.00001152357,0.000026764268,0.001639938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992219,0.000018922208,0.00023332587,0.00023715156,0.000088230096,0.00020047366],"domain_scores_gemma":[0.99945223,0.00010628922,0.00009607691,0.00015543263,0.000056913243,0.00013302767],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000067566965,0.0001642916,0.0002778057,0.000037462418,0.0001614218,0.000010386244,0.00006902509,0.00010446429,0.0025090124],"category_scores_gemma":[0.0000044216204,0.000112640984,0.00004123612,0.000100652105,0.00027450157,0.000052117255,0.00002139376,0.00019078053,0.000002444493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006758059,0.00010107187,0.0055287452,0.000030530555,0.00042630557,0.0000033906326,0.0014024113,3.5541848e-7,0.86156493,0.00007328178,0.003431407,0.1267618],"study_design_scores_gemma":[0.0077990065,0.00037816862,0.025394646,0.000016238686,0.00042540408,0.00002029864,0.00014823524,0.00014279726,0.67985976,0.0011221503,0.28453118,0.00016215864],"about_ca_topic_score_codex":0.0009543549,"about_ca_topic_score_gemma":0.00020266356,"teacher_disagreement_score":0.28109977,"about_ca_system_score_codex":0.000017591343,"about_ca_system_score_gemma":0.000109546374,"threshold_uncertainty_score":0.99840283},"labels":[],"label_agreement":null},{"id":"W2017811988","doi":"10.1007/s00280-008-0743-5","title":"A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Tolerability; Pharmacokinetics; Perfusion; Urology; Extracorporeal; Internal medicine; Chemotherapy; Cancer; Adverse effect","score_opus":0.020385617590590877,"score_gpt":0.3470636198025388,"score_spread":0.3266780022119479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017811988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99342686,0.004321935,0.000013696028,0.0003274318,0.00006137597,0.0017450299,0.000024779212,0.000016115486,0.000062768675],"genre_scores_gemma":[0.98622936,0.012051395,0.00040296416,0.0005174974,0.00008412559,0.0004464233,0.000008780874,0.00003395149,0.00022550696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984625,0.000119821976,0.00032672714,0.00044196026,0.00027402813,0.00037498382],"domain_scores_gemma":[0.9991715,0.000153755,0.00016433523,0.00014075635,0.0001734921,0.00019618547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001480151,0.0002685651,0.0008402566,0.00019888251,0.00010811399,0.0000033406502,0.000075225245,0.00008344294,0.000714659],"category_scores_gemma":[0.000007182064,0.00018224017,0.000022298482,0.00028034853,0.00045950888,0.00008972055,0.000027649869,0.0002926475,4.700183e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035217848,0.004876472,0.8555147,0.00023332793,0.00040529482,0.00012986029,0.0035965005,0.00003323446,0.05482939,4.5020803e-7,0.00010674179,0.045056205],"study_design_scores_gemma":[0.1572756,0.02247047,0.8058365,0.00029319854,0.000793192,0.000061519866,0.0005003784,0.0019524732,0.009887475,0.0000031021846,0.0006078005,0.00031827835],"about_ca_topic_score_codex":0.00027303366,"about_ca_topic_score_gemma":0.000066052795,"teacher_disagreement_score":0.12205774,"about_ca_system_score_codex":0.00012015145,"about_ca_system_score_gemma":0.0003485254,"threshold_uncertainty_score":0.7825015},"labels":[],"label_agreement":null},{"id":"W2017908039","doi":"10.1007/s00280-013-2176-z","title":"Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Topotecan; Mitoxantrone; Doxorubicin; Pharmacology; Medicine; Distribution (mathematics); Anticancer drug; Chemotherapy; Drug; Cancer research; Internal medicine","score_opus":0.005373125667298539,"score_gpt":0.2637172799360422,"score_spread":0.2583441542687437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017908039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98863924,0.008842516,0.000056822708,0.0019399696,0.00017440693,0.00026453563,0.000029206893,0.0000029332593,0.000050387323],"genre_scores_gemma":[0.9838212,0.0141615495,0.000025328116,0.001632466,0.00014620993,0.000059510396,0.0000074638983,0.000010558517,0.00013572583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993906,0.000035833666,0.0001371942,0.00021005541,0.000049884587,0.0001764012],"domain_scores_gemma":[0.9997571,0.000010390986,0.00006436428,0.00008458957,0.000033596825,0.00004992189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007527759,0.00011095331,0.00015402248,0.000016221615,0.000049770068,0.0000095214755,0.000069786525,0.00008338394,0.00010307049],"category_scores_gemma":[0.0000017023903,0.00008805541,0.00002129576,0.0000580242,0.00021852495,0.0000061574133,0.0000535942,0.00008085974,1.5478604e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118455726,0.000024471174,0.003866632,0.00003605322,0.000044445085,2.3826303e-7,0.00027034138,0.0000044130943,0.9431092,0.000109902976,0.00045546723,0.051960353],"study_design_scores_gemma":[0.001682295,0.00014286242,0.022429401,0.000019036155,0.000023383112,0.000006461629,0.00009784398,0.00012608532,0.95074016,0.00031936952,0.024287278,0.00012580895],"about_ca_topic_score_codex":0.00036761377,"about_ca_topic_score_gemma":0.00006884333,"teacher_disagreement_score":0.051834542,"about_ca_system_score_codex":0.0000143983025,"about_ca_system_score_gemma":0.000041576244,"threshold_uncertainty_score":0.35907954},"labels":[],"label_agreement":null},{"id":"W2018133817","doi":"10.1007/s00280-010-1442-6","title":"Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Cancer research; Apoptosis; Biology; CHOP; Cell growth; Growth inhibition; Lymphoma; Immunology; Biochemistry","score_opus":0.009250837476188,"score_gpt":0.2699156145872909,"score_spread":0.2606647771111029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018133817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899449,0.003314857,0.000006765789,0.004065798,0.00051426835,0.0010735409,0.00014938536,0.00006890804,0.0008615744],"genre_scores_gemma":[0.98506016,0.0031033258,0.00037587815,0.009176986,0.00053348107,0.00058941485,0.000017099997,0.00006394636,0.0010796862],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983287,0.00003914438,0.00027547215,0.0006654414,0.0001712119,0.0005200569],"domain_scores_gemma":[0.99903095,0.00007139285,0.0001406005,0.0002834317,0.00009181168,0.0003818016],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013522431,0.00036628207,0.0005154849,0.00010676017,0.00018193971,0.000031583848,0.00011011069,0.00029427488,0.0012264907],"category_scores_gemma":[0.0000043676837,0.0003073248,0.00010634432,0.000144413,0.00018600158,0.00010662138,0.00006115724,0.00020241254,0.000010132307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007895248,0.0057404744,0.015606177,0.0003510749,0.00026863493,0.000016811344,0.0010427982,8.642529e-8,0.9574952,0.000095673975,0.0143865375,0.0042070127],"study_design_scores_gemma":[0.05403436,0.00031906096,0.014268279,0.0000357028,0.00029714778,0.000028201039,0.000042916872,0.00010454016,0.89241326,0.00005746331,0.03810905,0.00029004933],"about_ca_topic_score_codex":0.00020906812,"about_ca_topic_score_gemma":0.000014853895,"teacher_disagreement_score":0.06508196,"about_ca_system_score_codex":0.00009720737,"about_ca_system_score_gemma":0.00018270747,"threshold_uncertainty_score":0.9999379},"labels":[],"label_agreement":null},{"id":"W2018801391","doi":"10.1007/s00280-010-1512-9","title":"Metastatic gastrointestinal stromal tumors","year":2010,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Stromal cell; Medicine; GiST; Cancer research; Pathology; Internal medicine; Oncology","score_opus":0.07303234549703767,"score_gpt":0.43347715911941015,"score_spread":0.36044481362237246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018801391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012439956,0.9962476,0.00002317772,0.00045573738,0.0001792555,0.0013236413,0.0001043981,0.0000625914,0.00035959337],"genre_scores_gemma":[0.00008193678,0.99445826,0.0027001204,0.00048688264,0.00061612384,0.0005589896,0.00008381288,0.000087793174,0.00092609884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980782,0.00011899186,0.0004248389,0.0005501742,0.00019708528,0.000630685],"domain_scores_gemma":[0.9987513,0.00019824774,0.00022594845,0.00019729555,0.000085756474,0.00054146134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015492419,0.00053411786,0.001719445,0.00019246955,0.00008936958,0.000023060375,0.00014683022,0.00007966116,0.0031039272],"category_scores_gemma":[0.000022783994,0.00038609814,0.00034166698,0.00018689295,0.0003246998,0.000035502395,0.000048514798,0.0012328443,0.000042645916],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028653548,0.00029808117,0.00023828424,0.010140363,0.0004765502,0.0015688834,0.00001607484,7.2055826e-8,0.0004956363,0.000022823311,0.0019135602,0.98454314],"study_design_scores_gemma":[0.002687636,0.0015413283,0.000056777175,0.0056485864,0.001876924,0.01620452,0.0000073183887,0.0000128999645,0.00021894662,0.000025640054,0.97145796,0.00026145513],"about_ca_topic_score_codex":0.000030166164,"about_ca_topic_score_gemma":0.0000047284243,"teacher_disagreement_score":0.98428166,"about_ca_system_score_codex":0.00015082437,"about_ca_system_score_gemma":0.0009234283,"threshold_uncertainty_score":0.9998591},"labels":[],"label_agreement":null},{"id":"W2020299781","doi":"10.1007/s00280-011-1671-3","title":"PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Aldose Reductase and Taurine","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Neutropenia; Internal medicine; Gastroenterology; Discontinuation; Liver function; Cohort; Pharmacokinetics; Pharmacology; Oncology; Toxicity","score_opus":0.011152513875904433,"score_gpt":0.24495265218455115,"score_spread":0.2338001383086467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020299781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964617,0.0025739789,0.000033279848,0.00006941525,0.00016254904,0.00032780351,0.000018272802,0.000008287645,0.00034470842],"genre_scores_gemma":[0.997036,0.0012843123,0.00013908846,0.001063206,0.00016441876,0.0000904471,0.000052748877,0.00002659661,0.00014317382],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921936,0.000031406216,0.00012728435,0.0003210127,0.00005253066,0.00024839953],"domain_scores_gemma":[0.9996944,0.0000032110677,0.00006023863,0.000121097415,0.000042983196,0.00007805042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039456398,0.00016454904,0.00017235508,0.000036112437,0.00003876729,0.0000032920993,0.000095347226,0.000101046964,0.000247193],"category_scores_gemma":[9.582012e-7,0.00014118371,0.000026555856,0.00007325562,0.00010595745,0.000006448364,0.00002991798,0.000091862275,0.0000016013839],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004454075,0.0002975085,0.68906844,0.00005732453,0.00017831422,0.000021282762,0.0006510415,0.000010488001,0.2946434,0.000021792815,0.0010551518,0.009541161],"study_design_scores_gemma":[0.0100889485,0.00073220977,0.06831817,0.000009173106,0.000032442218,0.0000037393575,0.000030871157,0.000043375458,0.90034896,0.000026792037,0.020071479,0.0002938223],"about_ca_topic_score_codex":0.000048180955,"about_ca_topic_score_gemma":0.000011318231,"teacher_disagreement_score":0.62075025,"about_ca_system_score_codex":0.000025028095,"about_ca_system_score_gemma":0.00008931247,"threshold_uncertainty_score":0.5757305},"labels":[],"label_agreement":null},{"id":"W2020371671","doi":"10.1007/s00280-013-2229-3","title":"Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Gefitinib; Paclitaxel; Epidermal growth factor receptor; Cancer research; Chemotherapy; Medicine; Pharmacology; Cell cycle; Cancer; Oncology; Biology; Internal medicine","score_opus":0.0884284157506157,"score_gpt":0.4195852517613815,"score_spread":0.3311568360107658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020371671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989235,0.004632916,0.000052182793,0.0038667405,0.00017719311,0.001833012,0.0001657636,0.000010749641,0.000026471955],"genre_scores_gemma":[0.9891379,0.007698632,0.00085423177,0.0008853473,0.00038462578,0.00082554005,0.0000085088195,0.000029583938,0.00017565393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893075,0.00006343981,0.00028794634,0.0003102724,0.00013109724,0.0002765019],"domain_scores_gemma":[0.99920774,0.00019769714,0.00015520777,0.000114489405,0.00016106112,0.00016383246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012883541,0.00017289919,0.0004165431,0.00007248528,0.00010001848,0.0000138646865,0.000054143544,0.00010283623,0.00080162205],"category_scores_gemma":[0.000009144609,0.000121998884,0.000053143278,0.00008260964,0.00023762022,0.00007351711,0.000027085542,0.00009589298,3.3093846e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075340056,0.00009641114,0.038402975,0.00047558232,0.0002166799,5.716975e-7,0.00368598,0.000019248013,0.9278444,0.000015948293,0.0015919807,0.0268968],"study_design_scores_gemma":[0.004474232,0.0011614854,0.018257622,0.00012106008,0.000083741295,0.0000035863732,0.00025642203,0.00032345107,0.970789,0.00004121214,0.0043633236,0.0001248485],"about_ca_topic_score_codex":0.0014040421,"about_ca_topic_score_gemma":0.000024350773,"teacher_disagreement_score":0.04294459,"about_ca_system_score_codex":0.000100067715,"about_ca_system_score_gemma":0.00008511997,"threshold_uncertainty_score":0.87771994},"labels":[],"label_agreement":null},{"id":"W2020714490","doi":"10.1007/s00280-010-1410-1","title":"A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Howard Hughes Medical Institute; Sidney Kimmel Comprehensive Cancer Center; National Center for Research Resources; Alvin J. Siteman Cancer Center; Johns Hopkins University","keywords":"Irinotecan; Medicine; Pharmacokinetics; Pharmacodynamics; Internal medicine; Gastroenterology; Pharmacology; Urology; Colorectal cancer; Cancer","score_opus":0.008558402501655257,"score_gpt":0.29609063095178156,"score_spread":0.2875322284501263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020714490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990065,0.00013603641,0.000026525218,0.00009745232,0.00011800505,0.00056324934,0.00001849717,0.000003589945,0.000030116145],"genre_scores_gemma":[0.9990645,0.00012852196,0.000055507895,0.0005241321,0.000039901308,0.00012972191,0.00001202085,0.000019728448,0.000025942536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992753,0.00003413251,0.00016759305,0.0002606762,0.00008168695,0.00018058233],"domain_scores_gemma":[0.9996666,0.000006657042,0.000103584825,0.000116506126,0.00006523902,0.000041445794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009540615,0.0001340587,0.00019628982,0.000071497016,0.00002695782,0.000005690259,0.00008743886,0.000059572514,0.0000538872],"category_scores_gemma":[0.0000010974613,0.00010917392,0.000012583473,0.00012049006,0.00008302246,0.0000050591457,0.000017707087,0.00012469303,6.6441004e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070441435,0.0029748918,0.025879927,0.000028737342,0.00007688352,0.000004990529,0.0007718176,0.00001935517,0.9575663,0.000022661248,0.000023899587,0.0055863447],"study_design_scores_gemma":[0.048996285,0.012686424,0.04122927,0.000025683696,0.000036592257,0.000001875634,0.0002709686,0.000048112728,0.89386207,0.000043667198,0.0025541312,0.00024490224],"about_ca_topic_score_codex":0.00014455711,"about_ca_topic_score_gemma":0.0021810129,"teacher_disagreement_score":0.06370426,"about_ca_system_score_codex":0.000018372417,"about_ca_system_score_gemma":0.00008945196,"threshold_uncertainty_score":0.4451983},"labels":[],"label_agreement":null},{"id":"W2021381932","doi":"10.1007/s00280-006-0224-7","title":"Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Ottawa","keywords":"A549 cell; Gene silencing; RNA interference; Cisplatin; Doxorubicin; Cancer research; Transfection; Biology; MTT assay; Flow cytometry; Cell; Molecular biology; Cell culture; Chemistry; Chemotherapy; RNA; Gene; Biochemistry","score_opus":0.006711336621092121,"score_gpt":0.268401795022745,"score_spread":0.2616904584016529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021381932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95041853,0.047343247,0.00012116358,0.0007082717,0.0005044517,0.00046990864,0.00014697197,0.000007397586,0.00028007696],"genre_scores_gemma":[0.97488797,0.01805606,0.00034382512,0.004201457,0.00092865876,0.00017188324,0.000023185861,0.000040460436,0.0013464844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859303,0.000050378003,0.00034146706,0.0005478874,0.00008673862,0.00038052094],"domain_scores_gemma":[0.9994797,0.000021821563,0.00015290632,0.00015543925,0.00007426382,0.0001158361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013967653,0.0002561856,0.0003764367,0.000091358335,0.00006399755,0.000011122232,0.00012712923,0.00021515622,0.00013954891],"category_scores_gemma":[0.0000028521126,0.00026889177,0.000051248797,0.00022330527,0.00007914025,0.0000075374837,0.00005226086,0.00014491967,3.1724278e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048331587,0.000060600407,0.002881376,0.00013196666,0.00004585646,0.000001160428,0.0004606077,0.000040863742,0.95328057,0.0000020457774,0.039252847,0.003358766],"study_design_scores_gemma":[0.0034943484,0.00007978429,0.0039054102,0.000040506995,0.000051656236,0.00000176398,0.000040524515,0.000093018774,0.95254296,0.000014651658,0.039448656,0.0002867082],"about_ca_topic_score_codex":0.0011920065,"about_ca_topic_score_gemma":0.0009486551,"teacher_disagreement_score":0.029287186,"about_ca_system_score_codex":0.00004207188,"about_ca_system_score_gemma":0.0001290946,"threshold_uncertainty_score":0.99997634},"labels":[],"label_agreement":null},{"id":"W2023396498","doi":"10.1007/s00280-006-0244-3","title":"Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Deutsche Forschungsgemeinschaft; Broad Institute","keywords":"Mitoxantrone; Daunorubicin; P-glycoprotein; Pharmacology; Efflux; Cytotoxicity; Multiple drug resistance; Abcg2; ATP-binding cassette transporter; Chemistry; Potency; In vitro; Transporter; Biology; Biochemistry; Chemotherapy; Immunology; Leukemia; Antibiotics","score_opus":0.012653364079430508,"score_gpt":0.2511435030696107,"score_spread":0.23849013899018018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023396498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98321706,0.00523754,0.002920908,0.006509843,0.0003670378,0.000700246,0.000023720468,0.00015388854,0.0008697318],"genre_scores_gemma":[0.989091,0.00039630974,0.0030338333,0.0024201653,0.00075748895,0.00013217046,0.000022188666,0.00007063013,0.004076213],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984798,0.000022746724,0.00032697993,0.0004865131,0.00022044333,0.0004635212],"domain_scores_gemma":[0.9994727,0.000029414845,0.00013326333,0.00016037078,0.00007345149,0.00013079621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011701165,0.0003179171,0.00044873403,0.000107035936,0.00017388912,0.000016143103,0.00008614137,0.00014707776,0.00025350152],"category_scores_gemma":[0.000001592828,0.00023482289,0.000075922726,0.00023769701,0.00028082315,0.000080252554,0.0000074001964,0.00029914774,0.0000013438136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027163539,0.00032560193,0.0047035436,0.00043505454,0.00011866147,0.000041175063,0.00029651233,0.00066220073,0.9882132,0.00007562505,0.00060513173,0.001806944],"study_design_scores_gemma":[0.010716646,0.00020937136,0.0062261457,0.0003098446,0.00015414663,0.000016668706,0.00006578202,0.0036916363,0.95917255,0.00006419702,0.01899069,0.00038231042],"about_ca_topic_score_codex":0.00023341802,"about_ca_topic_score_gemma":0.0005143017,"teacher_disagreement_score":0.029040635,"about_ca_system_score_codex":0.000108360546,"about_ca_system_score_gemma":0.00016431222,"threshold_uncertainty_score":0.95758},"labels":[],"label_agreement":null},{"id":"W2026686575","doi":"10.1007/s00280-004-0828-8","title":"Ascorbate modulation of H2O2 and camptothecin-induced cell death in Jurkat cells","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Vitamin C and Antioxidants Research","field":"Nursing","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Cancer Research Society","keywords":"Jurkat cells; Apoptosis; Programmed cell death; Camptothecin; Necrosis; Intracellular; Biology; Lactate dehydrogenase; Ascorbic acid; Molecular biology; Biochemistry; Immunology; T cell; Enzyme","score_opus":0.026227356420781778,"score_gpt":0.34263332505016486,"score_spread":0.3164059686293831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026686575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967187,0.0010678886,0.000051199273,0.0012591367,0.00034051255,0.0002497758,0.000009073369,0.000012080608,0.00029162748],"genre_scores_gemma":[0.9961096,0.0024900783,0.0001248368,0.0010088608,0.00010869131,0.000016224436,0.0000013772973,0.000018592436,0.000121741905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992231,0.000053475473,0.00017276176,0.00023048157,0.00008329977,0.00023688858],"domain_scores_gemma":[0.99971867,0.000047842703,0.00006606644,0.000064575346,0.00003915674,0.000063663894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012474132,0.000116850584,0.00020827772,0.00010362018,0.000049578746,0.000009421307,0.00006624732,0.00009585886,0.00019885725],"category_scores_gemma":[0.000001869635,0.00010922403,0.000023964532,0.00012952057,0.0000757575,0.000080823105,0.000015226644,0.00015499815,0.0000016034619],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003409444,0.00009573489,0.0051710424,0.00012005609,0.000014658198,0.000003574979,0.0011128788,0.00018922919,0.97441673,0.000015787771,0.00010201766,0.018417329],"study_design_scores_gemma":[0.0045451424,0.00018080165,0.020949882,0.000039009126,0.000011687933,0.0000026131963,0.00004976162,0.0006232917,0.9722633,0.00044308603,0.0007744243,0.00011700722],"about_ca_topic_score_codex":0.00033570654,"about_ca_topic_score_gemma":0.000032844328,"teacher_disagreement_score":0.018300321,"about_ca_system_score_codex":0.000065320186,"about_ca_system_score_gemma":0.000039591443,"threshold_uncertainty_score":0.44540265},"labels":[],"label_agreement":null},{"id":"W2026761112","doi":"10.1007/s002800050044","title":"N , N -diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE), a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs","year":2000,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Medical Research Council Canada; Research Manitoba; Manitoba Health Research Council; Bristol-Myers Squibb","keywords":"Cytochrome P450; CYP3A4; Chemistry; Isozyme; Microsome; Pharmacology; Glucuronidation; Metabolism; Biochemistry; In vitro; Enzyme; Biology","score_opus":0.048768260185246576,"score_gpt":0.36296607132866276,"score_spread":0.31419781114341616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026761112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97351646,0.023850903,0.00009650943,0.00073210686,0.0004063754,0.0008031748,0.00006701543,0.00004689898,0.00048055765],"genre_scores_gemma":[0.977368,0.015814489,0.00014098565,0.0021288267,0.00022857507,0.00018686,0.000023387998,0.000054317392,0.0040545627],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970667,0.00085738656,0.00075288117,0.0007718196,0.00006033881,0.0004909127],"domain_scores_gemma":[0.9985842,0.0007059266,0.0004166449,0.00015572026,0.000045939818,0.0000915578],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012788881,0.0004226736,0.0011624031,0.00015463846,0.00021203092,0.000025980213,0.00011107381,0.000360495,0.0075971186],"category_scores_gemma":[0.000036759848,0.00033513666,0.0000966111,0.00016373678,0.0006785328,0.00012123177,0.00006639357,0.00061864447,0.000011784432],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009592905,0.00036550217,0.0076574427,0.00023340058,0.0011525861,0.00002276357,0.004745436,0.000018936276,0.763901,0.000027253911,0.0006957385,0.21158707],"study_design_scores_gemma":[0.06391365,0.0029204837,0.078431144,0.0004303632,0.0014132207,0.00052319746,0.002170739,0.0010377128,0.40981933,0.00016941948,0.43725437,0.0019163874],"about_ca_topic_score_codex":0.00067429297,"about_ca_topic_score_gemma":0.00051510136,"teacher_disagreement_score":0.43655863,"about_ca_system_score_codex":0.00009379385,"about_ca_system_score_gemma":0.00005673994,"threshold_uncertainty_score":0.99991006},"labels":[],"label_agreement":null},{"id":"W2026772196","doi":"10.1007/s00280-008-0739-1","title":"Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cytotoxicity; Nucleoside transporter; Human kidney; Fludarabine; Transporter; Nucleoside; Proximal tubule; Human cell; Cell culture; Pharmacology; Kidney; Cancer research; Hematopoietic cell; Chemistry; Biology; Cell biology; Biochemistry; Medicine; Internal medicine; Gene; Endocrinology; Genetics; Chemotherapy; In vitro; Stem cell","score_opus":0.013442763202349479,"score_gpt":0.30197691392643766,"score_spread":0.28853415072408817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026772196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532974,0.00399253,0.000044757802,0.00015676038,0.000026031346,0.00027995167,0.000050935385,0.0000051547277,0.00011411469],"genre_scores_gemma":[0.99716365,0.0015589779,0.00007531512,0.00086349074,0.00013449322,0.00004279966,0.000021544705,0.000013929883,0.00012576694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906677,0.000045422654,0.00027759385,0.00034395614,0.000058694244,0.00020756724],"domain_scores_gemma":[0.9997078,0.000006251815,0.00009398572,0.00008181483,0.00003923296,0.00007089836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007626287,0.00017343166,0.00027245283,0.000025452506,0.000096707794,0.0000027074777,0.000079068595,0.00014296289,0.00032805878],"category_scores_gemma":[5.8741404e-7,0.00015404756,0.000055912216,0.000052345407,0.000368681,0.0000075050098,0.000009445816,0.00012687426,6.371224e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031938448,0.00014567081,0.051417258,0.0000772422,0.000043639408,0.000016572265,0.0020444891,0.000010830003,0.9445654,0.0000050934545,0.0012706493,0.00008373086],"study_design_scores_gemma":[0.0030758095,0.00036516838,0.038412955,0.000014463352,0.000029375142,0.000012971993,0.000043471526,0.00001865831,0.95608693,0.000032354183,0.0017365761,0.00017128883],"about_ca_topic_score_codex":0.00012941987,"about_ca_topic_score_gemma":0.0000365773,"teacher_disagreement_score":0.013004306,"about_ca_system_score_codex":0.000010542559,"about_ca_system_score_gemma":0.000049494738,"threshold_uncertainty_score":0.6281878},"labels":[],"label_agreement":null},{"id":"W2028767751","doi":"10.1007/s00280-011-1771-0","title":"A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Institutes of Health; Eisai","keywords":"Bexarotene; Vinorelbine; Cisplatin; Pharmacology; Pharmacokinetics; Lung cancer; Medicine; Chemotherapy; Oncology; Internal medicine; Chemistry; Biochemistry","score_opus":0.007263555608815975,"score_gpt":0.27197506356176077,"score_spread":0.2647115079529448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028767751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447477,0.004164238,0.0001321882,0.000019595076,0.00007559864,0.0009213027,0.000017246906,0.0000061792025,0.00018885311],"genre_scores_gemma":[0.99596524,0.002926459,0.00025177604,0.00034543817,0.00006677247,0.0003139703,0.000012887462,0.000037277798,0.000080189355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989442,0.00004871577,0.00022208809,0.00044321184,0.00008770989,0.0002540411],"domain_scores_gemma":[0.99950355,0.000010228134,0.00016556094,0.00012844536,0.00010479292,0.00008741456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006646296,0.00024562323,0.00029058065,0.000059464975,0.00004591655,0.0000049823025,0.00012908404,0.00009146017,0.00014788352],"category_scores_gemma":[0.0000011148444,0.0001911736,0.0000170642,0.00014198295,0.00014235756,0.0000094373545,0.000040884697,0.00013907166,8.1715655e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084740175,0.0020920339,0.36294922,0.00029071167,0.0002786776,0.000009384564,0.0020963042,0.00009366029,0.60626876,4.6748215e-7,0.00008346315,0.017363299],"study_design_scores_gemma":[0.051500116,0.006084507,0.025658008,0.00006276439,0.0002069641,0.000002582886,0.00019823344,0.00018286378,0.9154883,0.0000027003953,0.0002740983,0.00033887278],"about_ca_topic_score_codex":0.000112979986,"about_ca_topic_score_gemma":0.000057373232,"teacher_disagreement_score":0.3372912,"about_ca_system_score_codex":0.000018993025,"about_ca_system_score_gemma":0.00011477528,"threshold_uncertainty_score":0.77958333},"labels":[],"label_agreement":null},{"id":"W2028849325","doi":"10.1007/s00280-011-1755-0","title":"A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Medicine; Pemetrexed; Sunitinib; Neutropenia; Lung cancer; Internal medicine; Dosing; Pharmacokinetics; Adverse effect; Febrile neutropenia; Oncology; Cancer; Pharmacology; Chemotherapy; Cisplatin","score_opus":0.015190002316557639,"score_gpt":0.34029376063834094,"score_spread":0.3251037583217833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028849325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99622023,0.00059478,0.000022158194,0.000037920083,0.000057536152,0.0029295438,0.000018555587,0.00001078981,0.00010849097],"genre_scores_gemma":[0.99766374,0.0007789098,0.00020113817,0.00026133205,0.000018240687,0.0009795344,0.00003930339,0.000030720457,0.000027093734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898493,0.00006636066,0.00026003292,0.0003178274,0.00012467298,0.00024618435],"domain_scores_gemma":[0.9995104,0.0000250657,0.00016206449,0.000087144144,0.00011755494,0.00009778462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008962817,0.00020535066,0.0003996191,0.00024203006,0.000030465038,0.0000042844713,0.000040534065,0.000050908522,0.00011037223],"category_scores_gemma":[8.097374e-7,0.00015238288,0.000008462026,0.00039339502,0.000080343714,0.00017788196,0.000007722773,0.00014145854,3.6108265e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013350127,0.00815731,0.9459618,0.00016444316,0.00019040852,0.000018562983,0.015441299,0.00010646142,0.0049114786,8.565023e-7,0.0000062372415,0.011691023],"study_design_scores_gemma":[0.13037066,0.0071716816,0.8446384,0.00017838925,0.0003331726,0.0000015699543,0.00089072704,0.0006483273,0.01558876,0.0000018691211,0.000008496211,0.00016794998],"about_ca_topic_score_codex":0.0013979945,"about_ca_topic_score_gemma":0.0020350623,"teacher_disagreement_score":0.11702053,"about_ca_system_score_codex":0.0001762983,"about_ca_system_score_gemma":0.00015546664,"threshold_uncertainty_score":0.6213994},"labels":[],"label_agreement":null},{"id":"W2030098953","doi":"10.1007/s00280-006-0225-6","title":"Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Decitabine; Deoxycytidine; Histone deacetylase inhibitor; Chemistry; Cancer research; Histone deacetylase; Pharmacology; Azacitidine; Histone; Medicine; Internal medicine; Chemotherapy; DNA methylation; Biochemistry; DNA","score_opus":0.011365571777535558,"score_gpt":0.3456122280967449,"score_spread":0.33424665631920936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030098953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99753803,0.0013531678,0.000064249405,0.00009263811,0.0003993198,0.00023603918,0.00006509123,0.0000065271374,0.00024491537],"genre_scores_gemma":[0.9983631,0.00059892057,0.000019018531,0.00010627884,0.00060052273,0.000024996394,0.000052152376,0.000025625564,0.00020942427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991007,0.00010756607,0.00024644742,0.00028547223,0.000093152754,0.000166653],"domain_scores_gemma":[0.9995076,0.00006201427,0.00018981706,0.00012901712,0.00006270982,0.000048808302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015293295,0.00018411009,0.00026023597,0.00007443597,0.000053056596,0.0000033571034,0.00006910222,0.00015240307,0.0000801705],"category_scores_gemma":[0.0000038657013,0.00016629064,0.00007542291,0.000076329416,0.00011877759,0.0000029573073,0.000016316153,0.000091783186,9.864626e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015450638,0.00031501552,0.0019565446,0.00014466583,0.000044956007,0.0000012398327,0.0000196771,0.00026903563,0.99021024,0.000014497311,0.00095122744,0.004527867],"study_design_scores_gemma":[0.005505969,0.00234967,0.0041478816,0.000021175872,0.000049424987,0.0000022303718,0.0000024170347,0.00006524437,0.9856571,0.000013914015,0.0020462293,0.00013874123],"about_ca_topic_score_codex":0.000089999165,"about_ca_topic_score_gemma":0.000014294977,"teacher_disagreement_score":0.0045531075,"about_ca_system_score_codex":0.000027944508,"about_ca_system_score_gemma":0.000032510296,"threshold_uncertainty_score":0.6781136},"labels":[],"label_agreement":null},{"id":"W2031710547","doi":"10.1007/s00280-011-1796-4","title":"Going past the data for temozolomide","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Temozolomide; Medicine; Adjuvant; Oncology; Radiation therapy; Internal medicine; Clinical trial; Adjuvant therapy; Glioblastoma; Randomized controlled trial; Cancer; Cancer research","score_opus":0.11105953602588882,"score_gpt":0.3787718905292375,"score_spread":0.2677123545033487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031710547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742192,0.008473523,0.000126716,0.0140806185,0.00059920864,0.0010122394,0.000104678686,0.000037205755,0.0013465855],"genre_scores_gemma":[0.9791315,0.004558421,0.0006205669,0.01440242,0.00064732344,0.0003571283,0.000030442572,0.000020529162,0.00023163242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994773,0.000015895319,0.00009655371,0.0002133163,0.00003458295,0.00016233315],"domain_scores_gemma":[0.99957275,0.00009150055,0.000041539282,0.00020804373,0.000025485086,0.00006066972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010154402,0.00009120361,0.00015420336,0.000019218913,0.000087401924,0.000004836819,0.000113444454,0.000041358657,0.000821946],"category_scores_gemma":[0.0000031911889,0.000054845295,0.00003036358,0.000045608533,0.00008617387,0.00003468768,0.00003129714,0.00006029612,0.000004029642],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037980494,0.00097550306,0.13720563,0.00024404547,0.0021738722,0.000056527988,0.0026205305,0.0000012100026,0.15832834,0.0006586448,0.3912082,0.30272943],"study_design_scores_gemma":[0.009038966,0.00036512682,0.019220471,0.000025952335,0.0005220427,0.000050908788,0.00007120072,0.00053405145,0.2283646,0.0002545755,0.74141836,0.00013376537],"about_ca_topic_score_codex":0.000034314333,"about_ca_topic_score_gemma":0.00000963058,"teacher_disagreement_score":0.35021013,"about_ca_system_score_codex":0.000020056663,"about_ca_system_score_gemma":0.000034983666,"threshold_uncertainty_score":0.8999733},"labels":[],"label_agreement":null},{"id":"W2032395096","doi":"10.1007/s00280-013-2237-3","title":"A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Novartis Pharmaceuticals Corporation","keywords":"Panobinostat; Medicine; Pharmacology; Active metabolite; Metabolite; CYP2D6; Pharmacokinetics; Internal medicine; Chemistry; Biochemistry","score_opus":0.008480293005227362,"score_gpt":0.3258972695176337,"score_spread":0.31741697651240636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032395096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982661,0.00074194866,0.0000018115196,0.00012510698,0.00016803308,0.00062789174,0.000026055099,0.0000032593737,0.000039812527],"genre_scores_gemma":[0.9979616,0.00124966,0.000026573693,0.00037120632,0.000099575416,0.00020586234,0.000023780209,0.000019125013,0.00004263392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893934,0.00020234915,0.0002856468,0.00028070537,0.00010894957,0.00018300647],"domain_scores_gemma":[0.99946404,0.00006415539,0.00015794829,0.0001112417,0.0001230575,0.00007958235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016764402,0.00013776662,0.00027266095,0.00006113519,0.00001883791,0.0000023877446,0.00008014676,0.00013874832,0.00011425869],"category_scores_gemma":[0.000010410325,0.000109915665,0.000039147264,0.00010663209,0.0003479204,0.000007990477,0.000018617635,0.00015580734,0.0000010136254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020866878,0.000066362736,0.35726002,0.000086336746,0.000059050195,3.7929476e-7,0.00008267515,0.00006312863,0.6275129,5.5569046e-7,0.0008474077,0.01193452],"study_design_scores_gemma":[0.005776572,0.0022430862,0.14264227,0.00005287327,0.000011249671,1.4282597e-7,0.000006017002,0.000017971666,0.848777,0.000003171316,0.0003737108,0.00009594935],"about_ca_topic_score_codex":0.000120149816,"about_ca_topic_score_gemma":0.00003840641,"teacher_disagreement_score":0.2212641,"about_ca_system_score_codex":0.000032032505,"about_ca_system_score_gemma":0.00012444519,"threshold_uncertainty_score":0.44822305},"labels":[],"label_agreement":null},{"id":"W2034826891","doi":"10.1007/s00280-013-2078-0","title":"An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Heart, Lung, and Blood Institute; Georgia Cancer Coalition; Health Canada; National Institute on Aging; Aflac; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health","keywords":"Bortezomib; In vivo; Protein kinase B; PI3K/AKT/mTOR pathway; Angiogenesis; Proteasome inhibitor; Phosphoinositide 3-kinase; Cancer research; Medicine; Pharmacology; Multiple myeloma; Biology; Immunology; Signal transduction; Cell biology","score_opus":0.013212464662288427,"score_gpt":0.2847992486588463,"score_spread":0.2715867839965579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034826891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348044,0.003576613,0.00019035459,0.0009990956,0.00087666046,0.00058720366,0.000072083596,0.000041204476,0.00017633317],"genre_scores_gemma":[0.99016416,0.002754069,0.00023589587,0.0050941603,0.0009838785,0.00047613654,0.000036186924,0.000063270345,0.00019224008],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981972,0.00013334124,0.00028385717,0.00069776917,0.00011816379,0.00056965195],"domain_scores_gemma":[0.9992069,0.000041687206,0.00013941326,0.00029104218,0.00010742962,0.00021351832],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016879049,0.00036449375,0.00034164812,0.0000817446,0.00013694528,0.000054490694,0.00028521134,0.0003594826,0.0009720444],"category_scores_gemma":[0.000013153324,0.00036055196,0.000089800546,0.00015556687,0.00036185794,0.000039979175,0.000070234244,0.00034145123,0.000008828296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006039325,0.00016688772,0.014410138,0.00003973485,0.0000972749,0.000008435149,0.00026335468,0.0001085758,0.9178061,0.0000022180743,0.008261505,0.058231883],"study_design_scores_gemma":[0.0033188132,0.00038795028,0.006690207,0.000024812132,0.000016578188,0.0000061931,0.000053869935,0.0010155168,0.9346609,0.00003647347,0.053367548,0.0004211141],"about_ca_topic_score_codex":0.00077692064,"about_ca_topic_score_gemma":0.00035556918,"teacher_disagreement_score":0.05781077,"about_ca_system_score_codex":0.00013033909,"about_ca_system_score_gemma":0.00022043649,"threshold_uncertainty_score":0.99994123},"labels":[],"label_agreement":null},{"id":"W2035008632","doi":"10.1007/s00280-009-1182-7","title":"Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Sulforaphane; Cancer cell; Cancer research; Cytotoxic T cell; Biology; Cancer; Cell culture; Pharmacology; Biochemistry; In vitro; Genetics","score_opus":0.010332737099755804,"score_gpt":0.30223571200281507,"score_spread":0.2919029749030593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035008632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98378265,0.0137839755,0.000015740234,0.001127172,0.00009077678,0.000629574,0.00016845074,0.000013986083,0.00038770164],"genre_scores_gemma":[0.9872056,0.005726817,0.00025460141,0.005699705,0.00027792098,0.00018964788,0.00010340818,0.000038221868,0.0005040713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813807,0.00019456378,0.0004052002,0.00068320945,0.00008766615,0.00049127004],"domain_scores_gemma":[0.9993451,0.000034903973,0.00018954682,0.00019403774,0.000082332204,0.00015404333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018432102,0.00034899687,0.00042731027,0.00009316676,0.00010152905,0.000019051065,0.00025099862,0.00021580196,0.000059905862],"category_scores_gemma":[0.000008122178,0.00036735297,0.00006841132,0.0001874821,0.0001563916,0.000013976996,0.000060103022,0.00023739086,6.412907e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001324194,0.00025088168,0.002682641,0.00005544488,0.000049813454,0.000012585574,0.0021385348,0.00027138248,0.9909316,0.0000136569,0.0008710799,0.0013981994],"study_design_scores_gemma":[0.0043419013,0.00018661674,0.009242931,0.000057147994,0.00002134868,9.1768607e-7,0.0002729584,0.000037846337,0.9826415,0.0006355634,0.0021499274,0.00041129388],"about_ca_topic_score_codex":0.0009265631,"about_ca_topic_score_gemma":0.003110483,"teacher_disagreement_score":0.008290038,"about_ca_system_score_codex":0.0001640971,"about_ca_system_score_gemma":0.00011832792,"threshold_uncertainty_score":0.99987787},"labels":[],"label_agreement":null},{"id":"W2035597050","doi":"10.1007/s00280-014-2535-4","title":"Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Daunorubicin; Pharmacogenomics; Pharmacokinetics; Medicine; Oncology; Biopharmaceutics; Internal medicine; Pharmacology; Chemotherapy; Pharmacognosy; Genetics; Biology","score_opus":0.011274481276181707,"score_gpt":0.3070790529990172,"score_spread":0.29580457172283553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035597050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893917,0.00524906,0.000157811,0.0042014685,0.00028579778,0.0008226141,0.00004767663,0.000026427306,0.00027000153],"genre_scores_gemma":[0.9674819,0.017444074,0.00024502902,0.013634322,0.00098496,0.00007294324,0.00006551038,0.00003485563,0.000036379763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985758,0.00016889337,0.00043182683,0.0004275708,0.00012459361,0.0002713311],"domain_scores_gemma":[0.99918586,0.00022361455,0.00023286015,0.00018172504,0.00004873398,0.00012722496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043094918,0.00023271887,0.0005511796,0.000078101824,0.000069149944,0.000008375626,0.00011560605,0.00019193057,0.0002809811],"category_scores_gemma":[0.000012859179,0.0001895438,0.000082174105,0.0001655504,0.00034823618,0.00005282214,0.000040297637,0.00041320873,7.1816123e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006736109,0.00014903887,0.15041883,0.000023089518,0.0004347063,0.0000076525985,0.0007006935,0.000011499085,0.75069284,0.000020328469,0.0013173741,0.09555034],"study_design_scores_gemma":[0.013184422,0.0002835391,0.20004946,0.00004044689,0.00037153048,0.00042667313,0.000040895517,0.00045017747,0.7653227,0.00018266523,0.019432446,0.00021505532],"about_ca_topic_score_codex":0.0004707592,"about_ca_topic_score_gemma":0.00003095921,"teacher_disagreement_score":0.09533529,"about_ca_system_score_codex":0.00009643201,"about_ca_system_score_gemma":0.00009806212,"threshold_uncertainty_score":0.7729372},"labels":[],"label_agreement":null},{"id":"W2035613220","doi":"10.1007/s00280-001-0395-1","title":"The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Tirapazamine; Quinone; Chemistry; Moiety; Benzoquinone; Enzyme; Stereochemistry; Mitomycin C; Cytotoxicity; Pharmacology; Biochemistry; Combinatorial chemistry; In vitro; Medicine","score_opus":0.05966073775841671,"score_gpt":0.40343111872770565,"score_spread":0.3437703809692889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035613220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994012,0.0022375283,0.000039670198,0.0016100438,0.0013228693,0.00042161174,0.000056363315,0.000015410635,0.00028452283],"genre_scores_gemma":[0.98625946,0.012376946,0.000004337386,0.0006443343,0.00030916743,0.0000830934,0.000017717926,0.000016007343,0.000288906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879736,0.00034901497,0.00024284708,0.0002774499,0.000105535866,0.00022779962],"domain_scores_gemma":[0.9991532,0.00036257214,0.00023941771,0.0000764851,0.00007248976,0.000095854215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035575073,0.00019688455,0.00026926448,0.000070653085,0.00023489674,0.0000072752323,0.00009213911,0.00017391425,0.0005512468],"category_scores_gemma":[0.000009256101,0.00014550514,0.00005844548,0.00017683672,0.0006879511,0.00008852671,0.000025306968,0.00030837048,0.000001274798],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008073665,0.0002165411,0.014718908,0.000064812906,0.00049794087,0.0000016879878,0.00037956293,0.000046536952,0.89796776,0.00008697046,0.018749781,0.059195843],"study_design_scores_gemma":[0.004390244,0.0009276569,0.009764044,0.000017637263,0.00013612007,0.000016608097,0.00009232218,0.00031457184,0.93520784,0.000105754785,0.04888299,0.00014421913],"about_ca_topic_score_codex":0.000029641935,"about_ca_topic_score_gemma":0.0000011054054,"teacher_disagreement_score":0.059051625,"about_ca_system_score_codex":0.000051423867,"about_ca_system_score_gemma":0.000028195183,"threshold_uncertainty_score":0.6035766},"labels":[],"label_agreement":null},{"id":"W2036337218","doi":"10.1007/s00280-004-0850-x","title":"A 150-kDa glycoprotein isolated from Solanum nigrum L. has cytotoxic and apoptotic effects by inhibiting the effects of protein kinase C alpha, nuclear factor-kappa B and inducible nitric oxide in HCT-116 cells","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Phytochemical Studies and Bioactivities","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Chonnam National University","keywords":"Cytotoxic T cell; Apoptosis; Solanum nigrum; Nitric oxide; Chemistry; Molecular biology; Cytotoxicity; Tumor necrosis factor alpha; Biochemistry; Alpha (finance); Kinase; Glycoprotein; Biology; Pharmacology; Immunology; In vitro; Medicine; Endocrinology; Botany","score_opus":0.005917512531633621,"score_gpt":0.22933492527757068,"score_spread":0.22341741274593707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036337218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826897,0.015596755,0.000029404115,0.00058841,0.00006761578,0.00095691124,0.000047850248,0.000011196802,0.000012182105],"genre_scores_gemma":[0.993907,0.004601476,0.00004892452,0.0010871221,0.00013171959,0.0001607881,0.000009617051,0.000028751456,0.000024650695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988326,0.00009272293,0.0002093821,0.00044647924,0.000076727825,0.00034211413],"domain_scores_gemma":[0.99955684,0.000090958136,0.0001327556,0.00010426209,0.000024120978,0.00009103538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007862303,0.00026656038,0.00034461456,0.000039401195,0.00014233876,0.000026873442,0.00010746681,0.00022241124,0.000017301574],"category_scores_gemma":[0.000018191213,0.00020757178,0.000042801574,0.00012794617,0.00037407162,0.000012344993,0.0001162712,0.00023951086,3.5732486e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005555552,0.00011104446,0.00031877792,0.00028651825,0.00015954793,0.000006319584,0.00032258368,0.0000016725206,0.99482,0.000001684201,0.00025970035,0.0031566117],"study_design_scores_gemma":[0.0043593547,0.00045733846,0.0006973052,0.00012855673,0.000032824286,0.00000341942,0.00008197542,0.000023218137,0.99270284,0.00013776621,0.0011348709,0.00024055083],"about_ca_topic_score_codex":0.0006638508,"about_ca_topic_score_gemma":0.00003305442,"teacher_disagreement_score":0.011217276,"about_ca_system_score_codex":0.00003684418,"about_ca_system_score_gemma":0.000045274453,"threshold_uncertainty_score":0.84645313},"labels":[],"label_agreement":null},{"id":"W2038893680","doi":"10.1007/s00280-009-1096-4","title":"UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neonatal Health and Biochemistry","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Bilirubin; Unconjugated hyperbilirubinemia; Internal medicine; Gastroenterology; Cirrhosis; Glucuronosyltransferase; Doxorubicin; Pharmacology; Chemotherapy; Chemistry; Biochemistry; Microsome","score_opus":0.010973269801906781,"score_gpt":0.3202515898681827,"score_spread":0.3092783200662759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038893680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683991,0.01518364,0.000001037745,0.015277172,0.00012555471,0.00029148097,0.000008849433,0.000020622743,0.0006925167],"genre_scores_gemma":[0.9574042,0.011031881,0.00007420215,0.030815842,0.0002220042,0.000029504245,0.0000061862875,0.000008976519,0.0004071979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923694,0.000019003819,0.00017357194,0.00025780944,0.000060621118,0.00025207328],"domain_scores_gemma":[0.99964166,0.000025465224,0.00004463006,0.00006809749,0.00002293798,0.00019719587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055373635,0.00013044308,0.00025421724,0.000045462853,0.00004245811,0.0000037622601,0.000031150514,0.00012358057,0.0004250597],"category_scores_gemma":[0.00000330949,0.00011212465,0.000022083961,0.000098424374,0.00008933335,0.000027095468,0.0000085667325,0.00020948723,0.000001009188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021922553,0.00012089111,0.004004469,0.00015463843,0.00001971323,0.00007389464,0.00075907365,3.3882083e-7,0.6130951,0.000004930804,0.00333547,0.3762392],"study_design_scores_gemma":[0.014148776,0.0011497327,0.032845493,0.00017314123,0.000055767283,0.00028552554,0.00017046036,0.00023012019,0.8938954,0.00027717077,0.056447867,0.00032056065],"about_ca_topic_score_codex":0.00007712391,"about_ca_topic_score_gemma":0.0000057739967,"teacher_disagreement_score":0.37591866,"about_ca_system_score_codex":0.000060513084,"about_ca_system_score_gemma":0.00010338704,"threshold_uncertainty_score":0.46541056},"labels":[],"label_agreement":null},{"id":"W2040107189","doi":"10.1007/s00280-004-0843-9","title":"Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGF?-RII, KRAS2, TP53 and/or CDNK2A","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital; McGill University Health Centre; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Cancer research; Radiosensitivity; Ovarian cancer; Biology; Cancer; Cell culture; Oncology; Internal medicine; Medicine; Pathology; Radiation therapy; Genetics","score_opus":0.02130002559684653,"score_gpt":0.3164080200461256,"score_spread":0.2951079944492791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040107189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906571,0.006204145,0.00048967986,0.0017635393,0.00023485617,0.0004453001,0.00010600292,0.000012226547,0.00008714344],"genre_scores_gemma":[0.98759663,0.007720901,0.0020082286,0.0013726951,0.000931398,0.00009079721,0.000018887731,0.000036544265,0.00022389353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987156,0.0000935117,0.00030094018,0.00052223913,0.000077349956,0.00029037407],"domain_scores_gemma":[0.9994601,0.000040743562,0.00015949672,0.00013919082,0.00008183036,0.000118656186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015519443,0.0002461655,0.00032084514,0.000057961326,0.00014080596,0.000020666126,0.00007435525,0.00020015825,0.00011692669],"category_scores_gemma":[0.000011237623,0.00024320405,0.0000419822,0.0001161114,0.00027675132,0.000017436443,0.00006387874,0.0001516915,2.0001858e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033005187,0.00007766905,0.0029908167,0.00010914279,0.000089385954,0.000011130935,0.0008626573,0.00049730774,0.97735643,0.000015388558,0.0003448115,0.017315231],"study_design_scores_gemma":[0.0050234697,0.00019198509,0.0135138985,0.000048946065,0.000063380576,0.000056762343,0.000088279805,0.00020623168,0.978786,0.00017207098,0.0015669112,0.0002820597],"about_ca_topic_score_codex":0.0016918026,"about_ca_topic_score_gemma":0.0027279337,"teacher_disagreement_score":0.01703317,"about_ca_system_score_codex":0.00009910652,"about_ca_system_score_gemma":0.00047455714,"threshold_uncertainty_score":0.99175733},"labels":[],"label_agreement":null},{"id":"W2040176056","doi":"10.1007/s00280-009-1041-6","title":"A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Lapatinib; Pharmacokinetics; Medicine; Toxicity; Pharmacology; Gastroenterology; Phases of clinical research; Internal medicine; Oral administration; Cancer; Breast cancer; Trastuzumab","score_opus":0.029161902429656193,"score_gpt":0.41835744305058226,"score_spread":0.38919554062092604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040176056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914737,0.0022805014,0.000023289438,0.0046039405,0.0005347071,0.0009912007,0.000020834324,0.000015431751,0.000056438585],"genre_scores_gemma":[0.9876,0.008831218,0.00015458732,0.0031388963,0.00014420263,0.00008571372,0.000009664936,0.000012285346,0.000023396078],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988465,0.00007446583,0.000497415,0.00027865198,0.00010897496,0.0001940128],"domain_scores_gemma":[0.9994196,0.00012040688,0.00017649934,0.00008892584,0.00005313604,0.00014140086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018625877,0.0001768933,0.0005125653,0.00011420761,0.000033931745,0.000003850789,0.000038313883,0.00012542626,0.00021369789],"category_scores_gemma":[0.000017320921,0.00012922932,0.000091855465,0.00012934415,0.000104695646,0.000036906713,0.000014263261,0.0001852549,7.153284e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09824826,0.01230354,0.037001383,0.00006279305,0.00037958173,0.00008231888,0.0005149629,0.000011808422,0.0769966,0.00004043502,0.0018717927,0.7724865],"study_design_scores_gemma":[0.77060485,0.036287136,0.033109542,0.00012945705,0.00064679096,0.0000258967,0.00002143986,0.0047147595,0.1385519,0.00013792371,0.0154663995,0.00030390135],"about_ca_topic_score_codex":0.000013671485,"about_ca_topic_score_gemma":0.000006176808,"teacher_disagreement_score":0.77218264,"about_ca_system_score_codex":0.000042607662,"about_ca_system_score_gemma":0.00006108458,"threshold_uncertainty_score":0.52698183},"labels":[],"label_agreement":null},{"id":"W2040193157","doi":"10.1007/s00280-008-0750-6","title":"Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Cancer Research Society","keywords":"Cytidine deaminase; Deoxycytidine; Cytidine; Deamination; Deoxycytidine kinase; Molecular biology; Adenosine deaminase; Chemistry; Biology; Biochemistry; Enzyme; Chemotherapy; Gemcitabine","score_opus":0.017088398571403533,"score_gpt":0.3026246787053595,"score_spread":0.28553628013395593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040193157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045616,0.0073575424,0.0014376865,0.00032348235,0.00017338272,0.0001493222,0.000031918607,0.0000040012283,0.000066515866],"genre_scores_gemma":[0.96082044,0.038482167,0.000081224665,0.00017631987,0.0002033613,0.000022980144,0.00004737588,0.000011655551,0.0001544987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993782,0.000053306423,0.0002068138,0.00017551056,0.00006997369,0.00011617315],"domain_scores_gemma":[0.9995821,0.000032337648,0.00017496407,0.00009108686,0.00008633185,0.000033182507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010746937,0.00010669897,0.00015633105,0.000027324935,0.00006744298,0.0000017448269,0.00005793083,0.00009128512,0.00009640478],"category_scores_gemma":[0.000009831406,0.00008437678,0.000042133353,0.00008677951,0.00021729515,0.0000043591913,0.000021976899,0.000062574305,2.7933936e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029357523,0.000070926086,0.001959894,0.00004557244,0.00006314797,5.1830733e-7,0.00009688049,0.000057143432,0.99199826,0.000006065258,0.0008965437,0.0045114825],"study_design_scores_gemma":[0.0011385292,0.0003278104,0.0018723733,0.000007926658,0.000030039013,0.000004681896,0.000016292357,0.0001042809,0.9867688,0.000043674187,0.009601369,0.00008422365],"about_ca_topic_score_codex":0.000045116572,"about_ca_topic_score_gemma":0.000012306165,"teacher_disagreement_score":0.031124627,"about_ca_system_score_codex":0.000007129827,"about_ca_system_score_gemma":0.000047624224,"threshold_uncertainty_score":0.3440785},"labels":[],"label_agreement":null},{"id":"W2041411173","doi":"10.1007/s00280-004-0997-5","title":"Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Clusterin; Docetaxel; Paclitaxel; In vivo; Chemistry; LNCaP; Chitosan; Pharmacology; Prostate; Medicine; Chemotherapy; Cancer; Apoptosis; Internal medicine; Biochemistry; Biology","score_opus":0.03062380523653499,"score_gpt":0.3576672029075239,"score_spread":0.3270433976709889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041411173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520224,0.001320399,0.00008428228,0.0012833258,0.000099682205,0.0017766567,0.000090556496,0.000033303644,0.00010956349],"genre_scores_gemma":[0.9949963,0.0014556933,0.0012909508,0.0017267274,0.00018889118,0.0002341895,0.00002794671,0.00004446104,0.000034810368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998366,0.00015255297,0.0006278603,0.00036172345,0.00013508236,0.00035680982],"domain_scores_gemma":[0.9990292,0.00013613116,0.00037201605,0.00017760792,0.000100548255,0.00018449302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016408076,0.00025615338,0.0009814091,0.00018484709,0.00004223509,0.000006344281,0.000085353204,0.000092114984,0.00031694525],"category_scores_gemma":[0.000012285993,0.00019849795,0.000068468515,0.00021732945,0.00029232743,0.00016963185,0.00002791659,0.00020952277,1.8086382e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2787368,0.0013690593,0.017002605,0.0006535915,0.00048645548,0.00014907603,0.005491367,0.01902129,0.6425934,0.000057484118,0.00006388563,0.03437499],"study_design_scores_gemma":[0.28541908,0.0051759896,0.10597595,0.00069517165,0.0008254371,0.00027755575,0.0005698445,0.26382303,0.33609068,0.00010978697,0.000363154,0.0006742922],"about_ca_topic_score_codex":0.0002744427,"about_ca_topic_score_gemma":0.00034270732,"teacher_disagreement_score":0.3065027,"about_ca_system_score_codex":0.000072521834,"about_ca_system_score_gemma":0.00027417374,"threshold_uncertainty_score":0.80945116},"labels":[],"label_agreement":null},{"id":"W2042603355","doi":"10.1007/s00280-013-2155-4","title":"Bevacizumab and central nervous system (CNS) hemorrhage","year":2013,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Bevacizumab; Central nervous system; Medicine; Neuroscience; Chemotherapy; Internal medicine; Biology","score_opus":0.060671572450236556,"score_gpt":0.37634657304408864,"score_spread":0.31567500059385206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042603355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042996504,0.99258167,0.000014955276,0.00067338295,0.00040516217,0.0013124336,0.000044570454,0.00008359071,0.00058457116],"genre_scores_gemma":[0.0014160937,0.9945381,0.000109088556,0.0018481266,0.00048856635,0.00055542885,0.000027227386,0.00004680984,0.00097050273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986019,0.00010839261,0.00035491565,0.00050178973,0.000076348304,0.00035663092],"domain_scores_gemma":[0.9992408,0.000104697676,0.00016938322,0.00018403251,0.000038331887,0.00026271457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000050638042,0.00035769612,0.0014381878,0.00008296306,0.00010103888,0.000023446772,0.00011142489,0.0002997918,0.0012968103],"category_scores_gemma":[0.000002395545,0.00024810166,0.0001579215,0.00012750633,0.00015992706,0.00003078842,0.00004571927,0.00042519878,0.000019955722],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036841342,0.00004260761,0.000015536238,0.015643042,0.00021592059,0.00007212009,0.000026722128,6.273037e-8,0.00013220901,0.00006642975,0.0025961262,0.98115236],"study_design_scores_gemma":[0.0010566377,0.00019774272,0.00009921744,0.0005656007,0.0010441525,0.0017546432,0.000006661651,0.00007134873,0.000038678616,0.000011119311,0.994928,0.00022622307],"about_ca_topic_score_codex":0.00001965396,"about_ca_topic_score_gemma":4.6025488e-7,"teacher_disagreement_score":0.99233186,"about_ca_system_score_codex":0.00009548028,"about_ca_system_score_gemma":0.00012256758,"threshold_uncertainty_score":0.99999714},"labels":[],"label_agreement":null},{"id":"W2044562269","doi":"10.1007/s00280-011-1772-z","title":"The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"University of Texas Health Science Center at San Antonio; National Institutes of Health; Eisai","keywords":"Bexarotene; Pharmacology; Atorvastatin; Fenofibrate; Pharmacokinetics; Medicine; Carboplatin; Chemotherapy; Paclitaxel; Drug interaction; Lung cancer; Oncology; Internal medicine; Cisplatin; Chemistry","score_opus":0.006956540471565487,"score_gpt":0.2784354975765501,"score_spread":0.27147895710498465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044562269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946589,0.0029584453,0.00010477559,0.00006927759,0.0003554189,0.0014069391,0.00021706625,0.000006782608,0.00022240914],"genre_scores_gemma":[0.989805,0.008829284,0.00018937663,0.00036339823,0.00024117103,0.00036570727,0.00006871406,0.00004969422,0.00008765081],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983548,0.0001649501,0.00048521603,0.00050679717,0.00015765119,0.00033056692],"domain_scores_gemma":[0.9989501,0.00012521043,0.00045740829,0.00026369153,0.00011785589,0.00008571114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025231615,0.00032493085,0.0004637974,0.000050567407,0.0000657496,0.000006330708,0.00030263228,0.00017716154,0.000101070495],"category_scores_gemma":[0.000011699833,0.00022509122,0.00008307911,0.00014288897,0.0002585517,0.00000763791,0.000037074242,0.00020426147,2.246272e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31750733,0.0004300413,0.0062476187,0.00015903266,0.0003322204,0.0000023677114,0.0008213659,0.0002128261,0.6387293,6.2411925e-7,0.0003704656,0.03518686],"study_design_scores_gemma":[0.18689553,0.005336846,0.0010118167,0.000061054474,0.00009370212,1.6990808e-7,0.000019250549,0.00016098331,0.8048824,0.0000058408627,0.001328009,0.00020437848],"about_ca_topic_score_codex":0.00019039646,"about_ca_topic_score_gemma":0.000019955003,"teacher_disagreement_score":0.16615316,"about_ca_system_score_codex":0.0000486786,"about_ca_system_score_gemma":0.00019573221,"threshold_uncertainty_score":0.9178954},"labels":[],"label_agreement":null},{"id":"W2046529949","doi":"10.1007/s00280-010-1288-y","title":"An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Epirubicin; Toxicity; Pharmacokinetics; Lean body mass; Internal medicine; Medicine; Pharmacology; Endocrinology; Cancer; Breast cancer","score_opus":0.02030484285912247,"score_gpt":0.37386616716232884,"score_spread":0.35356132430320636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046529949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99837637,0.000510925,0.000011832902,0.00018195741,0.00033940253,0.00050373375,0.000020565676,0.000013510421,0.000041702035],"genre_scores_gemma":[0.99669725,0.0020085815,0.00003605929,0.0009883847,0.0001983471,0.000040666353,0.0000031934273,0.000016820746,0.000010709723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992836,0.00004733297,0.00023466522,0.00021133902,0.000092479575,0.00013057407],"domain_scores_gemma":[0.99950606,0.00003237491,0.00013558847,0.00011219636,0.00008083549,0.0001329773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011344992,0.00012899646,0.00036611184,0.00007332558,0.000038512193,0.0000030266312,0.000052312655,0.000076030265,0.00048666948],"category_scores_gemma":[0.0000013756693,0.000111956666,0.000027074131,0.00007459363,0.00019814057,0.000057347093,0.000015462934,0.00019899209,1.9239728e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014615819,0.0008629654,0.056769464,0.00010530089,0.00011076459,0.000006927609,0.0038858424,0.0000018955037,0.9186206,0.000004010141,0.00009668721,0.018073995],"study_design_scores_gemma":[0.0071371817,0.0022489903,0.035277702,0.000017593173,0.00022999404,0.000019918676,0.00035562424,0.00042938633,0.95308375,0.000016051932,0.0010783446,0.000105442006],"about_ca_topic_score_codex":0.00021202599,"about_ca_topic_score_gemma":0.00008264636,"teacher_disagreement_score":0.034463204,"about_ca_system_score_codex":0.000014529645,"about_ca_system_score_gemma":0.000063551284,"threshold_uncertainty_score":0.5328689},"labels":[],"label_agreement":null},{"id":"W2046548773","doi":"10.1007/s00280-012-1821-2","title":"Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"Astex Pharmaceuticals","keywords":"Pharmacokinetics; Tolerability; Adverse effect; Medicine; Pharmacology; Internal medicine","score_opus":0.13440256156235775,"score_gpt":0.4982005911692453,"score_spread":0.36379802960688756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046548773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9097255,0.084804125,0.000011132594,0.0038407312,0.0008820793,0.0005056589,0.000069792746,0.000013980467,0.00014704],"genre_scores_gemma":[0.89809304,0.09693994,0.00017085545,0.0041154963,0.00055003806,0.00008243081,0.000006086849,0.000014168509,0.000027948998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987724,0.00007805512,0.0005029194,0.00027236366,0.000091402275,0.0002828703],"domain_scores_gemma":[0.9992218,0.00034433935,0.000116265284,0.00008549361,0.000074774,0.00015734491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029761618,0.00018280243,0.0007685019,0.00005350626,0.00005270778,0.0000020588375,0.000040784143,0.00008258979,0.00045234646],"category_scores_gemma":[0.000018354032,0.00014567592,0.000057387664,0.000117130374,0.00054927927,0.000053577176,0.0000533508,0.00020480205,5.75683e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012886726,0.0011021212,0.7906847,0.00021150138,0.0010786654,0.0000059541203,0.0038604278,0.0000012361849,0.00540375,0.000011961498,0.0019207344,0.1828322],"study_design_scores_gemma":[0.08618493,0.0062017706,0.8200436,0.0002032352,0.001151107,0.000019943458,0.001227698,0.00066295645,0.020286223,0.00036627488,0.06317347,0.00047874608],"about_ca_topic_score_codex":0.00023750252,"about_ca_topic_score_gemma":0.00021013188,"teacher_disagreement_score":0.18235345,"about_ca_system_score_codex":0.00010431273,"about_ca_system_score_gemma":0.00006976595,"threshold_uncertainty_score":0.59404916},"labels":[],"label_agreement":null},{"id":"W2047075888","doi":"10.1007/s00280-011-1770-1","title":"A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Center for Research Resources; National Institutes of Health; Eisai","keywords":"Bexarotene; Carboplatin; Pharmacokinetics; Pharmacology; Paclitaxel; Medicine; Lung cancer; Chemotherapy; Concomitant; Oncology; Internal medicine; Cisplatin; Chemistry","score_opus":0.0075742791439560265,"score_gpt":0.27052403872635666,"score_spread":0.26294975958240063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047075888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938129,0.004825575,0.000088292545,0.000016841632,0.00007840655,0.0009158273,0.000021353311,0.000006016792,0.00023477747],"genre_scores_gemma":[0.996429,0.0025212541,0.00023091094,0.00031067402,0.000064818596,0.00032554835,0.000010566825,0.00003692803,0.00007027093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989398,0.000055866123,0.00021595524,0.0004436913,0.00008561537,0.000259067],"domain_scores_gemma":[0.999509,0.000010888136,0.00016198872,0.00012903113,0.00009970488,0.00008941535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069048125,0.00024304887,0.0002889098,0.000054965785,0.00004388995,0.0000050194058,0.000120833305,0.00009367012,0.00009603643],"category_scores_gemma":[0.0000011684863,0.00019085276,0.00001769837,0.00012806527,0.0001429893,0.000008998322,0.000036941612,0.00013925624,6.119566e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070790607,0.001875547,0.36234245,0.00030940317,0.00027391902,0.000009339215,0.0032453153,0.000082403334,0.60969794,4.3913968e-7,0.00006643806,0.015017752],"study_design_scores_gemma":[0.045160376,0.0056629092,0.026631461,0.000059324764,0.00019506204,0.00000198702,0.00033707067,0.00013439672,0.9212158,0.0000032339065,0.00025124746,0.0003471757],"about_ca_topic_score_codex":0.00016249849,"about_ca_topic_score_gemma":0.000073556956,"teacher_disagreement_score":0.335711,"about_ca_system_score_codex":0.000020109503,"about_ca_system_score_gemma":0.00012590674,"threshold_uncertainty_score":0.77827495},"labels":[],"label_agreement":null},{"id":"W2047269416","doi":"10.1007/s00280-014-2474-0","title":"A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Everolimus; Medicine; Panitumumab; Internal medicine; Regimen; Mucositis; Refractory (planetary science); Fluorouracil; Sirolimus; Oxaliplatin; Colorectal cancer; Gastroenterology; Oncology; Toxicity; Surgery; Chemotherapy; Cancer; KRAS","score_opus":0.008706825118384477,"score_gpt":0.2963860966402916,"score_spread":0.2876792715219071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047269416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806654,0.00083645195,0.00014438062,0.00010711321,0.00016414534,0.00057424436,0.000019712732,0.0000066087136,0.00008078829],"genre_scores_gemma":[0.9980007,0.0007811736,0.00007414818,0.0007692526,0.00014740488,0.00013421942,0.000032929827,0.000030200481,0.000029979556],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988729,0.00012231445,0.00026593838,0.00037715278,0.000116533585,0.0002452027],"domain_scores_gemma":[0.9994939,0.00003363832,0.00019607508,0.00013061086,0.000077935845,0.00006781484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001978311,0.00019794892,0.0003433529,0.00009384341,0.00003222024,0.0000075371145,0.00010303075,0.00014302896,0.000044151646],"category_scores_gemma":[0.000008887419,0.00017045446,0.000021401478,0.0001207822,0.00023805849,0.000012820702,0.0000245097,0.00015702359,1.7206014e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32013148,0.003677313,0.045370698,0.00034028752,0.00040453026,0.000014347456,0.001654781,0.00046177598,0.5390021,0.00004356246,0.0007135135,0.08818561],"study_design_scores_gemma":[0.5540081,0.02230226,0.01531292,0.00015539087,0.00009284381,0.0000067147166,0.00005575794,0.0010338131,0.3961176,0.00008413088,0.010177772,0.0006526337],"about_ca_topic_score_codex":0.000077243596,"about_ca_topic_score_gemma":0.00011817789,"teacher_disagreement_score":0.23387669,"about_ca_system_score_codex":0.000070714275,"about_ca_system_score_gemma":0.00016314248,"threshold_uncertainty_score":0.6950931},"labels":[],"label_agreement":null},{"id":"W2047405239","doi":"10.1007/s00280-005-0161-x","title":"Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lipid Membrane Structure and Behavior","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Liposome; In vivo; Pharmacokinetics; Bioavailability; Chemistry; Ethylene glycol; PEG ratio; Pharmacology; Toxicity; Drug; Phosphatidylcholine; Drug delivery; Solubility; Chromatography; Medicine; Biochemistry; Phospholipid; Biology; Organic chemistry; Membrane","score_opus":0.02425954105668785,"score_gpt":0.3342592471305177,"score_spread":0.3099997060738298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047405239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455094,0.0033280104,0.00025493032,0.0008328046,0.00039407515,0.00047639158,0.00011274139,0.000010381031,0.000039740244],"genre_scores_gemma":[0.9877382,0.0073850686,0.0003476088,0.0025929217,0.0014045303,0.00017591991,0.000051614526,0.000029384979,0.0002747496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992249,0.000010629281,0.00020454326,0.00028075816,0.000060334813,0.00021881457],"domain_scores_gemma":[0.99960774,0.000017443093,0.00012528505,0.00011074055,0.000080072656,0.000058707166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005876849,0.00017094311,0.00023693737,0.000039112347,0.00007429983,0.0000072957646,0.00011356792,0.00015508739,0.00024628395],"category_scores_gemma":[0.0000012133734,0.00015035366,0.00008861868,0.00005768124,0.000087155706,0.000010159077,0.000017676442,0.000068637535,2.8937762e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006177052,0.00015717403,0.0015629901,0.00004561929,0.00013312195,8.011808e-8,0.00014668198,0.00021829123,0.97243375,0.000014788697,0.0010302548,0.023639549],"study_design_scores_gemma":[0.0043706694,0.00020165106,0.00076297804,0.0000072558146,0.000040797768,0.0000036526096,0.000008197759,0.00041392146,0.88529354,0.0000061863534,0.10872746,0.00016368218],"about_ca_topic_score_codex":0.000017461642,"about_ca_topic_score_gemma":0.000013767656,"teacher_disagreement_score":0.107697204,"about_ca_system_score_codex":0.00001647093,"about_ca_system_score_gemma":0.00007356572,"threshold_uncertainty_score":0.61312443},"labels":[],"label_agreement":null},{"id":"W2049287536","doi":"10.1007/s00280-008-0901-9","title":"Evaluation of the antitumoral effect of dihydrocucurbitacin-B in both in vitro and in vivo models","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Advances in Cucurbitaceae Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Universidade Federal de Santa Catarina; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"In vivo; In vitro; Pharmacology; Chemistry; Cancer research; Medicine; Biology; Biochemistry; Genetics","score_opus":0.020296621734548444,"score_gpt":0.3809015879668969,"score_spread":0.36060496623234845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049287536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908973,0.008117442,0.000022902528,0.00031034052,0.000056122215,0.0003812042,0.000010018859,8.897555e-7,0.00020377863],"genre_scores_gemma":[0.9960822,0.00362393,0.000022171853,0.00017868336,0.000034949808,0.000036869733,9.0272516e-7,0.000006092835,0.00001418657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990818,0.00026899244,0.00017022782,0.00019493458,0.00012646987,0.00015756981],"domain_scores_gemma":[0.9997556,0.00003783617,0.000062660976,0.00009004568,0.00003366064,0.00002018146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007261334,0.000089276,0.00018846724,0.00006285448,0.000010327882,0.0000015123616,0.00009602776,0.00007972457,0.00002112405],"category_scores_gemma":[0.000016978403,0.00006489603,0.0000219786,0.00013088222,0.0001415392,0.000008504906,0.000028463628,0.00009229774,1.9025066e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009489267,0.00004093192,0.016408136,0.000035447767,0.000012143924,6.757142e-7,0.00009370843,0.0011822574,0.9625173,0.0000060750353,0.000025481164,0.018728891],"study_design_scores_gemma":[0.004243416,0.00019353391,0.0052998606,0.000031786556,0.000010622129,0.0000018986641,0.0000063869825,0.006068836,0.9832867,0.00070410385,0.000088111614,0.00006474951],"about_ca_topic_score_codex":0.000027801654,"about_ca_topic_score_gemma":0.000069899295,"teacher_disagreement_score":0.02076937,"about_ca_system_score_codex":0.000040822306,"about_ca_system_score_gemma":0.000082299106,"threshold_uncertainty_score":0.26463833},"labels":[],"label_agreement":null},{"id":"W2050286670","doi":"10.1007/s00280-002-0530-7","title":"Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"HL60; Anthracycline; Cytarabine; Pharmacology; Cancer research; Biology; Leukemia; Medicine; Myeloid leukemia; Cancer; Internal medicine; Immunology","score_opus":0.02620409909074753,"score_gpt":0.32018289020110385,"score_spread":0.2939787911103563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050286670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908577,0.003854128,0.00009250098,0.0025611087,0.00046348493,0.00039695363,0.000045615052,0.000057837067,0.0016706451],"genre_scores_gemma":[0.98680824,0.009071054,0.00016726644,0.0016835856,0.00043332792,0.000043142747,0.0000098576365,0.000034446966,0.0017490766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988655,0.00003357208,0.00029253977,0.00032614966,0.0001550891,0.0003271354],"domain_scores_gemma":[0.99942094,0.000026648326,0.00015658764,0.00016017928,0.000072380244,0.00016325257],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010824513,0.00022289106,0.00056302536,0.000108890315,0.000120366276,0.000005443152,0.000090124886,0.00012006931,0.0025874749],"category_scores_gemma":[0.0000018284545,0.00018776635,0.0001295048,0.00019134695,0.000293556,0.00006891324,0.000010037494,0.00022353811,0.0000026649416],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000991503,0.00053770567,0.0027444276,0.00033338772,0.00022380357,0.00005478928,0.00031855836,0.000002745085,0.9753859,0.00008298089,0.0016860602,0.017638115],"study_design_scores_gemma":[0.007819153,0.00043963344,0.009052048,0.00009544927,0.0002027113,0.0000086021855,0.000031489242,0.00024972874,0.9498124,0.000041080908,0.03202245,0.00022522597],"about_ca_topic_score_codex":0.000026962438,"about_ca_topic_score_gemma":0.00002279222,"teacher_disagreement_score":0.030336391,"about_ca_system_score_codex":0.000042657084,"about_ca_system_score_gemma":0.00003216154,"threshold_uncertainty_score":0.9983243},"labels":[],"label_agreement":null},{"id":"W2051365306","doi":"10.1007/s00280-009-1064-z","title":"A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Eli Lilly Canada","keywords":"Gemcitabine; Pemetrexed; Medicine; Oncology; Internal medicine; Metastatic breast cancer; Breast cancer; Phases of clinical research; Antimetabolite; Cancer; Chemotherapy; Cisplatin","score_opus":0.016613805612389933,"score_gpt":0.35902117151985685,"score_spread":0.3424073659074669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051365306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290925,0.0025599005,0.0000016526351,0.0030067186,0.00013218226,0.0012225965,0.00009509258,0.000017609484,0.000055019278],"genre_scores_gemma":[0.99468625,0.001944398,0.000036598867,0.002889536,0.000100488265,0.0001613042,0.0000142402405,0.00001836346,0.00014885468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989548,0.00005943086,0.00026219158,0.00033751273,0.00012396746,0.00026210424],"domain_scores_gemma":[0.99952096,0.000038007496,0.00012727754,0.000087575005,0.0000927998,0.00013339604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000077627454,0.00022536663,0.0005752095,0.00019360165,0.000060876002,0.000004048697,0.000048867314,0.000046891782,0.0012098775],"category_scores_gemma":[9.90457e-7,0.00017099183,0.000026691887,0.000327396,0.000113396854,0.000073402545,0.000015456446,0.00015970989,1.949555e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04158724,0.03124573,0.62156445,0.00018521749,0.0015157706,0.000058929465,0.005450283,0.000016240709,0.037022278,0.0000071085287,0.002418043,0.25892872],"study_design_scores_gemma":[0.21908566,0.031718314,0.7375176,0.00007093719,0.0012568368,0.000019811578,0.00020362074,0.00012967647,0.0077572935,0.00002388445,0.0019314822,0.00028491326],"about_ca_topic_score_codex":0.000368815,"about_ca_topic_score_gemma":0.00014997461,"teacher_disagreement_score":0.25864378,"about_ca_system_score_codex":0.000093338196,"about_ca_system_score_gemma":0.00012286898,"threshold_uncertainty_score":0.99970317},"labels":[],"label_agreement":null},{"id":"W2052488949","doi":"10.1007/s002800000231","title":"Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all- trans -retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Steacie Institute for Molecular Sciences; McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Connexin; Retinoic acid; Downregulation and upregulation; Intracellular; Gap junction; Neuroblastoma; Glutathione; Chemistry; Cell biology; Tretinoin; Biology; Cell culture; Biochemistry; Enzyme; Gene; Genetics","score_opus":0.014233740315112795,"score_gpt":0.2694739558026567,"score_spread":0.2552402154875439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052488949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487036,0.0031349722,0.0004925935,0.0011995662,0.00003476003,0.0001997096,0.000035080928,0.0000065907307,0.000026351936],"genre_scores_gemma":[0.9858579,0.012579909,0.00007051069,0.001267462,0.000030157991,0.00002048069,0.00010409918,0.000013530722,0.000055930348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991833,0.00016569451,0.00016727106,0.00030068724,0.000043246822,0.00013978522],"domain_scores_gemma":[0.9996594,0.000045980327,0.00011220887,0.00008576441,0.00004383224,0.000052779895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015529236,0.00014349385,0.00019750236,0.000038569113,0.000057772817,0.0000075832163,0.00003810168,0.00018342937,0.000067026966],"category_scores_gemma":[0.000004665029,0.00013367315,0.000016903527,0.000053360345,0.00027496353,0.000010754776,0.00003147912,0.000111524845,6.27609e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010712083,0.00007022062,0.005533272,0.000021416012,0.00006421084,0.0000010008803,0.0004856606,0.000006336169,0.9879614,0.0000033488488,0.00035812904,0.004423762],"study_design_scores_gemma":[0.0034884703,0.00033690632,0.0144420955,0.000035356385,0.000037476282,0.000032469514,0.000051960098,0.00054216274,0.97285277,0.000043096043,0.007973705,0.00016351945],"about_ca_topic_score_codex":0.000045966583,"about_ca_topic_score_gemma":0.00013268845,"teacher_disagreement_score":0.015108652,"about_ca_system_score_codex":0.000012590369,"about_ca_system_score_gemma":0.000016002004,"threshold_uncertainty_score":0.54510325},"labels":[],"label_agreement":null},{"id":"W2057044337","doi":"10.1007/s00280-004-0853-7","title":"Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pharmacokinetics; Geldanamycin; Pharmacology; Chemistry; Dosing; In vivo; Hsp90; Medicine; Heat shock protein; Biology; Biochemistry","score_opus":0.052465528900801674,"score_gpt":0.41054589129474733,"score_spread":0.35808036239394564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057044337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912754,0.0044172597,0.0020803583,0.0011285347,0.00009857644,0.000845622,0.000019306723,0.0000015784684,0.00013331957],"genre_scores_gemma":[0.9975561,0.0009727028,0.0005386575,0.0005660888,0.00015137532,0.00017999529,0.0000096130125,0.000013101161,0.000012390789],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99901646,0.00024603316,0.00019674757,0.00018913591,0.00017862237,0.00017297517],"domain_scores_gemma":[0.9995191,0.000035042296,0.00009782795,0.000115639974,0.00020921924,0.00002316931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146138,0.00009112306,0.00013352143,0.000035038225,0.00006556883,0.0000065416693,0.000186984,0.000087917935,0.000015600193],"category_scores_gemma":[0.000033481963,0.00006118602,0.00005034776,0.00014939069,0.00019960468,0.0000049620185,0.000041680447,0.0001140189,2.5033858e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008746263,0.000063006424,0.001188087,0.00007233235,0.00008371961,7.8069846e-8,0.00023657568,0.00583047,0.9774127,0.000008089527,0.00014137973,0.014876108],"study_design_scores_gemma":[0.002951533,0.000058888345,0.002119669,0.00001593755,0.000077098346,0.0000028216668,0.000080224585,0.005127554,0.98823184,0.00012546517,0.0011429891,0.00006598992],"about_ca_topic_score_codex":0.00012009462,"about_ca_topic_score_gemma":0.000041358286,"teacher_disagreement_score":0.014810118,"about_ca_system_score_codex":0.000054422708,"about_ca_system_score_gemma":0.00034230636,"threshold_uncertainty_score":0.24950935},"labels":[],"label_agreement":null},{"id":"W2058737189","doi":"10.1007/s00280-007-0417-8","title":"Role of NADPH cytochrome P450 reductase in activation of RH1","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Cytochrome P450; Reductase; Chemistry; Cytochrome P450 reductase; Pharmacology; Biochemistry; Cell biology; Enzyme; Biology; Cytochrome c; Apoptosis; Coenzyme Q – cytochrome c reductase","score_opus":0.06604078805472001,"score_gpt":0.44078947350474135,"score_spread":0.3747486854500213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058737189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941568,0.0027203686,0.00003504486,0.00043683097,0.00032693657,0.00033872473,0.000051208757,0.00001635582,0.0019177741],"genre_scores_gemma":[0.9954605,0.0026043283,0.00009930862,0.001435754,0.00023233012,0.000027240749,0.0000101040205,0.000018876586,0.00011155283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873334,0.00013841157,0.00042436863,0.00026695314,0.00009237629,0.0003445656],"domain_scores_gemma":[0.99922734,0.00020691082,0.00026803193,0.000086749984,0.00009289809,0.0001180489],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052197394,0.00018327887,0.00036598157,0.00019392,0.00006214065,0.0000027225485,0.00016308422,0.0002533097,0.002118866],"category_scores_gemma":[0.000008119573,0.0001830109,0.000064252876,0.0002996939,0.00038847007,0.00009689398,0.000035593283,0.00037714458,0.0000017606861],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017707825,0.00041835068,0.017839877,0.00009022531,0.0001642444,0.0000053712897,0.0012765542,0.000030235682,0.9332608,0.00028983472,0.0005604338,0.044293296],"study_design_scores_gemma":[0.003127755,0.00014537253,0.042495936,0.000023825643,0.000046896093,0.0000066238144,0.00030109996,0.00023228455,0.92151207,0.0005130448,0.031436566,0.00015851737],"about_ca_topic_score_codex":0.00014178517,"about_ca_topic_score_gemma":0.000026408263,"teacher_disagreement_score":0.04413478,"about_ca_system_score_codex":0.000074644624,"about_ca_system_score_gemma":0.00009182289,"threshold_uncertainty_score":0.9987933},"labels":[],"label_agreement":null},{"id":"W2060082838","doi":"10.1007/s00280-004-0776-3","title":"Inhibition of ?-glutamyl transpeptidase activity decreases intracellular cysteine levels in cervical carcinoma","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Sulfur Compounds in Biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Cysteine; In vivo; Glutathione; Intracellular; Cell culture; In vitro; Enzyme inhibitor; Enzyme; Biology; Biochemistry; Internal medicine; Chemistry; Molecular biology; Medicine","score_opus":0.01858617316590961,"score_gpt":0.2935874404988378,"score_spread":0.2750012673329282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060082838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488163,0.0028926493,0.00074181287,0.0009323206,0.00018236513,0.00023117366,0.000044781762,0.000009070955,0.00008416858],"genre_scores_gemma":[0.99704975,0.0014051928,0.0002093379,0.0009544356,0.00026140345,0.00005708095,0.000025539499,0.000019328774,0.00001793689],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904567,0.000098634664,0.00020974503,0.00034831776,0.00005465872,0.00024299113],"domain_scores_gemma":[0.999642,0.000024658724,0.00008293728,0.00012673759,0.000043485026,0.00008019614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011553257,0.00017217037,0.0002539196,0.00006334031,0.000032597087,0.0000034876614,0.00009619555,0.00022864138,0.0001741246],"category_scores_gemma":[0.000006476519,0.00017242316,0.00005963377,0.00010747804,0.00026456895,0.000006244892,0.000029577754,0.00013578682,7.7062066e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008630503,0.00020195027,0.00580068,0.000061556,0.00005496775,0.00001569467,0.0001834272,0.00014445829,0.98646224,0.000025900114,0.000031088475,0.0061550117],"study_design_scores_gemma":[0.004973619,0.00046472758,0.013534696,0.000017894214,0.000021100746,0.000029126479,0.000020569847,0.00003161604,0.9790304,0.00029741053,0.0014071608,0.0001717328],"about_ca_topic_score_codex":0.00016540496,"about_ca_topic_score_gemma":0.0001266822,"teacher_disagreement_score":0.007734016,"about_ca_system_score_codex":0.000046011148,"about_ca_system_score_gemma":0.00012520609,"threshold_uncertainty_score":0.70312124},"labels":[],"label_agreement":null},{"id":"W2061780793","doi":"10.1007/s00280-007-0449-0","title":"Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Paclitaxel; Ovarian cancer; Tolerability; Medicine; Drug delivery; Drug; Biocompatible material; Pharmacology; Intraperitoneal chemotherapy; Chemotherapy; Oncology; Cancer; Internal medicine; Adverse effect; Chemistry; Biomedical engineering","score_opus":0.02333756305921233,"score_gpt":0.3146053325226493,"score_spread":0.29126776946343697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061780793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322766,0.005167582,0.00030588434,0.000287289,0.00022845111,0.0005869565,0.00010555647,0.000062239655,0.000028395152],"genre_scores_gemma":[0.997734,0.00046680984,0.0005320208,0.0009740388,0.00014525327,0.000107082655,0.0000027293372,0.000027126021,0.0000109046605],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981117,0.00013244711,0.0005696334,0.0005069484,0.00016164231,0.0005175784],"domain_scores_gemma":[0.9990691,0.00027117942,0.00020165535,0.0001830765,0.0000959858,0.00017899177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089653855,0.00025402033,0.00052396796,0.00014825496,0.00013437313,0.000024745013,0.00019156723,0.00011410953,0.0002424594],"category_scores_gemma":[0.0000036212882,0.00023872133,0.000050882172,0.00025455028,0.00047378204,0.00013202385,0.00005628834,0.00016797335,8.163558e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012821461,0.00052396586,0.0129414955,0.0002726834,0.00005071576,0.0000050009826,0.0015767725,0.00090168917,0.9751334,0.00013396585,0.000041643005,0.007136483],"study_design_scores_gemma":[0.005967554,0.000107211206,0.015369138,0.00010659018,0.00007442421,0.0000070702695,0.00022740758,0.01097003,0.9667337,0.00007424903,0.00008502289,0.00027762025],"about_ca_topic_score_codex":0.0066814157,"about_ca_topic_score_gemma":0.00089005684,"teacher_disagreement_score":0.010068341,"about_ca_system_score_codex":0.00021393059,"about_ca_system_score_gemma":0.00018608371,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W2062565671","doi":"10.1007/s00280-014-2433-9","title":"DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Drug development; Identification (biology); Anticancer drug; Computational biology; Drug; Drug discovery; Molecular oncology; Medicine; Database; Bioinformatics; Pharmacology; Cancer; Computer science; Biology; Internal medicine","score_opus":0.023974330634110957,"score_gpt":0.3680921221212126,"score_spread":0.34411779148710164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062565671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6129818,0.0003749885,0.37802964,0.007730248,0.00029394717,0.00047714487,0.0000055680953,0.000034495446,0.00007217527],"genre_scores_gemma":[0.58543485,0.00019390428,0.36628443,0.046584755,0.00019791232,0.0011914829,0.000013138618,0.000036979003,0.00006257694],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859256,0.00019444665,0.00023841765,0.0005089818,0.00012540544,0.00034017433],"domain_scores_gemma":[0.9991514,0.0003703514,0.000084431405,0.00013285562,0.000056439727,0.00020451078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067309604,0.00017684637,0.0002633765,0.00015669277,0.00006478893,0.000017464425,0.00042169474,0.000082196806,0.00002234709],"category_scores_gemma":[0.000016191967,0.00016340449,0.000020075016,0.00032297772,0.00007444557,0.00016609963,0.00012159076,0.00019824324,0.0000026262205],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001055227,0.00024873865,0.0025760443,0.00029235324,0.0002119811,0.000028324464,0.025945948,0.02416739,0.2633401,0.016942663,0.007530489,0.6576608],"study_design_scores_gemma":[0.006049468,0.00036816183,0.0018550922,0.000074981086,0.000020539077,0.000019399204,0.000059633137,0.07330071,0.608573,0.00657594,0.30248082,0.0006222099],"about_ca_topic_score_codex":0.00002067372,"about_ca_topic_score_gemma":0.000014107591,"teacher_disagreement_score":0.65703857,"about_ca_system_score_codex":0.00017302432,"about_ca_system_score_gemma":0.0005306419,"threshold_uncertainty_score":0.66634417},"labels":[],"label_agreement":null},{"id":"W2064175713","doi":"10.1007/s002800100294","title":"Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Trichostatin A; DNA methylation; Molecular biology; Histone deacetylase; Cancer research; Biology; Histone deacetylase inhibitor; Retinoic acid receptor; Gene expression; Histone; Gene; Biochemistry","score_opus":0.0106146836701716,"score_gpt":0.27976561231300534,"score_spread":0.26915092864283374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064175713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827918,0.016377809,0.000029321454,0.0003375043,0.0001524676,0.00025840555,0.00003904862,0.0000030058372,0.0000106344605],"genre_scores_gemma":[0.97106415,0.028535215,0.00005255454,0.00009621816,0.00017070913,0.000029815996,0.000012918203,0.000015666239,0.000022732615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992244,0.00014222815,0.00018421767,0.0002691475,0.00004595876,0.00013404292],"domain_scores_gemma":[0.9995943,0.0000883409,0.00013516158,0.000089451416,0.000036349193,0.00005643232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019444374,0.00015852881,0.00021668096,0.000048118098,0.000051646206,0.0000051021143,0.000044137698,0.00013311079,0.000038650254],"category_scores_gemma":[0.000007980496,0.0001133524,0.000024812687,0.00006432252,0.00018990423,0.0000054979796,0.000035456967,0.00008700012,1.0860292e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013228813,0.000070938775,0.016507437,0.00008887029,0.000024064368,3.50309e-7,0.00017976132,0.0000052488,0.9633877,0.0000016677194,0.00012783188,0.01828319],"study_design_scores_gemma":[0.0026753703,0.00061830296,0.003231584,0.000037319962,0.000016805847,0.0000065561208,0.00004066579,0.00006869297,0.9911008,0.000007871861,0.0020896185,0.00010643611],"about_ca_topic_score_codex":0.00002629422,"about_ca_topic_score_gemma":0.000006356403,"teacher_disagreement_score":0.02771302,"about_ca_system_score_codex":0.000011850823,"about_ca_system_score_gemma":0.000024437706,"threshold_uncertainty_score":0.46223766},"labels":[],"label_agreement":null},{"id":"W2066832802","doi":"10.1007/s00280-003-0711-z","title":"Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Etoposide; Pharmacokinetics; Dexrazoxane; Pharmacology; Medicine; Toxicity; Chemotherapy; Cancer; Internal medicine; Breast cancer; Anthracycline","score_opus":0.019167464852908944,"score_gpt":0.35378738882824584,"score_spread":0.3346199239753369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066832802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98786217,0.008597985,0.000003152842,0.0017701852,0.00010249469,0.0011609402,0.000038679198,0.000023353625,0.0004410527],"genre_scores_gemma":[0.96078306,0.03523724,0.00013904352,0.0027444805,0.00008206606,0.0004090372,0.000007854999,0.000047879348,0.00054930756],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984283,0.00011683112,0.0002806041,0.00045835963,0.00026210013,0.0004538201],"domain_scores_gemma":[0.9992427,0.000086197484,0.00011313406,0.00013366321,0.00020665475,0.00021761702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013052946,0.00029714234,0.0005866091,0.00016327293,0.00006944744,0.00000888321,0.0000731121,0.00009146854,0.00058841327],"category_scores_gemma":[0.000010177788,0.0002103466,0.000027731507,0.00038010962,0.00045992376,0.00006646536,0.000027662474,0.00031094035,7.0541324e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015460669,0.00079941534,0.76530516,0.00080567395,0.0014709978,0.00017309411,0.0022509708,0.00012366766,0.2015324,0.000048248843,0.0023953656,0.009634353],"study_design_scores_gemma":[0.041315366,0.0033733314,0.1729878,0.00039169766,0.0005362854,0.00004596435,0.00012052457,0.00006551742,0.76869863,0.000031978456,0.012055344,0.00037752886],"about_ca_topic_score_codex":0.0026237052,"about_ca_topic_score_gemma":0.0007247034,"teacher_disagreement_score":0.59231734,"about_ca_system_score_codex":0.0002646915,"about_ca_system_score_gemma":0.00034181672,"threshold_uncertainty_score":0.85776854},"labels":[],"label_agreement":null},{"id":"W2067495120","doi":"10.1007/s00280-011-1606-z","title":"A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"FOLFOX; Oxaliplatin; Bevacizumab; Capecitabine; Medicine; Pharmacokinetics; Dosing; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Pharmacology; Gastroenterology; Cancer","score_opus":0.06911846102860347,"score_gpt":0.3775572727830627,"score_spread":0.30843881175445925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067495120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904628,0.0010492592,0.000025143621,0.00057922874,0.00020253421,0.0072987103,0.00008684588,0.000014487561,0.0002810116],"genre_scores_gemma":[0.9930152,0.0014869841,0.00039095813,0.0018301159,0.000035588982,0.002834733,0.0000036821575,0.00004873228,0.00035398515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983496,0.00025008133,0.0003885885,0.00042784974,0.00023014472,0.00035373875],"domain_scores_gemma":[0.9990618,0.00020278148,0.00023109079,0.00013688148,0.00024002817,0.00012741206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026923663,0.00033936332,0.001060996,0.00009947527,0.00009547981,0.000016243901,0.00021575196,0.000027072378,0.0008348282],"category_scores_gemma":[0.000007616525,0.0001652979,0.00003574166,0.00034732066,0.00031279022,0.00008885442,0.00009833516,0.0001917936,8.186775e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7202562,0.006959935,0.2173601,0.00012074477,0.004748732,0.000050496576,0.029188287,0.00001892043,0.0007448877,0.000001902844,0.00032398556,0.020225829],"study_design_scores_gemma":[0.827695,0.012158711,0.13856493,0.00018320272,0.0023559444,0.000005234772,0.0018379991,0.00019332238,0.015650235,0.000009447549,0.00096043525,0.00038551557],"about_ca_topic_score_codex":0.0017819245,"about_ca_topic_score_gemma":0.0029354286,"teacher_disagreement_score":0.10743883,"about_ca_system_score_codex":0.00016062897,"about_ca_system_score_gemma":0.00023019759,"threshold_uncertainty_score":0.9140783},"labels":[],"label_agreement":null},{"id":"W2071607258","doi":"10.1007/s002800000228","title":"A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity","year":2000,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Toxicity; Maximum tolerated dose; Limiting; Pharmacology; Medicine; Oncology; Internal medicine","score_opus":0.7038922919024159,"score_gpt":0.6398705854915662,"score_spread":0.0640217064108497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071607258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005950843,0.9947292,0.0002024797,0.00019727829,0.00032911764,0.0027141005,0.0010288047,0.000031586656,0.00017230932],"genre_scores_gemma":[0.00001916551,0.98013383,0.017982196,0.0005412351,0.00079970155,0.0003827101,0.000022739718,0.00006808641,0.000050360795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879943,0.007511492,0.0032641494,0.0006430054,0.00019228783,0.0003947487],"domain_scores_gemma":[0.9297882,0.0680238,0.0016623408,0.00026154058,0.00006875929,0.00019536984],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012667941,0.00051251566,0.0068195187,0.00019282497,0.00007981591,0.000009595438,0.00027111528,0.0006041017,0.0021744638],"category_scores_gemma":[0.012558181,0.00040593155,0.0003946587,0.00052332616,0.00026463077,0.00007516701,0.000065920816,0.0010240996,0.0000018397429],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013798577,0.00019910223,0.00010893447,0.08898635,0.0005609463,0.000002587031,0.000059224956,3.223397e-8,0.000017379287,0.0001883701,0.0012642876,0.9084748],"study_design_scores_gemma":[0.010655638,0.00023230024,0.000038619768,0.11284838,0.0079527525,0.000012047466,0.000007095257,0.000017345536,0.00025979118,0.082186654,0.7850688,0.000720584],"about_ca_topic_score_codex":0.000009067291,"about_ca_topic_score_gemma":9.411305e-7,"teacher_disagreement_score":0.9077542,"about_ca_system_score_codex":0.00007559129,"about_ca_system_score_gemma":0.0002859503,"threshold_uncertainty_score":0.99983925},"labels":[],"label_agreement":null},{"id":"W2071913509","doi":"10.1007/s00280-008-0712-z","title":"A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Pharmacokinetics; Gastroenterology; Internal medicine; Nausea; Chemotherapy; Pharmacology; Toxicity","score_opus":0.024059450511623004,"score_gpt":0.33412436485760605,"score_spread":0.31006491434598304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071913509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597985,0.003008507,0.0000147946785,0.00012252017,0.000039447616,0.0007693323,0.000033184493,0.0000057526927,0.000026630229],"genre_scores_gemma":[0.9901592,0.008987704,0.00009282419,0.00046792434,0.000050093513,0.00018110964,0.000010422468,0.000011811298,0.000038884373],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989323,0.000100784295,0.00018760587,0.00042088682,0.00008997008,0.00026844672],"domain_scores_gemma":[0.99965507,0.000023881028,0.00006870152,0.000078068304,0.00006744002,0.000106811814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009987484,0.00017896389,0.00028768778,0.000059887872,0.00008346275,0.000004871966,0.00009237463,0.00011099309,0.000069198984],"category_scores_gemma":[0.0000063650386,0.00013030565,0.000016391441,0.00010861008,0.00045870032,0.000008626256,0.000077101424,0.00013753673,1.0124196e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007900901,0.0022214267,0.36354402,0.00003561033,0.00016572389,0.000023259132,0.0005691728,0.000008385987,0.60243523,0.0000032734363,0.00017313958,0.022919895],"study_design_scores_gemma":[0.087387145,0.02446981,0.50333196,0.000023603181,0.00006185061,0.000036383015,0.00034072314,0.00008815917,0.3778999,0.00002252198,0.0057845623,0.0005533899],"about_ca_topic_score_codex":0.00003780634,"about_ca_topic_score_gemma":0.000021104452,"teacher_disagreement_score":0.22453532,"about_ca_system_score_codex":0.000010947244,"about_ca_system_score_gemma":0.00005115939,"threshold_uncertainty_score":0.531371},"labels":[],"label_agreement":null},{"id":"W2073746430","doi":"10.1007/s002800000223","title":"Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum; BioPhage Pharma (Canada)","funders":"","keywords":"Cytidine; Cytidine deaminase; In vivo; Leukemia; Nucleoside; Cytarabine; Cancer research; Chemistry; Biology; Pharmacology; Biochemistry; Immunology; Enzyme","score_opus":0.059812744456622755,"score_gpt":0.39303638163254234,"score_spread":0.3332236371759196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073746430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996938,0.0009284143,0.00010468212,0.00031807277,0.0001534699,0.0013375906,0.000044924313,0.000051008752,0.00012387021],"genre_scores_gemma":[0.99646926,0.0014122284,0.00015270227,0.0010084088,0.00043142936,0.00019521081,0.000015728123,0.00004831094,0.0002667478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795943,0.00014556394,0.00042242603,0.0006339634,0.00028396148,0.00055467564],"domain_scores_gemma":[0.998733,0.00027688703,0.0002583772,0.0002647629,0.00015988752,0.00030708086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024429784,0.00037224687,0.0010065265,0.00022331113,0.00022386968,0.000024018918,0.00015753532,0.00012237558,0.00034317543],"category_scores_gemma":[0.000016659946,0.00030519432,0.00006448379,0.00040251584,0.0005607682,0.00016281083,0.000089437,0.00042278448,0.0000011056666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009657382,0.0023795525,0.0036588935,0.00037113926,0.0006398703,0.0003448547,0.0036388116,0.0001468449,0.97201514,0.0000056355575,0.0008808881,0.0062609673],"study_design_scores_gemma":[0.2002911,0.004737624,0.037380196,0.00045476688,0.0006021685,0.00053809566,0.0019439479,0.027603738,0.72390383,0.000016619366,0.0017716176,0.00075629004],"about_ca_topic_score_codex":0.0016492567,"about_ca_topic_score_gemma":0.0004006562,"teacher_disagreement_score":0.24811132,"about_ca_system_score_codex":0.002046034,"about_ca_system_score_gemma":0.0013837365,"threshold_uncertainty_score":0.99994004},"labels":[],"label_agreement":null},{"id":"W2074046269","doi":"10.1007/s00280-005-0098-0","title":"Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer","year":2005,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Androgen; Androgen receptor; Medicine; Cancer research; Clusterin; Cancer; Internal medicine; Oncology; Biology; Hormone; Apoptosis; Genetics","score_opus":0.03139075232972255,"score_gpt":0.4092197528021406,"score_spread":0.3778290004724181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074046269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011072654,0.98470527,0.000002885706,0.0014868382,0.00027267323,0.0019201332,0.00023675348,0.000016265692,0.00028654985],"genre_scores_gemma":[0.0013794649,0.9939755,0.00021468363,0.0013668718,0.00036815146,0.0020751548,0.0000667612,0.000059731054,0.0004936877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983006,0.00019783434,0.0005961661,0.00047683174,0.000094842784,0.00033372064],"domain_scores_gemma":[0.99908483,0.00014831335,0.00038375086,0.00022140903,0.00006722927,0.00009448038],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013778463,0.0003799295,0.0013173874,0.000104677674,0.000053770604,0.000005652042,0.000120688615,0.000195504,0.0010804279],"category_scores_gemma":[0.000007651247,0.00026550656,0.00019902992,0.00026879593,0.00022299137,0.00003286265,0.000028803137,0.00026406944,0.0000011741163],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006226472,0.00012076973,0.00017172038,0.006040732,0.00044911512,0.000084302854,0.0007471322,0.00005101114,0.0021958076,0.00001966703,0.0011330255,0.98836404],"study_design_scores_gemma":[0.003007681,0.0001645217,0.00004504994,0.0011833174,0.000988525,0.000022709457,0.00003281219,0.00001543223,0.0021168818,0.000038684702,0.9921663,0.00021810632],"about_ca_topic_score_codex":0.00006127907,"about_ca_topic_score_gemma":0.00021425581,"teacher_disagreement_score":0.99103326,"about_ca_system_score_codex":0.0005682327,"about_ca_system_score_gemma":0.0007490079,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W2074712302","doi":"10.1007/s00280-003-0699-4","title":"Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"Cytarabine; In vivo; Pharmacology; Nucleoside; In vitro; Chemistry; Leukemia; Biology; Biochemistry; Immunology","score_opus":0.014840424263793414,"score_gpt":0.297704482429017,"score_spread":0.2828640581652236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074712302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542207,0.000896514,0.000018566232,0.0026977733,0.00014180041,0.00045402668,0.00002448472,0.000012082095,0.00033267905],"genre_scores_gemma":[0.99627936,0.0016518811,0.0001670561,0.0010113149,0.00005483111,0.000035812798,0.000009187687,0.000017229713,0.00077331724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991076,0.00008666633,0.00022866091,0.00025064865,0.00009289096,0.00023352561],"domain_scores_gemma":[0.99962187,0.00007392594,0.0001009965,0.000098558885,0.000027907661,0.00007673509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001227123,0.00018610789,0.0003995515,0.000087123844,0.000085796215,0.000004346415,0.000051701634,0.00005753129,0.0007098356],"category_scores_gemma":[0.0000032127236,0.00013378727,0.000043958957,0.00018458882,0.0002077581,0.00004354962,0.000021999236,0.0001616919,6.2723444e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004051762,0.00022671025,0.18583304,0.0001288223,0.00023269698,0.000013143792,0.00059449335,0.000011009762,0.80869603,0.00006223858,0.0016920366,0.0021046163],"study_design_scores_gemma":[0.010849968,0.00016434265,0.109547555,0.00006540017,0.0001580997,0.000019572943,0.000051687108,0.00016523014,0.8691927,0.000068741334,0.009573232,0.00014342411],"about_ca_topic_score_codex":0.00011142059,"about_ca_topic_score_gemma":0.00012662863,"teacher_disagreement_score":0.07628548,"about_ca_system_score_codex":0.00013171246,"about_ca_system_score_gemma":0.00011608203,"threshold_uncertainty_score":0.7772202},"labels":[],"label_agreement":null},{"id":"W2075096471","doi":"10.1007/s00280-011-1657-1","title":"A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Capecitabine; Gemcitabine; Medicine; Internal medicine; Gallbladder cancer; Gallbladder; Gastroenterology; Regimen; Cancer; Oncology; Biliary tract cancer; Colorectal cancer","score_opus":0.05717419124661998,"score_gpt":0.355581271116952,"score_spread":0.298407079870332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075096471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195486,0.003961249,0.000006332035,0.0005223989,0.0003982556,0.002820073,0.000090024456,0.000027231312,0.00021957708],"genre_scores_gemma":[0.99483865,0.0019072816,0.00019113424,0.0012895748,0.00025675076,0.0010417752,0.000015696069,0.000053847758,0.0004053101],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980018,0.00014005283,0.00053946907,0.0005978297,0.00023590325,0.0004849366],"domain_scores_gemma":[0.9990663,0.00012757843,0.00023858831,0.00019893337,0.00016537326,0.00020320839],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000251202,0.00038566932,0.0011313811,0.00024514936,0.00012488256,0.000008410505,0.00012658666,0.00010489039,0.0025897278],"category_scores_gemma":[0.000015130362,0.00024755567,0.00006068601,0.0004509544,0.00033188777,0.0001353779,0.00009493509,0.00031134443,5.9224993e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48784047,0.016440269,0.44526756,0.00033822324,0.0021478564,0.00020099009,0.020613434,7.990021e-7,0.0020764018,0.000004564629,0.0013166226,0.023752827],"study_design_scores_gemma":[0.5728618,0.067107484,0.3516672,0.000089079105,0.0013695573,0.000017327597,0.0018500641,0.000026065762,0.001877102,0.000008932967,0.0027291588,0.00039627095],"about_ca_topic_score_codex":0.0020737587,"about_ca_topic_score_gemma":0.0040140944,"teacher_disagreement_score":0.093600355,"about_ca_system_score_codex":0.00015570369,"about_ca_system_score_gemma":0.00035632754,"threshold_uncertainty_score":0.9999977},"labels":[],"label_agreement":null},{"id":"W2075881224","doi":"10.1007/s00280-007-0544-2","title":"Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Synthesis and pharmacology of benzodiazepine derivatives","field":"Chemistry","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacology; In vivo; Glioma; Receptor; Cell culture; Chemistry; Biology; Cancer research; Biochemistry; Genetics","score_opus":0.016617771239689334,"score_gpt":0.3031539496841207,"score_spread":0.28653617844443136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075881224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911895,0.00096849655,0.0050535537,0.0017197378,0.0003802151,0.00024539357,0.00030986598,0.000032644126,0.000100621095],"genre_scores_gemma":[0.99381334,0.003871277,0.0002968712,0.0008354354,0.00057976274,0.00009435586,0.000047915433,0.000029204388,0.0004318334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892783,0.00001941374,0.00033287046,0.00037273957,0.000078291094,0.00026887454],"domain_scores_gemma":[0.9991843,0.00016875638,0.00031916302,0.00009458944,0.00012441694,0.000108755],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029760567,0.00020386642,0.00035094612,0.0000703961,0.00013931312,0.000016701824,0.00010679197,0.00014936113,0.0011051237],"category_scores_gemma":[0.000014643143,0.00020751127,0.000058310274,0.00009379995,0.00026164897,0.00014168212,0.000023403662,0.0001265683,5.127054e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081283605,0.00019993125,0.0031187239,0.00026789092,0.00018911797,5.4792133e-7,0.0006907173,0.000002405643,0.9332615,0.000046902584,0.00032386137,0.061085533],"study_design_scores_gemma":[0.0025319606,0.000050826704,0.020983994,0.000025436848,0.00006752755,0.0000055295855,0.00004500334,0.00046645,0.95256954,0.000020031724,0.023031624,0.0002020743],"about_ca_topic_score_codex":0.000015241782,"about_ca_topic_score_gemma":0.0000046541627,"teacher_disagreement_score":0.060883462,"about_ca_system_score_codex":0.00004257722,"about_ca_system_score_gemma":0.000052034186,"threshold_uncertainty_score":0.999808},"labels":[],"label_agreement":null},{"id":"W2077355516","doi":"10.1007/s002800050033","title":"Modulation of Adriamycin cytotoxicity and transport in drug-sensitive and multidrug-resistant Chinese hamster ovary cells by hyperthermia and cyclosporin A","year":2000,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"National Cancer Institute","keywords":"Cytotoxicity; Hyperthermia; Pharmacology; Chinese hamster ovary cell; Doxorubicin; Membrane permeability; P-glycoprotein; Clonogenic assay; Multiple drug resistance; Intracellular; Cell culture; Biology; Chemistry; Chemotherapy; Drug resistance; Biochemistry; In vitro; Membrane","score_opus":0.0054470357018174,"score_gpt":0.2585138945395139,"score_spread":0.2530668588376965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077355516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478203,0.00359772,0.000024112127,0.00077201513,0.000066217784,0.00052801805,0.00008723606,0.000016282787,0.0001263883],"genre_scores_gemma":[0.9802559,0.017857825,0.0001748719,0.0010194087,0.000071750095,0.000028131763,0.000019999634,0.00002451366,0.0005475818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990344,0.00003855599,0.00027989116,0.00035536778,0.000088794106,0.00020298286],"domain_scores_gemma":[0.9996813,0.000034893837,0.00006262223,0.00006697188,0.000026142776,0.00012810057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013261302,0.00021537462,0.000475202,0.00006559118,0.000045746187,0.0000034903458,0.000025472884,0.00012080792,0.00021427144],"category_scores_gemma":[5.2206394e-7,0.00017457193,0.000032276857,0.00010302365,0.00019778022,0.00007345997,0.000004062339,0.00015785934,1.7792432e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040685055,0.00013805895,0.019925782,0.00025845753,0.000086403146,0.00004389492,0.0026950517,0.0000095833075,0.95923585,0.0000034154557,0.00008426339,0.0134507585],"study_design_scores_gemma":[0.011849832,0.00017700433,0.3747024,0.00013214751,0.00013480605,0.00002177695,0.00020622392,0.0013519427,0.60941523,0.00008081725,0.0016334297,0.00029437235],"about_ca_topic_score_codex":0.00029774316,"about_ca_topic_score_gemma":0.00016819026,"teacher_disagreement_score":0.35477662,"about_ca_system_score_codex":0.000023238032,"about_ca_system_score_gemma":0.000031183066,"threshold_uncertainty_score":0.71188366},"labels":[],"label_agreement":null},{"id":"W2082878515","doi":"10.1007/s00280-009-1110-x","title":"Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Institutes of Health; Cancer Research Society","keywords":"Tropomyosin receptor kinase A; Trk receptor; Low-affinity nerve growth factor receptor; Tropomyosin receptor kinase C; Neurotrophin; Biology; Cancer research; Receptor; Platelet-derived growth factor receptor; Growth factor","score_opus":0.016339139668434796,"score_gpt":0.29725041431848087,"score_spread":0.28091127465004606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082878515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959097,0.002228881,0.000008611759,0.0013482155,0.0002233301,0.00021145925,0.000013643057,0.000009894507,0.00004626511],"genre_scores_gemma":[0.9807745,0.017554434,0.000024697183,0.0013553854,0.00011734455,0.00001849552,3.4838928e-7,0.000009486654,0.00014530042],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906296,0.000110529,0.0002111913,0.00036910153,0.000064291606,0.00018192227],"domain_scores_gemma":[0.9997207,0.00007057657,0.000081535094,0.00005502177,0.000009863925,0.00006230549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006490129,0.00014876583,0.0002579111,0.00009911233,0.00005678028,0.000015736987,0.000060453105,0.00007597985,0.00016247263],"category_scores_gemma":[0.0000070499545,0.00013386155,0.000014916301,0.0001456244,0.0002329864,0.00010241138,0.000016253927,0.00011512045,6.074351e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077302137,0.00006667743,0.0042935866,0.000044352095,0.000003312519,0.0000074182867,0.00048272125,0.000010677736,0.98105097,0.00007412377,0.00017122332,0.013021909],"study_design_scores_gemma":[0.0020834978,0.00014227157,0.012738896,0.000021425207,0.000009354838,0.000008523958,0.000016119975,0.00046516184,0.9831768,0.00027967797,0.00092696026,0.0001312942],"about_ca_topic_score_codex":0.000022400314,"about_ca_topic_score_gemma":0.000080272875,"teacher_disagreement_score":0.015325553,"about_ca_system_score_codex":0.000016762366,"about_ca_system_score_gemma":0.000019685574,"threshold_uncertainty_score":0.54587156},"labels":[],"label_agreement":null},{"id":"W2083324782","doi":"10.1007/s00280-006-0343-1","title":"Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Hospices Civils de Lyon","keywords":"Paclitaxel; Tubulin; Cancer research; Primary (astronomy); Oncology; Class (philosophy); Internal medicine; Medicine; Biology; Microtubule; Chemotherapy; Genetics; Computer science","score_opus":0.011221506565915439,"score_gpt":0.293799886724627,"score_spread":0.28257838015871156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083324782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540971,0.036504533,0.000003832964,0.0045218435,0.00012651997,0.0003967052,0.000072497176,0.000008140398,0.0042688325],"genre_scores_gemma":[0.98349345,0.010625146,0.0001673369,0.0037432602,0.0001533192,0.00011978562,0.000014626297,0.000018210163,0.0016648764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990499,0.000035148347,0.000350175,0.00025919054,0.00010699643,0.00019860326],"domain_scores_gemma":[0.99950445,0.00008337547,0.00015103421,0.00012850089,0.00006689505,0.000065751265],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009953045,0.0001478093,0.0005068502,0.00009027856,0.000018026016,0.0000018532597,0.000042969397,0.000093691306,0.0012274181],"category_scores_gemma":[0.0000013848004,0.0001306281,0.000082657745,0.00018539182,0.00016881348,0.00002939744,0.000014307626,0.00010632366,6.5216534e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072145234,0.0013052481,0.6510362,0.0012840134,0.00041900657,0.00005775813,0.0017520195,0.00000997192,0.26202852,0.00028836733,0.06333046,0.011273913],"study_design_scores_gemma":[0.016845025,0.00028550532,0.54399484,0.00020751481,0.00021142916,0.000005299716,0.000024670257,0.00003825151,0.30020192,0.00023382978,0.13778648,0.00016525846],"about_ca_topic_score_codex":0.0011061148,"about_ca_topic_score_gemma":0.000639669,"teacher_disagreement_score":0.10704138,"about_ca_system_score_codex":0.00019229378,"about_ca_system_score_gemma":0.00019509073,"threshold_uncertainty_score":0.9996856},"labels":[],"label_agreement":null},{"id":"W2088605318","doi":"10.1007/s00280-007-0579-4","title":"Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Pharmacokinetics; Dosing; Medicine; Adverse effect; Toxicity; Internal medicine; Tyrosine-kinase inhibitor; Incidence (geometry); Pharmacology; Clinical trial; Gastroenterology; Oncology; Cancer","score_opus":0.018120891819779165,"score_gpt":0.380221315198652,"score_spread":0.3621004233788728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088605318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595,0.000862981,0.00028257226,0.0010473753,0.00025647547,0.0012765747,0.00017565483,0.000021133541,0.00012726527],"genre_scores_gemma":[0.9927102,0.0036593063,0.00063719845,0.0023781827,0.00034889448,0.000060901693,0.000053915715,0.000056387802,0.00009502686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802685,0.00010759538,0.00066476135,0.0004569559,0.00027499217,0.00046884103],"domain_scores_gemma":[0.99865633,0.00026648547,0.0002638366,0.00015165741,0.00035102406,0.00031068234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045440605,0.0002673466,0.00068386446,0.00015240176,0.0000681952,0.000008645914,0.00008147581,0.00014636393,0.00030760447],"category_scores_gemma":[0.000019416957,0.0002096827,0.00003761998,0.00035711945,0.0006251605,0.0000800028,0.000038497084,0.0005541956,0.0000010003587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036223136,0.001162974,0.85456276,0.0003434265,0.00028908078,0.00013388321,0.0009988424,0.000027053513,0.029902762,0.000013726139,0.00039250916,0.075949825],"study_design_scores_gemma":[0.02972538,0.004384826,0.86893165,0.0007791701,0.00019394346,0.000026310958,0.0001098873,0.00034206873,0.0906793,0.0000067781425,0.0044937776,0.00032689434],"about_ca_topic_score_codex":0.00006234399,"about_ca_topic_score_gemma":0.00003264805,"teacher_disagreement_score":0.07562293,"about_ca_system_score_codex":0.00017145414,"about_ca_system_score_gemma":0.00031806043,"threshold_uncertainty_score":0.85506123},"labels":[],"label_agreement":null},{"id":"W2091073184","doi":"10.1007/s00280-004-0941-8","title":"Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemical synthesis and alkaloids","field":"Chemistry","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Windsor","funders":"University of Windsor","keywords":"Apoptosis; Cancer cell; DNA fragmentation; DNA damage; Programmed cell death; Biology; Caspase; Cell biology; DNA; Cancer research; Molecular biology; Cancer; Biochemistry; Genetics","score_opus":0.01018464371079852,"score_gpt":0.2613468441754455,"score_spread":0.251162200464647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091073184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634296,0.0017650377,0.000016992179,0.0012366283,0.000028652787,0.00012241972,0.000046959543,0.000009934552,0.00043044685],"genre_scores_gemma":[0.99438655,0.004602822,0.00009647709,0.00046258565,0.00015909772,0.000051587685,0.000006472745,0.000017399308,0.00021700344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991313,0.000035313067,0.00035554552,0.00021530122,0.00008991757,0.00017258951],"domain_scores_gemma":[0.99935246,0.0002686514,0.00020338525,0.00009379779,0.000032577453,0.00004912722],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011623089,0.00015017026,0.0003604684,0.000028845407,0.00005170157,0.000009592197,0.000104568324,0.000094744835,0.0017836528],"category_scores_gemma":[0.000008137467,0.000119044606,0.000047663394,0.0001112441,0.0002838725,0.000062811036,0.000022715347,0.000090580965,1.7656669e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005687998,0.00011556841,0.000912572,0.00012062084,0.00008628822,2.743397e-7,0.00081391505,0.000006360657,0.95766336,0.000050790928,0.00087910675,0.038782325],"study_design_scores_gemma":[0.0055022086,0.000024927303,0.00044058738,0.000047474645,0.000025145786,5.4747613e-7,0.000073787756,0.00010548982,0.9864926,0.000048933256,0.007118366,0.00011995693],"about_ca_topic_score_codex":0.00040541694,"about_ca_topic_score_gemma":0.000014810915,"teacher_disagreement_score":0.038662367,"about_ca_system_score_codex":0.000060259605,"about_ca_system_score_gemma":0.00003200473,"threshold_uncertainty_score":0.9991289},"labels":[],"label_agreement":null},{"id":"W2091972238","doi":"10.1007/s002800100348","title":"The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Cardiotoxicity; Medicine; Doxorubicin; Mitoxantrone; Cardioprotection; Pharmacology; Chemotherapy; Cumulative dose; Urology; Internal medicine; Myocardial infarction; Anthracycline; Cancer","score_opus":0.06302401746380445,"score_gpt":0.3387333388777059,"score_spread":0.2757093214139015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091972238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933186,0.0012786626,0.00013562318,0.0030257655,0.00022832933,0.0017551067,0.00017893879,0.0000146064,0.000064371154],"genre_scores_gemma":[0.9944486,0.004036502,0.00006486624,0.0010479767,0.00021700344,0.000100170815,0.0000011998135,0.000024663657,0.000059030448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862665,0.0002655464,0.00032668907,0.00028907342,0.00021611307,0.00027595198],"domain_scores_gemma":[0.9987478,0.00037356364,0.00026485694,0.0002650579,0.0002336821,0.000115034774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035727894,0.0002200982,0.00075114146,0.00006973051,0.00015512358,0.000008974009,0.000110687826,0.00011175775,0.000035647103],"category_scores_gemma":[0.00002899498,0.00014615039,0.00016863654,0.0003019751,0.00040811533,0.00007982463,0.000039405153,0.0002945545,1.5647088e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018913663,0.00006959073,0.0033087463,0.0001108165,0.0007429814,0.0000014082665,0.0015881562,0.000056942485,0.86942804,0.000012676992,0.00014683875,0.12264246],"study_design_scores_gemma":[0.0021660149,0.00030890875,0.07866196,0.00007418473,0.00017557658,0.000012542307,0.00023738622,0.00014895921,0.9143242,0.000020165327,0.0037481636,0.00012189846],"about_ca_topic_score_codex":0.0002592586,"about_ca_topic_score_gemma":0.00007852643,"teacher_disagreement_score":0.122520566,"about_ca_system_score_codex":0.000097031756,"about_ca_system_score_gemma":0.00016400134,"threshold_uncertainty_score":0.5959839},"labels":[],"label_agreement":null},{"id":"W2092074789","doi":"10.1007/s00280-004-0984-x","title":"Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Xeroderma pigmentosum; Cockayne syndrome; Cisplatin; Nucleotide excision repair; DNA repair; DNA damage; Molecular biology; Kinase; Biology; c-jun; Programmed cell death; Cancer research; Cell biology; Chemistry; Transcription factor; DNA; Gene; Apoptosis; Biochemistry; Genetics; Chemotherapy","score_opus":0.011896685481671339,"score_gpt":0.28246559295964296,"score_spread":0.27056890747797163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092074789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986468,0.00041588343,0.000044812205,0.00029573124,0.000100733174,0.00044905156,0.000010520842,0.0000102569575,0.00002621641],"genre_scores_gemma":[0.99865615,0.00020019272,0.00018020505,0.0006571829,0.00009926935,0.00007947809,0.000008408715,0.0000131801935,0.00010590858],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992267,0.00012943776,0.00015937802,0.00027143818,0.000059324517,0.00015371449],"domain_scores_gemma":[0.999737,0.000015524203,0.00007755511,0.00011054342,0.000019345167,0.00004003032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018265712,0.0001363165,0.00016815591,0.00003238683,0.00006352004,0.000004723845,0.000039897477,0.00010638938,0.000025693118],"category_scores_gemma":[0.0000026654054,0.00011053602,0.00008280949,0.00005911213,0.000071108596,0.0000066873536,0.000015757356,0.00006447173,9.655225e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029970208,0.00015931838,0.00211816,0.00002403912,0.000072015035,0.0000040023638,0.00041189042,0.000099315046,0.99164474,0.000004966745,0.000047804606,0.0051140455],"study_design_scores_gemma":[0.0029817752,0.00024409527,0.004215535,0.000016242617,0.00005312677,0.0000068549634,0.00003360608,0.0022034065,0.9891701,0.000009050303,0.0009585769,0.00010765483],"about_ca_topic_score_codex":0.0001328734,"about_ca_topic_score_gemma":0.00025367053,"teacher_disagreement_score":0.0050063906,"about_ca_system_score_codex":0.000053591033,"about_ca_system_score_gemma":0.00005071322,"threshold_uncertainty_score":0.4507528},"labels":[],"label_agreement":null},{"id":"W2094042165","doi":"10.1007/s00280-001-0385-3","title":"Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Cmax; Pharmacology; Bioavailability; Doxorubicin; Chemistry; Anthracycline; Cancer; Breast cancer; Internal medicine; Medicine; Chemotherapy","score_opus":0.011592364575569109,"score_gpt":0.2842237320510442,"score_spread":0.27263136747547506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094042165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946335,0.0039016197,0.000046620255,0.00062531704,0.00026101325,0.00033899938,0.000043805132,0.000012776489,0.0001363542],"genre_scores_gemma":[0.98815054,0.009643224,0.000118612734,0.0012564864,0.00036623137,0.00005187136,0.000019092824,0.000040231283,0.00035371567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889237,0.00005550124,0.00026872064,0.00037314594,0.00009474493,0.00031554152],"domain_scores_gemma":[0.99953574,0.000009484181,0.00016079232,0.0001216995,0.000079024016,0.00009325685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009560241,0.0002205636,0.00029424718,0.00008765884,0.00008556418,0.000010669191,0.00012055984,0.00010538092,0.0007199885],"category_scores_gemma":[7.5736165e-7,0.0001969263,0.000048170336,0.0001611739,0.00018160297,0.000008162812,0.000039044102,0.0001330801,0.0000010022198],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062245945,0.00016749324,0.005238602,0.000097166725,0.00013308045,0.0000120964405,0.00021518955,0.0005698187,0.9856734,0.000012765432,0.0012625421,0.00599536],"study_design_scores_gemma":[0.005774503,0.00036660928,0.0072038686,0.00006345164,0.00007395491,0.00004229085,0.000030072239,0.0016299412,0.9787465,0.000014969264,0.0057795704,0.00027432005],"about_ca_topic_score_codex":0.00015400899,"about_ca_topic_score_gemma":0.00013641639,"teacher_disagreement_score":0.0069269775,"about_ca_system_score_codex":0.000027044198,"about_ca_system_score_gemma":0.000030750576,"threshold_uncertainty_score":0.8030421},"labels":[],"label_agreement":null},{"id":"W2094118633","doi":"10.1007/s00280-004-0836-8","title":"Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Cancer Institute; National Institute of Biomedical Imaging and Bioengineering; National Institute of Mental Health","keywords":"Pharmacokinetics; NONMEM; Population; Medicine; Population pharmacokinetics; Pharmacology; Internal medicine","score_opus":0.007054605613093194,"score_gpt":0.28416593735180146,"score_spread":0.2771113317387083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094118633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965156,0.0015898664,0.0010039312,0.00023478504,0.00015519762,0.0003366035,0.00007199615,0.000008137472,0.00008391937],"genre_scores_gemma":[0.99223083,0.0039791204,0.0005894885,0.002761425,0.00007493921,0.00009464975,0.00014460027,0.000025165336,0.00009980772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893546,0.00004079173,0.00027095177,0.0003821063,0.00011159987,0.00025909417],"domain_scores_gemma":[0.99948275,0.000011512649,0.00016462067,0.0001403127,0.00013223302,0.00006854132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008868792,0.00020319081,0.0003506319,0.00017613139,0.000039223774,0.0000061083115,0.00011792065,0.00011765523,0.00017002974],"category_scores_gemma":[0.0000025286922,0.00018501119,0.00007776917,0.00040919118,0.0000750498,0.000008949475,0.000025166493,0.00009097261,1.5036709e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016945059,0.00023352174,0.035860624,0.000047396392,0.0010622696,0.0000020208793,0.00030806824,0.0127911335,0.92247266,0.000084496314,0.00009116663,0.025352126],"study_design_scores_gemma":[0.013089859,0.00085849455,0.1510421,0.000040700103,0.00075995683,0.000001319776,0.000052184627,0.00032236998,0.82852906,0.00016388009,0.004698649,0.00044140933],"about_ca_topic_score_codex":0.00019806762,"about_ca_topic_score_gemma":0.0005614071,"teacher_disagreement_score":0.11518148,"about_ca_system_score_codex":0.000052572563,"about_ca_system_score_gemma":0.00006141955,"threshold_uncertainty_score":0.7544537},"labels":[],"label_agreement":null},{"id":"W2094417916","doi":"10.1007/s00280-010-1379-9","title":"Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary; McGill University; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; Aptose Biosciences (Canada); Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nimotuzumab; Chills; Rash; Toxicity; Internal medicine; Lung cancer; Regimen; Oncology; Gastroenterology; Radiation therapy; Phases of clinical research; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.030605001814380035,"score_gpt":0.4110274883242362,"score_spread":0.38042248650985616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094417916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870829,0.004047579,0.00020446586,0.0011404825,0.0018143152,0.0051257005,0.00052943657,0.000018446986,0.000036676625],"genre_scores_gemma":[0.9742936,0.017748462,0.00028789093,0.005293462,0.00089775934,0.0009695238,0.00006145357,0.00009145035,0.00035640335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973851,0.0001562224,0.00074113614,0.00065060594,0.0002794172,0.00078755064],"domain_scores_gemma":[0.998339,0.00031218375,0.0004618233,0.00028487996,0.00019415372,0.00040793355],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057220925,0.00045392456,0.0009625147,0.00017087847,0.00019126425,0.000030456109,0.0003223936,0.00032375587,0.002086994],"category_scores_gemma":[0.00000891935,0.0002666938,0.00020698439,0.00038930748,0.0006570937,0.0001014383,0.000016169484,0.00073281507,2.1298123e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44526672,0.0040446375,0.27743754,0.00033560308,0.0010709781,0.00004286729,0.00125724,0.000017769731,0.13941002,0.0000035887701,0.0021846849,0.12892835],"study_design_scores_gemma":[0.71370006,0.0117513975,0.05131566,0.00044557868,0.00032851181,0.000018279537,0.0000776342,0.002506786,0.11578197,0.000002051365,0.10340435,0.00066772784],"about_ca_topic_score_codex":0.02209356,"about_ca_topic_score_gemma":0.03269015,"teacher_disagreement_score":0.26843333,"about_ca_system_score_codex":0.00031265581,"about_ca_system_score_gemma":0.0035898727,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W2094704437","doi":"10.1007/s00280-007-0442-7","title":"O6-benzylguanine and BCNU in multiple myeloma: a phase II trial","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Carmustine; Medicine; Multiple myeloma; Neutropenia; Internal medicine; Chemotherapy; Bone marrow; Toxicity; Oncology; Gastroenterology; Regimen; Pharmacology; Etoposide","score_opus":0.04729938861380173,"score_gpt":0.412195691664822,"score_spread":0.3648963030510203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094704437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185216,0.0043183053,0.000038911898,0.0020274555,0.00025165622,0.0010653985,0.000020040934,0.000029695133,0.00039638724],"genre_scores_gemma":[0.9923513,0.0037540675,0.00021510496,0.0023481569,0.0005303545,0.00012882092,0.00001714719,0.000022396718,0.00063267176],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988361,0.000039658255,0.00023904355,0.0003255467,0.00011960243,0.00044006968],"domain_scores_gemma":[0.9993699,0.00015783934,0.000051151874,0.00008938997,0.000038459104,0.0002932564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027492,0.00017488706,0.00035132174,0.00016087967,0.00011038157,0.000007327104,0.00004566823,0.00011785573,0.0010791068],"category_scores_gemma":[0.00002040506,0.00014621159,0.000039931565,0.00017171416,0.00016729819,0.000057387653,0.000034809338,0.00023237028,0.0000026574503],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21287332,0.002392398,0.030052781,0.000118030686,0.0003671024,0.0004541223,0.0012965412,6.719004e-7,0.3077685,0.00002042891,0.0020863877,0.4425697],"study_design_scores_gemma":[0.6668898,0.0055734683,0.02132101,0.000044369855,0.000095528136,0.00007582242,0.000101076745,0.0010814414,0.24853855,0.00005967604,0.055969767,0.0002495139],"about_ca_topic_score_codex":0.00014180112,"about_ca_topic_score_gemma":0.00016045396,"teacher_disagreement_score":0.45401645,"about_ca_system_score_codex":0.00009324704,"about_ca_system_score_gemma":0.00009497362,"threshold_uncertainty_score":0.99983406},"labels":[],"label_agreement":null},{"id":"W2095031513","doi":"10.1007/s00280-012-1889-8","title":"A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Institut national de la recherche scientifique; Amgen","keywords":"Everolimus; Bevacizumab; Panitumumab; Solid tumor; Medicine; Oncology; Internal medicine; Cancer research; Chemotherapy; Cancer; Colorectal cancer; KRAS","score_opus":0.017694038033376425,"score_gpt":0.3676464043998438,"score_spread":0.34995236636646737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095031513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988189,0.010855304,0.000025993926,0.000097586955,0.00032876828,0.00040677204,0.000020458157,0.000008011562,0.000068136236],"genre_scores_gemma":[0.99652714,0.0019943793,0.00005311313,0.00085841183,0.00031498712,0.00016154043,0.000006350684,0.000027056381,0.000057051082],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895996,0.00008679703,0.00025126652,0.00030170102,0.0000739077,0.0003263821],"domain_scores_gemma":[0.99957526,0.000021004063,0.00012193287,0.00013247438,0.00004108857,0.00010822717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001695018,0.0001818546,0.00029116517,0.00005966106,0.000042935506,0.000004532708,0.00010802402,0.00010505636,0.00013526139],"category_scores_gemma":[0.0000065421523,0.00018076398,0.000028014181,0.000094988216,0.00014561902,0.000011124549,0.0000515218,0.00012336277,4.259507e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018056426,0.0010160356,0.017624924,0.000053947697,0.00012651972,0.0000030407368,0.0016755918,0.000047501195,0.952681,0.0000034170394,0.00026451662,0.024697851],"study_design_scores_gemma":[0.02377674,0.0026191168,0.0052289697,0.00002004955,0.000063815365,0.000017706487,0.00049165305,0.00008842928,0.95929515,0.000028234284,0.008066293,0.00030386864],"about_ca_topic_score_codex":0.0000504591,"about_ca_topic_score_gemma":0.0000346159,"teacher_disagreement_score":0.024393983,"about_ca_system_score_codex":0.000031592754,"about_ca_system_score_gemma":0.00006261694,"threshold_uncertainty_score":0.7371341},"labels":[],"label_agreement":null},{"id":"W2100822088","doi":"10.1007/s00280-004-0813-2","title":"Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Natural product bioactivities and synthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"Canadian Institutes of Health Research","keywords":"Matrigel; MAPK/ERK pathway; Angiogenesis; Cell biology; Endothelial stem cell; Chemistry; Biology; Cancer research; Biochemistry; Signal transduction; In vitro","score_opus":0.008358183458473594,"score_gpt":0.24970636205964786,"score_spread":0.24134817860117427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100822088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962916,0.00069148233,0.000043164426,0.0025317858,0.00007003737,0.00026250613,0.000076647855,0.0000047641115,0.000028053802],"genre_scores_gemma":[0.99625844,0.0020234112,0.000034712994,0.001437115,0.00008010654,0.000026030099,0.00002682237,0.000014775342,0.00009861034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99932605,0.00006307664,0.00016564802,0.00023702352,0.00008412987,0.00012406784],"domain_scores_gemma":[0.99958694,0.000022731025,0.00020253504,0.00008806517,0.000068170215,0.000031545846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008781031,0.00013504985,0.00018143842,0.000022419094,0.00008293616,0.000007453594,0.000052586838,0.00014344745,0.00003009639],"category_scores_gemma":[0.000008685268,0.00009944437,0.00003588067,0.000080030775,0.00019789979,0.000014750467,0.000017530798,0.00008416481,4.13188e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038159982,0.00006257633,0.0009912801,0.000046362486,0.00017616525,2.075496e-7,0.00024674577,0.000059198926,0.994565,0.0000046323166,0.00037103635,0.0030952084],"study_design_scores_gemma":[0.0018380401,0.00022364916,0.0025628007,0.000044385146,0.000057269986,0.0000064508226,0.0000498678,0.00001766516,0.9945035,0.00003616966,0.0005471748,0.00011305046],"about_ca_topic_score_codex":0.00015270115,"about_ca_topic_score_gemma":0.0000525232,"teacher_disagreement_score":0.002982158,"about_ca_system_score_codex":0.00003026336,"about_ca_system_score_gemma":0.000072784496,"threshold_uncertainty_score":0.40552238},"labels":[],"label_agreement":null},{"id":"W2103111313","doi":"10.1007/s00280-013-2275-x","title":"Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Physiologically based pharmacokinetic modelling; Busulfan; Pharmacokinetics; Volume of distribution; Pharmacology; Chemistry; Distribution (mathematics); Medicine; Mathematics; Internal medicine; Chemotherapy","score_opus":0.022343166664552657,"score_gpt":0.2629195736374368,"score_spread":0.24057640697288413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103111313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346615,0.0044675567,0.009033436,0.0019167113,0.00012131333,0.0007874218,0.000025613062,0.000009238259,0.00017256846],"genre_scores_gemma":[0.983588,0.0077335546,0.0012194399,0.0068523292,0.00026281923,0.00020515705,0.000015930467,0.000022798748,0.00009998852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989231,0.00008528792,0.00024356556,0.00038716453,0.000077347366,0.00028350888],"domain_scores_gemma":[0.99957275,0.000035700185,0.000054883763,0.0001234901,0.000053038468,0.00016015691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010334824,0.00020655045,0.00022803493,0.000047785277,0.00004745141,0.0000115571065,0.00018418701,0.0001088964,0.00027249582],"category_scores_gemma":[0.0000028261384,0.0001527357,0.00004971477,0.000135718,0.00014980143,0.0000064228066,0.00003755599,0.00014875793,0.000001336648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011016643,0.00014278856,0.0006773821,0.00010054865,0.000078559075,7.4330285e-7,0.00045371993,0.023685118,0.9457623,0.000012451718,0.005143867,0.02284091],"study_design_scores_gemma":[0.012703068,0.00087054423,0.005576355,0.00008333868,0.00013486075,0.000015420948,0.00011426096,0.15576646,0.80373335,0.00015894712,0.020234253,0.0006091221],"about_ca_topic_score_codex":0.00027105375,"about_ca_topic_score_gemma":0.000004923015,"teacher_disagreement_score":0.14202888,"about_ca_system_score_codex":0.000008126869,"about_ca_system_score_gemma":0.00006752591,"threshold_uncertainty_score":0.6228381},"labels":[],"label_agreement":null},{"id":"W2106673894","doi":"10.1007/s00280-004-0914-y","title":"Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; Institut National de la Santé et de la Recherche Médicale","keywords":"Rhodamine 123; P-glycoprotein; Vinca; Vinblastine; Pharmacology; ATP-binding cassette transporter; Multiple drug resistance; Cell culture; Cytotoxicity; Verapamil; In vitro; Biology; Vinca alkaloid; Umbelliferone; Doxorubicin; Chemistry; Vincristine; Biochemistry; Transporter; Coumarin; Chemotherapy","score_opus":0.007670302057908099,"score_gpt":0.2630383083437881,"score_spread":0.25536800628588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106673894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883221,0.008079755,0.0006731765,0.0020236515,0.0001209489,0.00038290946,0.000051554653,0.000016151627,0.00032979756],"genre_scores_gemma":[0.9872144,0.0094069,0.000565438,0.00091506535,0.000110731875,0.00002898836,0.000025927555,0.000015261312,0.001717317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992857,0.000018260558,0.00025195206,0.00020778064,0.000103600105,0.00013268949],"domain_scores_gemma":[0.9996656,0.000015323132,0.00012337558,0.0000664731,0.00005504919,0.000074142285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012176643,0.0001195589,0.00030186973,0.000056628098,0.000037795206,8.924802e-7,0.000023006487,0.000112119735,0.0005808241],"category_scores_gemma":[7.571648e-7,0.000106982756,0.000047116802,0.00009863766,0.0001542078,0.00006794494,0.0000024286162,0.000111006884,3.759075e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003481149,0.00013585466,0.0022441468,0.0005103559,0.00007475032,0.0000024263425,0.00050277874,0.0000027223823,0.9808194,0.00004710416,0.0023542345,0.009825088],"study_design_scores_gemma":[0.00573995,0.00017282636,0.005101293,0.00015563393,0.00015115735,0.0000022637576,0.000063466345,0.000033412387,0.95107937,0.00010028722,0.037300266,0.00010004772],"about_ca_topic_score_codex":0.000028499962,"about_ca_topic_score_gemma":0.000041117462,"teacher_disagreement_score":0.034946032,"about_ca_system_score_codex":0.00002962108,"about_ca_system_score_gemma":0.00003931863,"threshold_uncertainty_score":0.63596165},"labels":[],"label_agreement":null},{"id":"W2107882830","doi":"10.1007/s00280-008-0894-4","title":"The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Sulfur Compounds in Biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Sulfasalazine; Antiporter; Glutamate receptor; Cystine; Medicine; Lung cancer; Cancer research; Pharmacology; Chemistry; Oncology; Internal medicine; Biochemistry; Membrane; Enzyme; Cysteine","score_opus":0.021945319597095087,"score_gpt":0.3029447925616004,"score_spread":0.28099947296450534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107882830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679392,0.027430927,0.0014764875,0.0013073859,0.0010773614,0.00060229114,0.00010744261,0.000016055874,0.000042871907],"genre_scores_gemma":[0.9476717,0.045662347,0.00056146557,0.0035407445,0.0007203319,0.0003418838,0.000047509926,0.00004875929,0.0014052194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873143,0.00009672953,0.00030095206,0.00040150434,0.0000647859,0.00040457828],"domain_scores_gemma":[0.9992424,0.00009520066,0.00021122627,0.00021429901,0.00016095028,0.00007588036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014209803,0.00023760684,0.00028378554,0.000033600943,0.00024910245,0.000012383971,0.00024603316,0.00020682758,0.00013709374],"category_scores_gemma":[0.0000085613065,0.0001823383,0.00012008413,0.00007582949,0.00046233053,0.0000059267118,0.00006227106,0.00011959782,5.8338344e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019368731,0.00007454569,0.0102106035,0.00005774482,0.00040455462,0.000004669437,0.00010772158,0.00014483334,0.97428375,0.00001319899,0.008508379,0.0042531323],"study_design_scores_gemma":[0.0030323665,0.00039875484,0.0013995232,0.000005774592,0.00009181144,0.000058471316,0.000011518771,0.00086261594,0.789724,0.00006959178,0.20412983,0.00021572608],"about_ca_topic_score_codex":0.00007141198,"about_ca_topic_score_gemma":0.00001680463,"teacher_disagreement_score":0.19562145,"about_ca_system_score_codex":0.000020762189,"about_ca_system_score_gemma":0.00021410777,"threshold_uncertainty_score":0.743554},"labels":[],"label_agreement":null},{"id":"W2113716960","doi":"10.1007/s00280-010-1283-3","title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Pharmacodynamics; Bortezomib; Dosing; Medicine; Multiple myeloma; Pharmacology; Toxicity; Proteasome inhibitor; Internal medicine","score_opus":0.01165579831940681,"score_gpt":0.33695038874226746,"score_spread":0.32529459042286063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113716960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776006,0.00039087597,0.0000020878392,0.00013217118,0.00014073667,0.0014483486,0.000038648774,0.000012776781,0.00007429773],"genre_scores_gemma":[0.9988017,0.0005955818,0.0001361136,0.00019950833,0.000053515327,0.00013007256,0.000012242142,0.000026479322,0.000044775854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988901,0.0000687087,0.00028856224,0.000305425,0.0001869341,0.00026025783],"domain_scores_gemma":[0.99933934,0.00012310546,0.0001348269,0.000121533434,0.00011796688,0.00016322931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001061271,0.00019017268,0.00045426234,0.00018343783,0.00003519555,0.0000031961558,0.000073093106,0.000055137985,0.00045545085],"category_scores_gemma":[0.000007986262,0.00014476829,0.000025808433,0.00020340957,0.00023596869,0.00006194653,0.000029706307,0.00029510475,3.6804593e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007052567,0.0017600278,0.6711757,0.000118380485,0.00035136638,0.000016582084,0.0006352944,0.0000062040476,0.280908,9.796461e-7,0.000028430773,0.037946463],"study_design_scores_gemma":[0.09634776,0.0017339973,0.7804666,0.000029603892,0.00018185936,0.000004751525,0.00006637616,0.0010480622,0.11983823,0.00000525534,0.00016237209,0.00011511089],"about_ca_topic_score_codex":0.00036971018,"about_ca_topic_score_gemma":0.00023966431,"teacher_disagreement_score":0.16106975,"about_ca_system_score_codex":0.000026127744,"about_ca_system_score_gemma":0.00007730915,"threshold_uncertainty_score":0.59034795},"labels":[],"label_agreement":null},{"id":"W2115126022","doi":"10.1007/s00280-004-0961-4","title":"Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"In vivo; In vitro; Pharmacology; Biology; Cancer research; Medicine; Chemistry; Biochemistry; Genetics","score_opus":0.009708236940939355,"score_gpt":0.3095653741582068,"score_spread":0.2998571372172674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115126022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986277,0.0006482395,0.0000020940856,0.00032819103,0.000042682765,0.00023891509,0.000014277909,0.00000109681,0.0000967527],"genre_scores_gemma":[0.9986341,0.00092646916,0.000008387941,0.00026712552,0.000096017415,0.000040861356,0.0000026132914,0.0000076308515,0.000016812532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99938273,0.00012234047,0.00014540605,0.00019406885,0.00003093534,0.00012449613],"domain_scores_gemma":[0.99977446,0.000040159248,0.0000832403,0.00007146516,0.000011096199,0.000019576475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020346045,0.0001019125,0.00020805256,0.000056768222,0.000014784783,0.0000017396377,0.00006694139,0.00008009455,0.000037329068],"category_scores_gemma":[0.000006999424,0.000082225495,0.00002257799,0.00006678451,0.00016916271,0.0000041138123,0.000021949818,0.0001230929,5.0944607e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015347393,0.00008909116,0.009371723,0.000054201668,0.00001636487,5.634443e-7,0.00016515613,0.000045606113,0.98231614,0.000003748166,0.000061429935,0.0063412325],"study_design_scores_gemma":[0.0021621345,0.00023410283,0.011115021,0.000018681016,0.0000046878217,0.0000010835153,0.000015914797,0.00004107657,0.98595905,0.000020355461,0.00035628944,0.0000715778],"about_ca_topic_score_codex":0.00008844189,"about_ca_topic_score_gemma":0.00010364997,"teacher_disagreement_score":0.0062696547,"about_ca_system_score_codex":0.000021944048,"about_ca_system_score_gemma":0.000020083853,"threshold_uncertainty_score":0.33530584},"labels":[],"label_agreement":null},{"id":"W2119247100","doi":"10.1007/s00280-013-2271-1","title":"Clinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Natural Sciences; Canadian Cancer Society Research Institute; Foundation for the National Institutes of Health; Cancer Research Institute; National Cancer Institute; National Science Foundation","keywords":"Medicine; Lung cancer; Verapamil; Chemotherapy; Perfusion; Arterial perfusion; Cancer; Internal medicine; Lung; Oncology; Surgery","score_opus":0.03531797604947373,"score_gpt":0.4054754355285837,"score_spread":0.37015745947911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119247100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435295,0.013151498,0.000020876088,0.00079977216,0.00039601413,0.0011809015,0.000019609593,0.000008861918,0.00006954409],"genre_scores_gemma":[0.9729436,0.025762826,0.00013638852,0.0007144086,0.00018979017,0.00019055791,0.000014360207,0.00002156919,0.000026468648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984175,0.0002068264,0.0006576085,0.0002882764,0.00026454052,0.00016525536],"domain_scores_gemma":[0.99898535,0.00010556154,0.0003575862,0.00011573202,0.00036527053,0.000070482274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063485146,0.00016992085,0.00062045106,0.00013641163,0.00002275445,0.0000032323405,0.000062931074,0.00019222355,0.0024571419],"category_scores_gemma":[0.000010054077,0.00015524836,0.00013803752,0.00018351487,0.0002989728,0.00010890304,0.000014343593,0.00018011108,1.7282956e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015660459,0.0002789575,0.015654488,0.00017958472,0.0002409324,8.2569855e-8,0.0012707164,0.000018144834,0.71734554,0.000005708705,0.00009329797,0.26334652],"study_design_scores_gemma":[0.020978225,0.00042702354,0.10758808,0.00025051215,0.00012661815,0.0000027967767,0.0001711603,0.004401989,0.8655459,0.0001854642,0.00019832171,0.00012386066],"about_ca_topic_score_codex":0.00017059993,"about_ca_topic_score_gemma":0.000010805116,"teacher_disagreement_score":0.26322266,"about_ca_system_score_codex":0.00008192402,"about_ca_system_score_gemma":0.0002324543,"threshold_uncertainty_score":0.99845475},"labels":[],"label_agreement":null},{"id":"W2137086876","doi":"10.1007/s00280-006-0371-x","title":"A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pharmacokinetics; Tolerability; Vomiting; Nausea; Pharmacology; Medicine; Pharmacodynamics; Internal medicine; Adverse effect","score_opus":0.014082082024975417,"score_gpt":0.3399569902318229,"score_spread":0.3258749082068475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137086876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722386,0.005970396,0.000009887723,0.004569295,0.0004243007,0.0016836717,0.000024380879,0.000019336634,0.000074863456],"genre_scores_gemma":[0.99572873,0.0009572572,0.000036868463,0.0025309052,0.000297813,0.00028895854,0.0000017706755,0.000030209958,0.00012746743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983423,0.00013894898,0.00050777907,0.00047535737,0.00017268807,0.00036292538],"domain_scores_gemma":[0.9994088,0.00010255971,0.00014744187,0.00019442687,0.00005090484,0.000095869145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022572573,0.0002425443,0.00055544154,0.00011629866,0.00006967789,0.0000054184966,0.00011209546,0.00008350555,0.000578973],"category_scores_gemma":[0.000004927361,0.0001943348,0.000048121186,0.00026500603,0.0002736015,0.000066911394,0.00004226215,0.0003470185,5.084114e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02071145,0.0068129366,0.69242436,0.0007011351,0.00018382396,0.00007871524,0.0055317003,0.0012591338,0.23172835,0.0000090959,0.00030064318,0.040258642],"study_design_scores_gemma":[0.20210555,0.0051672654,0.59560555,0.00036590916,0.00037830835,0.00016381031,0.0025518842,0.0035157746,0.16943356,0.0003724453,0.019534297,0.00080566877],"about_ca_topic_score_codex":0.0016790844,"about_ca_topic_score_gemma":0.0019383185,"teacher_disagreement_score":0.1813941,"about_ca_system_score_codex":0.00025123043,"about_ca_system_score_gemma":0.000107453714,"threshold_uncertainty_score":0.7924743},"labels":[],"label_agreement":null},{"id":"W2138513351","doi":"10.1007/s00280-013-2094-0","title":"Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; Barbara Ann Karmanos Cancer Institute; Mesothelioma Applied Research Foundation","keywords":"Antifolate; In vivo; Ribonucleotide; In vitro; Nucleoside; Cell culture; Biology; Purine metabolism; Chemistry; Biochemistry; Molecular biology; Antimetabolite; Nucleotide; Immunology; Enzyme","score_opus":0.02077438752416983,"score_gpt":0.30493655675241405,"score_spread":0.2841621692282442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138513351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97893393,0.006730031,0.000698581,0.009304761,0.00014833055,0.0038668795,0.00003946609,0.00009508941,0.00018291132],"genre_scores_gemma":[0.98710483,0.003577198,0.00008805414,0.0066512926,0.00023749785,0.0013850959,0.00002923886,0.00008606542,0.00084071135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787205,0.00007185859,0.00038015386,0.00059898756,0.00029829636,0.0007786378],"domain_scores_gemma":[0.99900967,0.00008920011,0.00015185418,0.00019659789,0.0003245933,0.00022808695],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033196365,0.0004097443,0.00055071246,0.00014013505,0.00030682707,0.000046661236,0.00021723032,0.00020903492,0.002452994],"category_scores_gemma":[0.0000034210368,0.00023514716,0.000099423654,0.0006018568,0.00031668303,0.00021635345,0.000016289683,0.00059013715,0.000019330864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002475498,0.0003117442,0.0017565818,0.00018356634,0.0012404461,0.000026530906,0.0015588521,0.000009735518,0.9822999,0.0000106908465,0.0012104332,0.008915968],"study_design_scores_gemma":[0.012631224,0.0012950528,0.009412573,0.00008321897,0.00040793585,0.00020051427,0.000117483425,0.017046517,0.94290316,0.000059743226,0.015380578,0.0004620089],"about_ca_topic_score_codex":0.0003299523,"about_ca_topic_score_gemma":0.0000159356,"teacher_disagreement_score":0.0393968,"about_ca_system_score_codex":0.00008599281,"about_ca_system_score_gemma":0.00020409806,"threshold_uncertainty_score":0.9984589},"labels":[],"label_agreement":null},{"id":"W2139011868","doi":"10.1007/s00280-005-0040-5","title":"Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"National Cancer Institute","keywords":"Topoisomerase; DNA; Chemistry; Benzoquinone; Carcinogen; Pharmacology; Stereochemistry; Cancer research; Biochemistry; Biology","score_opus":0.016196097049669407,"score_gpt":0.3171702543919485,"score_spread":0.3009741573422791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139011868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998484,0.00043459373,0.000051116633,0.00031604193,0.00028451177,0.000355077,0.000031426403,0.0000029593334,0.000040276682],"genre_scores_gemma":[0.99873066,0.00034391246,0.000055824275,0.0005181212,0.00023330854,0.000027572773,0.0000027089798,0.000014778986,0.000073088464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99940085,0.000051613188,0.00013587548,0.00021522312,0.00007554434,0.00012088225],"domain_scores_gemma":[0.999567,0.000006919753,0.00019547722,0.00013470727,0.00006465711,0.000031250434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047505782,0.00012332745,0.00016545855,0.000024901723,0.00007401482,0.0000030249307,0.000100321144,0.00006157623,0.00016788485],"category_scores_gemma":[0.0000010649554,0.00008837714,0.000034990608,0.00008155966,0.00009380096,0.0000070292135,0.00005094666,0.000089792586,3.312625e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009306638,0.00027136356,0.0009829593,0.000015889538,0.0003046623,1.6368547e-7,0.001620899,0.00024811196,0.960277,0.000004706796,0.000075482734,0.035268046],"study_design_scores_gemma":[0.0023902718,0.0010634154,0.0024557277,0.000009183137,0.000072916446,0.000004618317,0.00033397818,0.00014721607,0.9888225,0.000013750566,0.004588539,0.00009786019],"about_ca_topic_score_codex":0.00010161705,"about_ca_topic_score_gemma":0.00018849112,"teacher_disagreement_score":0.035170186,"about_ca_system_score_codex":0.000023732486,"about_ca_system_score_gemma":0.000051803934,"threshold_uncertainty_score":0.36039153},"labels":[],"label_agreement":null},{"id":"W2140095109","doi":"10.1007/s00280-004-0949-0","title":"A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vector Institute","keywords":"Gemcitabine; Conjugate; Deoxycytidine kinase; Nucleoside transporter; Pharmacology; Phospholipid; Nucleoside; Antimetabolite; Chemistry; Cancer research; Deoxycytidine; Biology; Chemotherapy; Biochemistry; Medicine; Internal medicine; Transporter","score_opus":0.013296316808104846,"score_gpt":0.2922853730567955,"score_spread":0.2789890562486907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140095109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7794696,0.0146613065,0.050237052,0.14410976,0.0026088639,0.0026915646,0.00026379916,0.0003723414,0.0055856924],"genre_scores_gemma":[0.7622626,0.0058897925,0.028267698,0.15313356,0.0017992378,0.00061598374,0.000027438706,0.00016671693,0.047836963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824935,0.000012257247,0.00033788476,0.0005853767,0.00022426553,0.0005908754],"domain_scores_gemma":[0.9991396,0.000025767156,0.00009612898,0.00022778525,0.00011863252,0.0003920804],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018520886,0.00033834248,0.00056311494,0.000099502,0.00015812692,0.000018431148,0.00016803847,0.00014626887,0.0053791655],"category_scores_gemma":[0.0000017270021,0.00029851723,0.000114350805,0.00026957123,0.00010992905,0.00009481916,0.000021825337,0.00026080184,0.00004510107],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026491787,0.0002797867,0.0001859652,0.00019321943,0.00033309244,0.000019418198,0.0012166528,0.000019643523,0.9453785,0.0013935171,0.037250955,0.0110801095],"study_design_scores_gemma":[0.0060956525,0.00007425228,0.0003926414,0.0000669268,0.00014780195,0.000011497065,0.000032907214,0.00017780709,0.5926939,0.00038864915,0.3996511,0.00026683518],"about_ca_topic_score_codex":0.000051507788,"about_ca_topic_score_gemma":0.0004269213,"teacher_disagreement_score":0.36240017,"about_ca_system_score_codex":0.00013344617,"about_ca_system_score_gemma":0.00014444468,"threshold_uncertainty_score":0.9999467},"labels":[],"label_agreement":null},{"id":"W2143746306","doi":"10.1007/s00280-003-0718-5","title":"Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Carcinogens and Genotoxicity Assessment","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; Canadian Institutes of Health Research; Cancer Institute, University of Pittsburgh","keywords":"DNA; Chemistry; In vitro; DNA damage; Cytotoxicity; Agarose; Biochemistry; Molecular biology; Stereochemistry; Biology","score_opus":0.010184799143635301,"score_gpt":0.2974872117290596,"score_spread":0.2873024125854243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143746306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724823,0.00014524716,0.0012970954,0.0000873704,0.000082282306,0.0010526231,0.00006223132,0.0000049935197,0.000019906505],"genre_scores_gemma":[0.9990259,0.00013404016,0.00020792974,0.00047266108,0.000043393375,0.000076836026,0.000018379482,0.000015147957,0.0000057552393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99910724,0.00013938893,0.000160674,0.00032206654,0.00009256387,0.00017805869],"domain_scores_gemma":[0.9996358,0.000033088916,0.00011517068,0.00009093591,0.000049840306,0.00007513097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014008173,0.00017102783,0.00022324869,0.00007589032,0.00006404172,0.000011212336,0.00004025194,0.00011251295,0.000028437473],"category_scores_gemma":[0.000008347556,0.00015342802,0.000020370298,0.00014046908,0.000051093917,0.000013190753,0.000015943244,0.00010762242,9.530636e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013511708,0.00017413327,0.004542613,0.000054547687,0.0001033999,0.0000033500473,0.0009267244,0.0003071902,0.9899708,0.000011643676,0.00001681346,0.0025375914],"study_design_scores_gemma":[0.0038351463,0.002007923,0.06791771,0.000017610906,0.000031527165,0.0000061719584,0.00018645062,0.00011672723,0.92562217,0.000055765136,0.000048756356,0.00015402187],"about_ca_topic_score_codex":0.00006806323,"about_ca_topic_score_gemma":0.0002184136,"teacher_disagreement_score":0.06434864,"about_ca_system_score_codex":0.000045866003,"about_ca_system_score_gemma":0.00004098307,"threshold_uncertainty_score":0.6256613},"labels":[],"label_agreement":null},{"id":"W2145604692","doi":"10.1007/s00280-006-0353-z","title":"Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; BC Cancer Agency; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Irinotecan; Cisplatin; Cytotoxicity; Drug; Cell culture; DNA; Cancer research; SN-38; Chemistry; Camptothecin; DNA adduct; Pharmacology; Biology; In vitro; Chemotherapy; Medicine; Cancer; Internal medicine; Biochemistry; Genetics","score_opus":0.03020654306366584,"score_gpt":0.3436383977097108,"score_spread":0.31343185464604495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145604692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98907906,0.0009188704,0.0087932255,0.00050163135,0.00015560408,0.00033975393,0.000026899137,0.0000120747945,0.00017286644],"genre_scores_gemma":[0.9966264,0.0006485135,0.00056260405,0.0015295633,0.00027125416,0.000099540266,0.00014975398,0.00002521833,0.00008719777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990375,0.000095245596,0.00025554327,0.00031886765,0.000064653206,0.00022816639],"domain_scores_gemma":[0.9996468,0.000028761417,0.00012431214,0.00010092437,0.00004374752,0.0000554812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016628264,0.00017361958,0.00017148246,0.00012661827,0.000066877285,0.00003014481,0.00007827784,0.00012405284,0.00009350421],"category_scores_gemma":[0.0000012398714,0.00018967678,0.000030783944,0.00012408283,0.000041162988,0.00003150836,0.000023637569,0.00016246825,2.999554e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004482813,0.00019570469,0.0013304513,0.00004210684,0.000007857983,0.0000024375502,0.00013603116,0.005591072,0.9850518,0.0000072761704,0.00015784918,0.00702912],"study_design_scores_gemma":[0.0043219295,0.00018420894,0.0023895614,0.000020581629,0.000017245986,0.0000032417117,0.0000550422,0.03228641,0.9568906,0.000106804066,0.0035165173,0.00020789576],"about_ca_topic_score_codex":0.0003504494,"about_ca_topic_score_gemma":0.0020250464,"teacher_disagreement_score":0.02816125,"about_ca_system_score_codex":0.00005459695,"about_ca_system_score_gemma":0.000059048845,"threshold_uncertainty_score":0.77347946},"labels":[],"label_agreement":null},{"id":"W2150807070","doi":"10.1007/s00280-007-0522-8","title":"Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"National Science Council","keywords":"In vivo; Apoptosis; Growth inhibition; In vitro; Cervical carcinoma; Cancer research; Hsp90; Biology; Pharmacology; Chemistry; Internal medicine; Medicine; Cervical cancer; Cancer; Heat shock protein; Gene; Biochemistry; Genetics","score_opus":0.016125795953849154,"score_gpt":0.3175938469495421,"score_spread":0.30146805099569296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150807070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984169,0.0007373624,0.00010640148,0.00017229424,0.000031041003,0.00048610228,0.00003010465,9.5228245e-7,0.000018843899],"genre_scores_gemma":[0.9980414,0.00158122,0.00015985123,0.0000946021,0.000051037005,0.000048428356,0.000010059843,0.000009192331,0.000004244231],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992609,0.00005857471,0.0002715278,0.00020132797,0.00005017069,0.00015748166],"domain_scores_gemma":[0.9997542,0.000045781253,0.000067792935,0.000042333337,0.00005289185,0.00003703319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033291793,0.000080882724,0.00019844691,0.00017331065,0.000009916328,0.0000013363772,0.00002476434,0.00017178331,0.000011037575],"category_scores_gemma":[0.000011018507,0.000085615786,0.00001906557,0.00014614129,0.00014989512,0.0000067948554,0.00002513259,0.000089774556,1.0357311e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003611505,0.0002470087,0.00640277,0.0003200208,0.000011133507,6.0262124e-7,0.00029123557,0.0000040496607,0.9840031,0.0000053979124,0.000017465969,0.0050856774],"study_design_scores_gemma":[0.008609644,0.0002737483,0.01223632,0.00002918594,0.000005234068,0.0000012970339,0.00005359969,0.0000529274,0.978552,0.000052982756,0.00006597365,0.00006710677],"about_ca_topic_score_codex":0.00027172227,"about_ca_topic_score_gemma":0.00009075678,"teacher_disagreement_score":0.005833551,"about_ca_system_score_codex":0.000026980751,"about_ca_system_score_gemma":0.000046480727,"threshold_uncertainty_score":0.34913105},"labels":[],"label_agreement":null},{"id":"W2151917263","doi":"10.1007/s00280-015-2777-9","title":"Development of a new equation to estimate creatinine clearance in cancer patients","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Carboplatin; Dosing; Medicine; Renal function; Creatinine; Body surface area; Urology; Lung cancer; Cancer; Retrospective cohort study; Chemotherapy; Internal medicine; Surgery; Cisplatin","score_opus":0.13157277190601038,"score_gpt":0.4725437734992171,"score_spread":0.3409710015932067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151917263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925588,0.0010898237,0.00020977702,0.005266307,0.00025636645,0.0003695281,0.0000030674191,0.000012607903,0.00023375265],"genre_scores_gemma":[0.9730542,0.0008539516,0.0118240565,0.013418297,0.0002161257,0.00015285,0.0000084947615,0.000016472019,0.00045556683],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994065,0.000014222869,0.00022177487,0.00013174795,0.00008370248,0.00014204148],"domain_scores_gemma":[0.9996168,0.000011871518,0.000062287414,0.000032741467,0.00008105627,0.00019522973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010841993,0.00007048921,0.00019532579,0.000074951306,0.000019041607,0.000001821184,0.000026828775,0.00003963997,0.00037820337],"category_scores_gemma":[0.0000063382417,0.00006677769,0.000009153492,0.00014013209,0.000018679259,0.000026893527,0.000008461733,0.000073698524,0.0000026253786],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007569719,0.00061101426,0.34149408,0.0006786371,0.000083329425,0.0000036590604,0.024615042,0.00018798083,0.051488303,0.00004656374,0.023016298,0.55020535],"study_design_scores_gemma":[0.032856945,0.0006032328,0.3830963,0.00065798184,0.00004468479,0.0000023244452,0.00013745941,0.0017451664,0.2975987,0.00015628366,0.28283834,0.00026258186],"about_ca_topic_score_codex":0.00013752466,"about_ca_topic_score_gemma":0.00007617975,"teacher_disagreement_score":0.5499428,"about_ca_system_score_codex":0.00014168017,"about_ca_system_score_gemma":0.00038428034,"threshold_uncertainty_score":0.41410616},"labels":[],"label_agreement":null},{"id":"W2157706519","doi":"10.1007/s00280-011-1798-2","title":"Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Research Resources; National Cancer Institute; Frank A. Campini Foundation","keywords":"Sunitinib; Medicine; Pharmacokinetics; Neutropenia; Dosing; Tolerability; Refractory (planetary science); Internal medicine; Tyrosine-kinase inhibitor; Pharmacology; Gastroenterology; Urology; Adverse effect; Toxicity; Cancer","score_opus":0.03107978894315848,"score_gpt":0.350450297542223,"score_spread":0.3193705085990645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157706519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620086,0.0005114493,0.0000026308387,0.00009649183,0.000079718964,0.0024611147,0.00001867966,0.000020127274,0.00060891005],"genre_scores_gemma":[0.997824,0.0009969444,0.000072960815,0.0005095789,0.00016672564,0.00031402984,0.00001778359,0.000032186745,0.000065796696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854225,0.00020253804,0.00038450447,0.00038570925,0.00017529541,0.000309705],"domain_scores_gemma":[0.9993093,0.00009943557,0.0001730504,0.00013218407,0.00014506814,0.00014094342],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031275264,0.00019603419,0.0005280018,0.00022455376,0.000041699805,0.0000037136952,0.00007572848,0.00010299977,0.005098005],"category_scores_gemma":[0.000007060626,0.00016029531,0.000030618914,0.0002651364,0.00016267964,0.00010513071,0.000035851408,0.00034742648,6.8471417e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009530779,0.0032509593,0.90415597,0.00016176332,0.00016396733,0.000010519489,0.005556425,7.2532583e-7,0.02608564,0.0000016056781,0.000066095214,0.051015567],"study_design_scores_gemma":[0.021836136,0.0060115843,0.95549184,0.00001788513,0.00015189538,0.000008128804,0.00014712372,0.000050386887,0.01589533,0.000015892054,0.00022027275,0.0001535061],"about_ca_topic_score_codex":0.00023578544,"about_ca_topic_score_gemma":0.00006525161,"teacher_disagreement_score":0.051335905,"about_ca_system_score_codex":0.00013704314,"about_ca_system_score_gemma":0.00015965205,"threshold_uncertainty_score":0.99581146},"labels":[],"label_agreement":null},{"id":"W2292096944","doi":"10.1007/s00280-015-2929-y","title":"Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cellular transport and secretion","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories","funders":"","keywords":"Metabolite; Pharmacokinetics; Metabolism; Hydroxylation; Pharmacology; Chemistry; Feces; Internal medicine; Biology; Endocrinology; Biochemistry; Medicine","score_opus":0.012525230348863457,"score_gpt":0.28500653046982105,"score_spread":0.2724813001209576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292096944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778045,0.011176698,0.00007812024,0.000486741,0.00021423987,0.00016915018,0.00001319369,0.0000025979643,0.000078821475],"genre_scores_gemma":[0.99505794,0.0039305133,0.000017739594,0.00063270726,0.00016969773,0.000019709818,0.00006559066,0.0000093243025,0.00009675587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99948764,0.00004839591,0.00012702047,0.00018446878,0.000044267366,0.000108210676],"domain_scores_gemma":[0.9997932,0.0000045079328,0.000051979947,0.00006619106,0.000026753762,0.000057388297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001102828,0.0000957658,0.00013488397,0.000027642087,0.00004091697,0.000005851736,0.000045992525,0.00009273101,0.000023760886],"category_scores_gemma":[0.0000012387932,0.00007545457,0.000023368177,0.000056597913,0.00017969203,0.0000057431594,0.0000231119,0.000072036026,5.7184955e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017810172,0.000028455355,0.026238337,0.000028139482,0.000027609365,7.808045e-7,0.000429142,0.0000038917133,0.9713242,0.000062155035,0.00015290841,0.0015262938],"study_design_scores_gemma":[0.0031812887,0.0001181794,0.034753196,0.000011634744,0.00004355011,0.000007035546,0.000064116466,0.00002362154,0.9073363,0.0002110356,0.054127526,0.00012250792],"about_ca_topic_score_codex":0.000084878084,"about_ca_topic_score_gemma":0.000095391326,"teacher_disagreement_score":0.06398787,"about_ca_system_score_codex":0.000007524192,"about_ca_system_score_gemma":0.000029797326,"threshold_uncertainty_score":0.3076948},"labels":[],"label_agreement":null},{"id":"W2323158095","doi":"10.1007/s00280-016-3018-6","title":"Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice","year":2016,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Cancer Institute; U.S. Public Health Service; American Lebanese Syrian Associated Charities","keywords":"Physiologically based pharmacokinetic modelling; Sorafenib; Multidrug resistance-associated protein 2; Pharmacology; Pharmacokinetics; Transporter; Efflux; Chemistry; CYP3A4; Metabolite; Organic anion-transporting polypeptide; Glucuronide; Abcg2; In vivo; ATP-binding cassette transporter; Cytochrome P450; Biology; Metabolism; Biochemistry; Cancer research; Hepatocellular carcinoma","score_opus":0.0252176359212309,"score_gpt":0.31581283572286145,"score_spread":0.29059519980163057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323158095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856561,0.003205095,0.0076135565,0.0030345412,0.00012583057,0.0003050769,0.000010115835,0.000026891734,0.000022790797],"genre_scores_gemma":[0.98834467,0.008108553,0.0004648136,0.0028252904,0.0001120655,0.00003974413,0.000004640394,0.000015902033,0.00008435119],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9992237,0.000031271862,0.00020654062,0.0002915223,0.00005938131,0.00018759364],"domain_scores_gemma":[0.9997289,0.00005666938,0.00004559771,0.00004669169,0.000028190309,0.00009391108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011827456,0.00014320241,0.00032133656,0.00006405236,0.000039325332,0.0000030557562,0.000028647275,0.000105154664,0.00018004046],"category_scores_gemma":[0.0000020838972,0.00009252517,0.00003136648,0.00006166138,0.000088308596,0.00005760256,0.000003128188,0.0000964827,2.3762516e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029854532,0.00010463436,0.009959829,0.0002066341,0.00007107911,0.000019463212,0.0004232756,0.001258114,0.9584454,0.000029036755,0.00000692249,0.02649015],"study_design_scores_gemma":[0.0663625,0.0007423424,0.10036879,0.0010107558,0.0009363019,0.000017072955,0.00016386934,0.4504126,0.36413676,0.0037387041,0.010990018,0.0011202996],"about_ca_topic_score_codex":0.000018759998,"about_ca_topic_score_gemma":0.000024690144,"teacher_disagreement_score":0.5943087,"about_ca_system_score_codex":0.000018941455,"about_ca_system_score_gemma":0.000033829343,"threshold_uncertainty_score":0.3773067},"labels":[],"label_agreement":null},{"id":"W2339737660","doi":"10.1007/s00280-016-3026-6","title":"The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Pancreatic cancer; Internal medicine; Interstitial lung disease; Gastroenterology; Lung cancer; Oncology; Incidence (geometry); Cancer; Lung; Epidermal growth factor receptor","score_opus":0.008902987812251021,"score_gpt":0.2873161042179896,"score_spread":0.27841311640573857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339737660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871577,0.003765334,0.000025592182,0.0059719384,0.0002677708,0.0011044353,0.000085393396,0.00002327302,0.000040483148],"genre_scores_gemma":[0.9907035,0.006131787,0.000009907509,0.002508321,0.00006939036,0.00026697098,0.000014371524,0.00003704208,0.0002586598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987395,0.00008596896,0.00030067447,0.000342198,0.00020672625,0.00032495512],"domain_scores_gemma":[0.99912816,0.00019398426,0.00025746075,0.00014071156,0.00014765492,0.00013199961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015445864,0.0002458012,0.0004317575,0.00008486837,0.00010987947,0.0000119792985,0.00008893609,0.00008765677,0.00046511216],"category_scores_gemma":[0.000014018005,0.00013593424,0.000042355063,0.0002387613,0.00038751838,0.00012545618,0.000018705074,0.00014300793,2.190469e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12224436,0.0005396227,0.6718639,0.0002673157,0.0017555448,0.000014511256,0.0020687906,0.0000062612626,0.07026951,0.000021525304,0.0013260569,0.12962258],"study_design_scores_gemma":[0.08648861,0.0020013945,0.87355685,0.001220796,0.0004909062,0.0000023924963,0.00009743524,0.0003869766,0.033653803,0.000039367485,0.0016751486,0.00038631182],"about_ca_topic_score_codex":0.0002380301,"about_ca_topic_score_gemma":0.00033406858,"teacher_disagreement_score":0.20169292,"about_ca_system_score_codex":0.00036291653,"about_ca_system_score_gemma":0.00028308074,"threshold_uncertainty_score":0.5543238},"labels":[],"label_agreement":null},{"id":"W2470744532","doi":"10.1007/s00280-016-3102-y","title":"A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"Novartis","keywords":"Refractory (planetary science); Pancreatic cancer; Chemotherapy; Medicine; Hsp90 inhibitor; Cancer; Oncology; Internal medicine; Hsp90; Chemistry; Materials science; Metallurgy","score_opus":0.01799644560490742,"score_gpt":0.36780365554293126,"score_spread":0.34980720993802383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470744532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923203,0.0036539088,0.000019280464,0.0024117613,0.00028479926,0.0011898149,0.000039319744,0.000009083506,0.00007170948],"genre_scores_gemma":[0.9870326,0.00940145,0.000020828173,0.0012873745,0.00034307354,0.00076652906,0.0000017056849,0.00004038909,0.0011060875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984451,0.00022501958,0.00031352736,0.00047031205,0.00016545993,0.00038057612],"domain_scores_gemma":[0.999332,0.00004074998,0.0001242928,0.00031840673,0.000088663444,0.00009585056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022597825,0.000218948,0.00031436462,0.00006800774,0.000110383146,0.000004853648,0.00030023925,0.00015926345,0.00061118667],"category_scores_gemma":[0.000020085614,0.000137842,0.00006227977,0.0002063298,0.00023025862,0.000010679431,0.000120904995,0.00017328351,6.994063e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020379385,0.0012027135,0.005603022,0.000033945616,0.00013616608,0.0000019164981,0.00064562645,0.0000062500267,0.85069966,0.0000012890223,0.001027248,0.13860422],"study_design_scores_gemma":[0.021251176,0.0028350092,0.0017883262,0.000055355038,0.000020169993,0.0000020416774,0.00010278747,0.000014921732,0.92030764,0.000017255239,0.053419344,0.00018597972],"about_ca_topic_score_codex":0.00019133708,"about_ca_topic_score_gemma":0.00028647995,"teacher_disagreement_score":0.13841824,"about_ca_system_score_codex":0.00009709973,"about_ca_system_score_gemma":0.00027665275,"threshold_uncertainty_score":0.66920656},"labels":[],"label_agreement":null},{"id":"W2576527888","doi":"10.1007/s00280-016-3226-0","title":"Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Regimen; Lung cancer; Hazard ratio; Chemotherapy; Chemoradiotherapy; Oncology; Vinblastine; Proportional hazards model; Chemotherapy regimen; Etoposide; Gastroenterology; Cisplatin; Surgery","score_opus":0.04700574394080015,"score_gpt":0.39529307686205317,"score_spread":0.348287332921253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576527888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755008,0.015384127,0.00020713052,0.004504107,0.0010968372,0.002689482,0.00020173694,0.000025745043,0.00039003746],"genre_scores_gemma":[0.97488487,0.01882156,0.0003142819,0.0025407139,0.00048415016,0.0015240709,0.000029264038,0.00007669085,0.0013243759],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982075,0.000033420336,0.00048513128,0.0005879344,0.00014760172,0.0005384227],"domain_scores_gemma":[0.9986432,0.00014867405,0.0005071177,0.0003737775,0.0001417221,0.0001854661],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016276984,0.0003707602,0.0010770696,0.000108048436,0.00019383673,0.000035890618,0.0002337885,0.00019140028,0.00091309194],"category_scores_gemma":[0.0000049302835,0.00032861455,0.00016791985,0.000084928186,0.00024148276,0.000099566205,0.000033032316,0.00022462508,4.663875e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004106061,0.0027667216,0.711156,0.0014031006,0.00081109046,0.000008342214,0.0034031828,0.00005735406,0.23173723,0.0000097378115,0.014171048,0.030370101],"study_design_scores_gemma":[0.07614,0.0008750208,0.01462084,0.00042230164,0.00024067759,0.0000029235678,0.00010002668,0.006889893,0.82715005,0.000005752389,0.07319388,0.00035864324],"about_ca_topic_score_codex":0.0011730065,"about_ca_topic_score_gemma":0.00070709974,"teacher_disagreement_score":0.69653517,"about_ca_system_score_codex":0.00058175606,"about_ca_system_score_gemma":0.0002716528,"threshold_uncertainty_score":0.9999166},"labels":[],"label_agreement":null},{"id":"W2595403257","doi":"10.1007/s00280-017-3260-6","title":"A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Oncolytics Biotech","keywords":"Chills; Medicine; Carboplatin; Internal medicine; Melanoma; Nausea; Oncology; Adverse effect; Paclitaxel; Phases of clinical research; Chemotherapy; Immunotherapy; Gastroenterology; myalgia; Cancer; Immunology; Cisplatin; Cancer research","score_opus":0.014822680131463905,"score_gpt":0.3479693058060301,"score_spread":0.33314662567456615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595403257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770105,0.0007447204,0.000026969325,0.00018884467,0.000041320036,0.0012263722,0.000045579694,0.0000031419183,0.00002199765],"genre_scores_gemma":[0.9987243,0.00054578925,0.0001065043,0.00015589647,0.00003585258,0.00032793824,0.0000264817,0.000023653427,0.00005360479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991744,0.000056035853,0.00014957388,0.00033811285,0.000087695655,0.00019418554],"domain_scores_gemma":[0.9994228,0.000017434888,0.00016881796,0.00021164861,0.00012344054,0.000055883327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014426472,0.00014475144,0.00022429525,0.00005024563,0.000170648,0.000011403639,0.00012441081,0.000067064226,0.000017317165],"category_scores_gemma":[0.000006589249,0.00011354263,0.000015076328,0.000041143212,0.0001788131,0.0000108933045,0.000040533872,0.00006739879,2.6846912e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062065586,0.0031469006,0.079093456,0.00007797705,0.00035001675,0.0000038225044,0.0011675626,0.00002582358,0.7545081,0.0000057959387,0.00006616395,0.09948881],"study_design_scores_gemma":[0.11098865,0.12742314,0.0271529,0.000039424318,0.00007076388,0.0000019701672,0.00023350233,0.0002134143,0.73251766,0.000046059264,0.0010020689,0.0003104257],"about_ca_topic_score_codex":0.00005022791,"about_ca_topic_score_gemma":0.00047427064,"teacher_disagreement_score":0.124276236,"about_ca_system_score_codex":0.000016263733,"about_ca_system_score_gemma":0.00006538527,"threshold_uncertainty_score":0.4630134},"labels":[],"label_agreement":null},{"id":"W2604986769","doi":"10.1007/s00280-017-3298-5","title":"Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Autophagy; Pantoprazole; Drug resistance; Pharmacology; Cancer research; Chemotherapy; Programmed cell death; Biology; Apoptosis; Chemistry; Biochemistry","score_opus":0.013776681150835128,"score_gpt":0.3230400342287358,"score_spread":0.30926335307790065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604986769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805863,0.0012123688,0.00016920517,0.016643211,0.00017645789,0.0007335252,0.00030360895,0.000026125837,0.00014922618],"genre_scores_gemma":[0.97325516,0.0019571276,0.0002019031,0.022576055,0.00013868789,0.00006100431,0.00001383503,0.000034644614,0.001761574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988082,0.00007072951,0.00029128502,0.00039743824,0.00017492278,0.00025742356],"domain_scores_gemma":[0.99885625,0.000064763764,0.00026088225,0.00032925745,0.00017761887,0.00031125147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025246255,0.00022904482,0.0005563284,0.000101594844,0.00015693223,0.000013359818,0.00009978931,0.00011782828,0.00054695946],"category_scores_gemma":[0.000016540129,0.00022042784,0.000059708647,0.00012780988,0.00020757734,0.00007746055,0.00004200953,0.00011563573,6.3856317e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003749928,0.00014947102,0.0012515603,0.00017996972,0.0002675587,0.00000755512,0.0038290145,0.0000011389437,0.96148765,0.0001443231,0.016429989,0.012501847],"study_design_scores_gemma":[0.0059163203,0.0001910481,0.016215913,0.000096577816,0.00010681119,0.0000064143856,0.00006557953,0.00017376791,0.96468407,0.0003489031,0.012003182,0.00019140072],"about_ca_topic_score_codex":0.0007328063,"about_ca_topic_score_gemma":0.000117783566,"teacher_disagreement_score":0.014964352,"about_ca_system_score_codex":0.00005651338,"about_ca_system_score_gemma":0.00014178752,"threshold_uncertainty_score":0.89887863},"labels":[],"label_agreement":null},{"id":"W2607270289","doi":"10.1007/s00280-017-3287-8","title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Amgen","keywords":"Carfilzomib; Medicine; Multiple myeloma; Pharmacokinetics; End stage renal disease; Stage (stratigraphy); Oncology; Disease; Internal medicine; Intensive care medicine; Proteasome inhibitor","score_opus":0.05407738287008189,"score_gpt":0.3948468544672407,"score_spread":0.3407694715971588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607270289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958524,0.0007902375,0.0000049482082,0.0004056611,0.000070340684,0.0024883342,0.0002922414,0.00001258373,0.000083264946],"genre_scores_gemma":[0.9975277,0.0012980533,0.00018589807,0.0003990249,0.00006917432,0.00017073608,0.00006147029,0.00003627573,0.00025162185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985122,0.00013087549,0.00027720482,0.0005119113,0.00020000139,0.00036778278],"domain_scores_gemma":[0.9988048,0.0000844734,0.0001920207,0.00029090233,0.00011791976,0.0005098487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018810149,0.0002557486,0.0004962676,0.0001047104,0.00025102176,0.000055187444,0.00018869108,0.00006143682,0.00036338714],"category_scores_gemma":[0.000025042807,0.00020104501,0.000013100549,0.00007148693,0.00043576004,0.00027139278,0.00015445174,0.00020781635,2.6456064e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07258107,0.011206839,0.798467,0.00017001075,0.00049154356,0.0002267435,0.0009701958,0.0000018370931,0.037058376,0.00000402385,0.00007474993,0.07874764],"study_design_scores_gemma":[0.23062229,0.009212991,0.7402699,0.00006870278,0.00023967681,0.0000030798537,0.00009531422,0.0008003764,0.016826067,0.0000067261326,0.0016401868,0.00021466555],"about_ca_topic_score_codex":0.00038791032,"about_ca_topic_score_gemma":0.0001356097,"teacher_disagreement_score":0.15804122,"about_ca_system_score_codex":0.0000702947,"about_ca_system_score_gemma":0.0001279154,"threshold_uncertainty_score":0.81983775},"labels":[],"label_agreement":null},{"id":"W2617943271","doi":"10.1007/s00280-008-0848-x","title":"Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Synthesis and pharmacology of benzodiazepine derivatives","field":"Chemistry","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Identification (biology); Benzodiazepine; Ligand (biochemistry); Peripheral; Pharmacology; Chemistry; GABAA receptor; Receptor; Biology; Medicine; Biochemistry; Internal medicine; Botany","score_opus":0.022173343416873204,"score_gpt":0.289562908502084,"score_spread":0.2673895650852108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617943271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448305,0.0010993341,0.0013080854,0.0020634676,0.00030663123,0.00023504178,0.00040152323,0.000033755805,0.0000690977],"genre_scores_gemma":[0.9864158,0.011235861,0.00022423349,0.0007664206,0.00047741598,0.00019189293,0.00005193812,0.00002895503,0.0006074832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900377,0.000026732947,0.00029065096,0.0003783238,0.000077096374,0.00022340292],"domain_scores_gemma":[0.99928087,0.00011339088,0.00029218566,0.000098060475,0.00011979956,0.000095706615],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000115345625,0.00020594355,0.00037866863,0.000057391368,0.00020238645,0.000010949888,0.00010726093,0.00013430609,0.001268133],"category_scores_gemma":[0.000012701537,0.00020885852,0.00006166894,0.00008407495,0.0003609273,0.0001544008,0.000023656972,0.00012034355,6.5387275e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005615609,0.00022049723,0.004221883,0.00023722123,0.00019993768,8.089892e-7,0.0009948411,0.0000046740897,0.9745975,0.000023023726,0.00074706913,0.018190954],"study_design_scores_gemma":[0.002703594,0.000052286337,0.019675227,0.00002173739,0.000057267447,0.000015570253,0.00002379568,0.00086270913,0.95602053,0.000012502931,0.020348718,0.00020603382],"about_ca_topic_score_codex":0.00001611991,"about_ca_topic_score_gemma":0.000001601107,"teacher_disagreement_score":0.019601649,"about_ca_system_score_codex":0.00003468038,"about_ca_system_score_gemma":0.0000763815,"threshold_uncertainty_score":0.9996448},"labels":[],"label_agreement":null},{"id":"W2743564890","doi":"10.1007/s00280-017-3412-8","title":"Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Cardiotoxicity; Doxorubicin; Medicine; Pharmacology; Liposome; Chemotherapy; Internal medicine; Chemistry","score_opus":0.029199937636791344,"score_gpt":0.35614252414482866,"score_spread":0.3269425865080373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743564890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968658,0.0012962534,0.000054349515,0.0006855904,0.00007777113,0.000623768,0.000033985136,0.000018169416,0.0003442793],"genre_scores_gemma":[0.99606895,0.0030559322,0.00018793142,0.0003649308,0.00016876924,0.000045063694,0.0000048760526,0.000018956995,0.000084557134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992105,0.00003995722,0.00020310297,0.00025530544,0.000094885516,0.00019624444],"domain_scores_gemma":[0.99928194,0.000056781377,0.00027772062,0.00019690825,0.000097971955,0.00008867992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012505898,0.00017103179,0.000530874,0.000048496957,0.00015423258,0.000009643904,0.00006179745,0.00012363552,0.000084548454],"category_scores_gemma":[0.000008653616,0.0001310319,0.00006351631,0.00005143706,0.00031528794,0.00008793056,0.000018426092,0.00011278474,1.1317026e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017721645,0.00012221134,0.073241055,0.00020368274,0.0005369472,0.0000071508202,0.0014432563,0.000007337852,0.9018687,0.000016239774,0.000016824348,0.020764407],"study_design_scores_gemma":[0.009325445,0.00082964817,0.060964864,0.00011693746,0.0001804911,0.000037572907,0.00007718481,0.00026108164,0.92747754,0.000019424762,0.00059798337,0.00011184874],"about_ca_topic_score_codex":0.00019496359,"about_ca_topic_score_gemma":0.000039565828,"teacher_disagreement_score":0.025608797,"about_ca_system_score_codex":0.000048875598,"about_ca_system_score_gemma":0.00011044715,"threshold_uncertainty_score":0.53433263},"labels":[],"label_agreement":null},{"id":"W2769776705","doi":"10.1007/s00280-017-3477-4","title":"Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Public Health Agency of Canada","keywords":"Medicine; Chemotherapy; Immunohistochemistry; Oncology; Internal medicine; Metastasis; Pancreatic ductal adenocarcinoma; Cancer research; Cancer; Pancreatic cancer","score_opus":0.024717676985180934,"score_gpt":0.3291384125174103,"score_spread":0.3044207355322293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769776705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98607814,0.010073714,0.000111393594,0.0028106677,0.00017586825,0.0002655277,0.000019740864,0.000007772495,0.00045714393],"genre_scores_gemma":[0.99208045,0.0032823507,0.0005697285,0.0018412531,0.000672487,0.00007950464,0.000010526281,0.000026156511,0.0014375669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908704,0.00004939693,0.00016360139,0.00039585333,0.000058073234,0.00024606727],"domain_scores_gemma":[0.9994714,0.00002895289,0.00009831929,0.00024675333,0.000024126546,0.00013040491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013842998,0.00016764831,0.00022764204,0.00004368782,0.00020712709,0.000030372523,0.00017576196,0.00016308454,0.000056061886],"category_scores_gemma":[0.000021347216,0.00016045595,0.000029425992,0.000036758247,0.00014826431,0.000013066453,0.00006843935,0.00012347449,0.0000012620495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030391235,0.000013141778,0.6271127,0.000027841044,0.000022036798,0.0000027004564,0.00026366036,8.439219e-7,0.3686792,0.000069888345,0.0023203152,0.0011837649],"study_design_scores_gemma":[0.0021364882,0.00005731341,0.7641388,0.000020373765,0.000020429588,0.0000031497648,0.00002157324,0.0000022246356,0.20322253,0.00031714773,0.029884359,0.00017558876],"about_ca_topic_score_codex":0.000032979646,"about_ca_topic_score_gemma":0.000048706057,"teacher_disagreement_score":0.16545667,"about_ca_system_score_codex":0.000014862885,"about_ca_system_score_gemma":0.000039012262,"threshold_uncertainty_score":0.65432036},"labels":[],"label_agreement":null},{"id":"W2773849850","doi":"10.1007/s00280-017-3494-3","title":"Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Mirati Therapeutics","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Internal medicine; Adverse effect; Cancer; Clinical endpoint; Phases of clinical research; Gastroenterology; Maximum tolerated dose; Oncology; Clinical trial","score_opus":0.012006969423434283,"score_gpt":0.36023163951508524,"score_spread":0.348224670091651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773849850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736065,0.0007413276,0.000024595654,0.00020878155,0.00006715794,0.0014720234,0.00008746211,0.0000045948696,0.000033390002],"genre_scores_gemma":[0.9980643,0.00060404814,0.00012916051,0.00022931384,0.00005381736,0.0007163346,0.000019045387,0.000036288126,0.00014773401],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906045,0.000037987862,0.0001844051,0.00037362674,0.00010185869,0.00024166657],"domain_scores_gemma":[0.9993567,0.000021431115,0.00021143639,0.00018407207,0.0001565581,0.00006984111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009367196,0.00017518741,0.00029730579,0.000055660646,0.00019341239,0.000010397164,0.00012435662,0.00006180558,0.00002661268],"category_scores_gemma":[0.000012389501,0.00014227905,0.000015657179,0.000048294936,0.00024111915,0.000016337559,0.000052551688,0.0000851672,5.1263847e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021999262,0.0037228102,0.08138785,0.00021383558,0.00029786804,0.0000035568326,0.001700078,0.00016295096,0.814177,0.000004221497,0.00024545938,0.076085135],"study_design_scores_gemma":[0.10823895,0.024968624,0.017186206,0.00011833284,0.00007875208,0.000001886656,0.00028128916,0.0002500316,0.84476894,0.000013745004,0.003714354,0.0003789069],"about_ca_topic_score_codex":0.00012597062,"about_ca_topic_score_gemma":0.0003840354,"teacher_disagreement_score":0.08623969,"about_ca_system_score_codex":0.000033980596,"about_ca_system_score_gemma":0.00008437236,"threshold_uncertainty_score":0.5801971},"labels":[],"label_agreement":null},{"id":"W2774981435","doi":"10.1007/s00280-017-3486-3","title":"Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CBC (Canada)","funders":"","keywords":"Dabrafenib; Vemurafenib; Trametinib; Tumour heterogeneity; Melanoma; Medicine; Oncology; Cancer research; Metastatic melanoma; Pathology; Internal medicine; Biology; Cancer; MAPK/ERK pathway; Kinase","score_opus":0.024330399213969414,"score_gpt":0.3176762638160448,"score_spread":0.2933458646020754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774981435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997424,0.00081060844,0.00019137093,0.0010829343,0.00008135064,0.00023893348,0.000111332425,0.000001746163,0.00005769637],"genre_scores_gemma":[0.9978599,0.0007149503,0.00008603614,0.00119228,0.000028086406,0.000065252534,0.00001699697,0.000009796679,0.00002672941],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991329,0.00016101713,0.00019742514,0.00026378382,0.00006715075,0.00017777311],"domain_scores_gemma":[0.999443,0.00006952063,0.00016069553,0.00027325717,0.000020339661,0.00003319935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024037265,0.00014389394,0.00027980664,0.00004761457,0.00010165604,0.00002057301,0.00033050103,0.0000795186,0.000017933786],"category_scores_gemma":[0.000018744053,0.000092214,0.00009351421,0.00009236362,0.00021950874,0.000005191933,0.000054632023,0.00011157783,7.0603626e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040987876,0.00018769415,0.20604567,0.00006500826,0.00051171565,0.0000046427335,0.00037820035,0.0013660036,0.78788984,0.00007380283,0.00006804131,0.0029995048],"study_design_scores_gemma":[0.003663389,0.00011938244,0.4662765,0.000011800971,0.00047635316,0.0000037047712,0.00007163753,0.13615291,0.39267036,0.00020722866,0.00015002942,0.00019671641],"about_ca_topic_score_codex":0.00018014209,"about_ca_topic_score_gemma":0.0027823055,"teacher_disagreement_score":0.39521948,"about_ca_system_score_codex":0.000012756772,"about_ca_system_score_gemma":0.00005568286,"threshold_uncertainty_score":0.3760378},"labels":[],"label_agreement":null},{"id":"W2790931628","doi":"10.1007/s00280-018-3521-z","title":"Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Cmax; Pharmacokinetics; Pharmacology; Posaconazole; Bioavailability; Dosing; Medicine; Pharmacodynamics; Crossover study; Itraconazole","score_opus":0.008819464249852981,"score_gpt":0.2969617970561452,"score_spread":0.28814233280629226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790931628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659497,0.001395726,0.00014760421,0.0004582663,0.00018674645,0.0010871823,0.000039878483,0.000014718857,0.000074888274],"genre_scores_gemma":[0.9969431,0.0006265711,0.00018082948,0.001926358,0.00021281355,0.00004558497,0.000014874987,0.00003525006,0.000014622743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989808,0.000061013277,0.00028683868,0.000271328,0.00015401705,0.0002460099],"domain_scores_gemma":[0.99932706,0.0000862199,0.00020271212,0.0001344166,0.00012462646,0.00012494587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008593856,0.00019721029,0.00037637353,0.00010351847,0.000055783785,0.00000498107,0.00007539073,0.00007019105,0.0001098964],"category_scores_gemma":[0.000006952011,0.0001478586,0.000029136976,0.00020646816,0.00027263022,0.00007243527,0.000021800335,0.00021253634,2.6187212e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082768705,0.00068031816,0.023325685,0.0003287998,0.00038677346,0.000005011459,0.0015424315,0.00040165934,0.9365904,0.00014211098,0.0009279579,0.027392032],"study_design_scores_gemma":[0.024505757,0.0049320497,0.025733635,0.00018951503,0.00015764715,0.0000033760575,0.0000251614,0.0007008751,0.942329,0.000058697904,0.0012107645,0.0001535487],"about_ca_topic_score_codex":0.000051201776,"about_ca_topic_score_gemma":0.000034445937,"teacher_disagreement_score":0.027238483,"about_ca_system_score_codex":0.000063935295,"about_ca_system_score_gemma":0.00017689317,"threshold_uncertainty_score":0.6029499},"labels":[],"label_agreement":null},{"id":"W2807339691","doi":"10.1007/s00280-018-3614-8","title":"Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments","year":2018,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Alberta Hospital","funders":"","keywords":"Chemotherapy; Soft tissue; Lean body mass; Dosing; Lean tissue; Medicine; Cancer; Body surface area; Oncology; Internal medicine; Pathology; Adipose tissue; Body weight","score_opus":0.07627704170520572,"score_gpt":0.4638383095801216,"score_spread":0.3875612678749159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807339691","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05594463,0.9410458,0.0000043289533,0.00067514327,0.0007950556,0.0012200166,0.00009774042,0.000026880141,0.00019037609],"genre_scores_gemma":[0.001519836,0.99349767,0.00013499676,0.0028811125,0.00056143233,0.0003130273,0.000043271066,0.000061992796,0.0009866912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984942,0.00008144217,0.0005905712,0.000424846,0.00010159663,0.00030736177],"domain_scores_gemma":[0.99917257,0.000113748225,0.00036535144,0.00012302888,0.00008687658,0.00013842211],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001220943,0.00034593028,0.0015050482,0.00030134097,0.00008021932,0.000008930935,0.00007396923,0.00022508804,0.0020747609],"category_scores_gemma":[0.0000045226766,0.00029854267,0.000099515244,0.00020952131,0.00023274028,0.000069949274,0.000022818751,0.00035488678,0.0000020178193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002508167,0.00034676792,0.005720456,0.013810168,0.0004480094,0.0000023783293,0.0006755017,7.408861e-8,0.0003077357,0.0000032413739,0.0033417991,0.97509307],"study_design_scores_gemma":[0.0064748544,0.00035411268,0.0012790357,0.008323713,0.00043863573,0.000011064776,0.000026907044,0.000008073649,0.002690909,0.000020942158,0.98012286,0.0002488886],"about_ca_topic_score_codex":0.000086131404,"about_ca_topic_score_gemma":0.000028664517,"teacher_disagreement_score":0.9767811,"about_ca_system_score_codex":0.00026038015,"about_ca_system_score_gemma":0.00019387442,"threshold_uncertainty_score":0.99994665},"labels":[],"label_agreement":null},{"id":"W2881471750","doi":"10.1007/s00280-018-3632-6","title":"An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Cancer Research UK","keywords":"Prostate cancer; Medicine; Repolarization; Ventricular Repolarization; Internal medicine; Pharmacokinetics; Prostate; Cancer; Oncology; Electrophysiology","score_opus":0.03939307538328744,"score_gpt":0.4318884542488405,"score_spread":0.392495378865553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2881471750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408305,0.0010470465,0.0000034129375,0.0012120941,0.00008162031,0.003454752,0.000024872568,0.000012310178,0.00008082987],"genre_scores_gemma":[0.9977514,0.0005606538,0.000033474727,0.000581184,0.00015132289,0.00076477544,0.000019460924,0.000022722623,0.00011501877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877787,0.0002691562,0.00022990191,0.00032197492,0.00017217713,0.00022890439],"domain_scores_gemma":[0.9994169,0.00008005916,0.00014553875,0.00015454825,0.000104839375,0.00009809749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003944471,0.0001617615,0.0002932051,0.000075043725,0.00014653767,0.000027972734,0.000121977566,0.000044203844,0.00011920078],"category_scores_gemma":[0.000009115508,0.0000911821,0.000010304807,0.00030382109,0.00026939096,0.00010974048,0.000021813496,0.00017435211,4.1466518e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033832077,0.0014895055,0.20468177,0.00015587415,0.00042421598,0.000089170244,0.0047533815,0.000040198996,0.73384845,0.000003154576,0.00020224569,0.020479951],"study_design_scores_gemma":[0.07787526,0.032255966,0.027213233,0.00023119358,0.00025992558,0.0000067889146,0.00035761253,0.0033426792,0.8579044,0.000007198723,0.0004004241,0.00014534393],"about_ca_topic_score_codex":0.0011653191,"about_ca_topic_score_gemma":0.00029745608,"teacher_disagreement_score":0.17746854,"about_ca_system_score_codex":0.00014533756,"about_ca_system_score_gemma":0.0001966309,"threshold_uncertainty_score":0.3718298},"labels":[],"label_agreement":null},{"id":"W2885544802","doi":"10.1007/s00280-018-3654-0","title":"A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nucro Technics","funders":"Paracelsus Medizinische Privatuniversität","keywords":"Tolerability; Curcumin; Medicine; Pharmacokinetics; Hemolysis; Pharmacology; Toxicity; Adverse effect; Cancer; Pharmacodynamics; Phases of clinical research; Gastroenterology; Internal medicine","score_opus":0.01766075689360954,"score_gpt":0.35294913302099534,"score_spread":0.3352883761273858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885544802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967205,0.00017036135,0.00041852993,0.0013040814,0.00006878591,0.0012076027,0.00008374444,0.0000050757217,0.000021345879],"genre_scores_gemma":[0.99837846,0.00020709726,0.000050654548,0.0008404272,0.00009683738,0.0003712941,0.000010873316,0.000014009142,0.000030360738],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990448,0.00011902629,0.00019948705,0.00036214656,0.00010700358,0.00016758997],"domain_scores_gemma":[0.9994703,0.000072486415,0.00012849855,0.00016658114,0.000095320334,0.0000668439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001593094,0.00015235132,0.00021805674,0.000029589435,0.000076061406,0.000005552596,0.00010321843,0.000060275568,0.00023074367],"category_scores_gemma":[0.000012958095,0.00009625094,0.000018382047,0.00017595902,0.00045974812,0.000007791312,0.000039395905,0.000105330335,3.3374954e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027195442,0.0054770405,0.07691294,0.00006961736,0.00036896166,9.481102e-7,0.0012070624,0.00002174939,0.6086316,0.000012253938,0.0003080221,0.27979434],"study_design_scores_gemma":[0.035111096,0.011836065,0.34807098,0.00004669689,0.00014696273,0.0000015148023,0.000158655,0.0005160695,0.5939061,0.00005615864,0.009785036,0.00036469908],"about_ca_topic_score_codex":0.000073867326,"about_ca_topic_score_gemma":0.00026543604,"teacher_disagreement_score":0.27942964,"about_ca_system_score_codex":0.000032013853,"about_ca_system_score_gemma":0.00010765199,"threshold_uncertainty_score":0.39249992},"labels":[],"label_agreement":null},{"id":"W2897175439","doi":"10.1007/s00280-018-3689-2","title":"Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Rash; Trastuzumab; Diarrhea; Metastatic breast cancer; Cancer; Adverse effect; Oncology; Gastroenterology; Breast cancer; Surgery; Epidermal growth factor receptor; Erlotinib","score_opus":0.028446106103640956,"score_gpt":0.4090134797091505,"score_spread":0.3805673736055095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897175439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952203,0.0006878667,0.00007797287,0.0012180322,0.00017466703,0.0021742573,0.00009096567,0.000013091478,0.00034284854],"genre_scores_gemma":[0.99489015,0.0022555059,0.0008116034,0.0011691354,0.00023699748,0.00044095496,0.000013160568,0.000040425446,0.00014207943],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99851257,0.00010767273,0.00027646765,0.0004219015,0.0002902288,0.00039115813],"domain_scores_gemma":[0.99934775,0.00006418871,0.00012620137,0.000119540164,0.00017009303,0.00017223854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020299277,0.00022123246,0.0005310777,0.00015836337,0.000059250917,0.000010123873,0.000079071186,0.000059386115,0.00090317323],"category_scores_gemma":[0.000002304351,0.00016398421,0.000024205272,0.00029879072,0.0006315771,0.0000732341,0.000024955425,0.00022390194,7.293919e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5995837,0.00644902,0.059679523,0.0012334227,0.0033693996,0.00015322122,0.0065627005,0.000041798507,0.008073529,0.0000298866,0.0029774886,0.31184635],"study_design_scores_gemma":[0.7659966,0.047355924,0.07284305,0.00060899963,0.00087097473,0.000016984208,0.00040572876,0.0006453528,0.1048363,0.000015458732,0.0058654207,0.0005392349],"about_ca_topic_score_codex":0.00030229316,"about_ca_topic_score_gemma":0.000083804916,"teacher_disagreement_score":0.3113071,"about_ca_system_score_codex":0.0001620407,"about_ca_system_score_gemma":0.0002709208,"threshold_uncertainty_score":0.98891133},"labels":[],"label_agreement":null},{"id":"W2898091448","doi":"10.1007/s00280-018-3706-5","title":"Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"National Health and Medical Research Council","keywords":"Carboplatin; Gemcitabine; Ovarian cancer; Medicine; Platinum; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; Cancer; Cisplatin; Chemistry","score_opus":0.027892984069719035,"score_gpt":0.3651652371962587,"score_spread":0.3372722531265397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898091448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584824,0.0006492755,0.0000070303736,0.0010736702,0.0005558201,0.0014450769,0.00013432335,0.000020676216,0.00026586247],"genre_scores_gemma":[0.99381334,0.001957246,0.0000499179,0.0031451574,0.00043199232,0.00037668028,0.000011487211,0.00004044289,0.00017373518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982387,0.00013532337,0.0005874988,0.000512613,0.00016519985,0.00036065772],"domain_scores_gemma":[0.99913687,0.00015642267,0.0002406746,0.0001492441,0.00017001071,0.00014680499],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023519121,0.00027416798,0.0006533822,0.00018623457,0.00007484774,0.000008115963,0.00007053561,0.00016301706,0.0035465928],"category_scores_gemma":[0.0000145694785,0.00024387873,0.000030024952,0.00040555632,0.00033534842,0.00010912259,0.000032329244,0.00031335367,0.0000012117601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05910412,0.007839944,0.68830633,0.00049217325,0.00083283713,0.0001978079,0.05750816,0.000055035096,0.1302396,0.000017182698,0.004576133,0.0508307],"study_design_scores_gemma":[0.27322757,0.01301295,0.37766537,0.0005839634,0.00024045119,0.000030362775,0.0014031439,0.0021633008,0.31598222,0.00007507944,0.0148698725,0.0007457125],"about_ca_topic_score_codex":0.0015451009,"about_ca_topic_score_gemma":0.017201487,"teacher_disagreement_score":0.31064093,"about_ca_system_score_codex":0.0002286371,"about_ca_system_score_gemma":0.0002283169,"threshold_uncertainty_score":0.9973643},"labels":[],"label_agreement":null},{"id":"W2901231185","doi":"10.1007/s00280-018-3726-1","title":"6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Synthesis and biological activity","field":"Chemistry","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Cancer Institute; University of Toledo Foundation; McMaster University","keywords":"Viability assay; Cyclin-dependent kinase 1; Programmed cell death; Tubulin; Apoptosis; Cancer research; Mitosis; Mitotic catastrophe; Cell cycle; Flow cytometry; Biology; Cell growth; Microtubule; Cell biology; Chemistry; Molecular biology; Biochemistry","score_opus":0.018193188634112643,"score_gpt":0.28785041135742856,"score_spread":0.26965722272331594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901231185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949899,0.0007330481,0.00004985272,0.0028372745,0.00023147628,0.00015646633,0.000057995752,0.00007038394,0.0008736179],"genre_scores_gemma":[0.99416816,0.0008043015,0.00007047396,0.0038988863,0.00090507814,0.00005337673,0.000002084186,0.000021379778,0.000076265496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863166,0.000046760564,0.00023698414,0.0005977503,0.00009317879,0.0003936824],"domain_scores_gemma":[0.9991413,0.0003757492,0.00011590589,0.00012817264,0.000064448184,0.00017444535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001822563,0.00027330927,0.0004147182,0.000038016427,0.00017343316,0.000027059152,0.00013903639,0.00025663307,0.0029367318],"category_scores_gemma":[0.000029850991,0.00021350915,0.000065124936,0.00011709377,0.00072070456,0.000085048436,0.000070585906,0.00024270902,0.0000039677307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006143712,0.00023897139,0.011672181,0.0001327653,0.000116742915,0.0000031694417,0.00018676884,1.666787e-7,0.9604346,0.000038126087,0.00034751705,0.026214616],"study_design_scores_gemma":[0.0025197966,0.0002018003,0.008666319,0.000025050556,0.000038003465,0.00005495066,0.000023141558,0.00016498884,0.98226374,0.00022171256,0.00553706,0.00028343624],"about_ca_topic_score_codex":0.000084196494,"about_ca_topic_score_gemma":0.000028422313,"teacher_disagreement_score":0.02593118,"about_ca_system_score_codex":0.000038908376,"about_ca_system_score_gemma":0.00004740037,"threshold_uncertainty_score":0.9979747},"labels":[],"label_agreement":null},{"id":"W2901454723","doi":"10.1007/s00280-018-3730-5","title":"Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nucro Technics","funders":"","keywords":"Curcumin; Pharmacokinetics; Pharmacology; Medicine; Volume of distribution; Cancer; Ramipril; Internal medicine; Blood pressure","score_opus":0.010417947066418243,"score_gpt":0.3572506904396505,"score_spread":0.3468327433732323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901454723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555457,0.002737289,0.000088634166,0.0008404992,0.00012457844,0.0004990593,0.000101550635,0.0000045955703,0.000049210572],"genre_scores_gemma":[0.99489546,0.0035028467,0.00007369029,0.0010074495,0.0002449901,0.00017720951,0.00006917763,0.000015250953,0.000013947941],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990267,0.000086553824,0.00030223507,0.00028129894,0.0001235131,0.00017966448],"domain_scores_gemma":[0.9994189,0.000051821145,0.00023885677,0.00009529107,0.000091467606,0.00010362891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015982999,0.00014607006,0.0002853572,0.00006759389,0.000039885224,0.00000274632,0.000113484544,0.000137675,0.00018989474],"category_scores_gemma":[0.0000067717997,0.00012088874,0.000019057254,0.00016383259,0.0006761231,0.000004809548,0.00004145262,0.000102674065,3.6977633e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009782588,0.00020619003,0.40594774,0.00016804277,0.000088427965,1.1056403e-7,0.00037386623,0.0000019518645,0.55315286,0.0000037200368,0.002726514,0.036352318],"study_design_scores_gemma":[0.0059702476,0.0023116502,0.05913505,0.00003266743,0.00006045266,0.0000013674446,0.000010795917,0.00011275699,0.89624274,0.0000064585097,0.03599137,0.00012446252],"about_ca_topic_score_codex":0.00008608563,"about_ca_topic_score_gemma":0.0000376739,"teacher_disagreement_score":0.3468127,"about_ca_system_score_codex":0.000017932702,"about_ca_system_score_gemma":0.00008913067,"threshold_uncertainty_score":0.49296996},"labels":[],"label_agreement":null},{"id":"W2904569076","doi":"10.1007/s00280-018-3738-x","title":"A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Regorafenib; Perindopril; Medicine; Refractory (planetary science); Incidence (geometry); Foot (prosody); Skin reaction; Internal medicine; Oncology; Surgery; Dermatology; Colorectal cancer; Biology","score_opus":0.0164618740842383,"score_gpt":0.355211686871391,"score_spread":0.33874981278715266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904569076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726295,0.00044037998,0.0000012418265,0.00037510786,0.0005361368,0.0012334981,0.000018998217,0.0000044521958,0.00012720372],"genre_scores_gemma":[0.9982331,0.0009874046,0.000009046941,0.0002669989,0.00021808383,0.00019541239,0.0000019530949,0.000009440221,0.00007860194],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993329,0.00007046884,0.00018973403,0.00019746994,0.00008701683,0.00012240188],"domain_scores_gemma":[0.99949944,0.00015633632,0.00015617501,0.00008183872,0.00007382088,0.000032366028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018096271,0.00011890691,0.00035759754,0.000045441266,0.00011499127,0.0000020990499,0.00003688986,0.00006814931,0.00003868685],"category_scores_gemma":[0.000037217505,0.00007751824,0.000050903604,0.00009350962,0.0002708176,0.000035391626,0.000025349482,0.00009802395,4.9126417e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43162468,0.001359889,0.047261246,0.00030991816,0.00031678184,8.87801e-7,0.0039442913,3.6034245e-7,0.14248076,0.0000018612537,0.0007044798,0.37199485],"study_design_scores_gemma":[0.22200763,0.04829827,0.115517184,0.00016522821,0.00018174046,0.000001672574,0.00002920637,0.000047699985,0.6058405,0.000014542097,0.0077938307,0.000102499245],"about_ca_topic_score_codex":0.00013113489,"about_ca_topic_score_gemma":0.00011358919,"teacher_disagreement_score":0.46335974,"about_ca_system_score_codex":0.0001104628,"about_ca_system_score_gemma":0.000052781383,"threshold_uncertainty_score":0.3161102},"labels":[],"label_agreement":null},{"id":"W2955507595","doi":"10.1007/s00280-019-03899-y","title":"Population pharmacokinetics of trabectedin in adolescent patients with cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Trabectedin; Pharmacokinetics; Medicine; Population pharmacokinetics; Population; Cancer; Oncology; Pharmacology; Internal medicine; Sarcoma; Pathology; Soft tissue sarcoma","score_opus":0.020476247915726567,"score_gpt":0.35171804403402446,"score_spread":0.3312417961182979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955507595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972037,0.0011819839,0.0000027200547,0.000515933,0.00015427527,0.0007973783,0.000033972236,0.0000092759155,0.00010075364],"genre_scores_gemma":[0.99569076,0.0030676192,0.00004952949,0.00084597175,0.0000679276,0.000074087424,0.000031574924,0.000016266684,0.00015623585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931026,0.00002925731,0.00014474196,0.00018554705,0.00013340102,0.00019680995],"domain_scores_gemma":[0.9996977,0.000021789365,0.00006245666,0.00005905974,0.000069960246,0.00008905406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000036144975,0.00010860206,0.00025269052,0.00008850383,0.000012401184,0.0000020903246,0.000033832457,0.00004992639,0.0018929999],"category_scores_gemma":[0.0000012546672,0.00008144478,0.000021399992,0.000144552,0.000041911222,0.000036709964,0.000007908813,0.00012812592,0.0000015218421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003714298,0.00040348794,0.91716534,0.00023450161,0.00014593954,0.0000037313773,0.00013736307,0.000036385733,0.033011254,0.0000016502732,0.00025747996,0.04488855],"study_design_scores_gemma":[0.020899247,0.0003414649,0.92144597,0.000102117185,0.000052095846,8.442558e-7,0.000006881918,0.00052705227,0.05520981,0.0000033683643,0.0013355062,0.0000756439],"about_ca_topic_score_codex":0.000382815,"about_ca_topic_score_gemma":0.000046663645,"teacher_disagreement_score":0.044812903,"about_ca_system_score_codex":0.00010515318,"about_ca_system_score_gemma":0.00006195566,"threshold_uncertainty_score":0.9990194},"labels":[],"label_agreement":null},{"id":"W2973076369","doi":"10.1007/s00280-019-03956-6","title":"Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy","year":2019,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Fluidigm (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Oxaliplatin; FOLFOX; Medicine; Peripheral neuropathy; Cumulative dose; Colorectal cancer; Internal medicine; Neurotoxicity; Gastroenterology; Chemotherapy; Cancer; Oncology; Toxicity; Endocrinology","score_opus":0.012279270525962987,"score_gpt":0.3243970405063564,"score_spread":0.3121177699803934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973076369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919204,0.0030703004,0.0000030524004,0.0015772495,0.0015106025,0.0013127287,0.000037684862,0.000047634563,0.0005203079],"genre_scores_gemma":[0.98742425,0.0022080902,0.000063865366,0.009090921,0.0003147535,0.0005240671,0.00007545305,0.000043361764,0.00025524924],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869156,0.00008045619,0.00027425002,0.0004225003,0.00014402668,0.00038719468],"domain_scores_gemma":[0.9995256,0.00011899898,0.000113269874,0.00007024611,0.00004937765,0.00012250082],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008980463,0.00026374115,0.00046825068,0.00014769357,0.00006414696,0.0000107340065,0.00006855286,0.00018069778,0.004443994],"category_scores_gemma":[0.0000013906549,0.00023858903,0.00012182995,0.00024315149,0.000062680316,0.00008273623,0.000012451601,0.0002582156,0.000010531097],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004417176,0.00057355355,0.55266434,0.00006570058,0.00030322364,0.000015934069,0.00063054083,0.000080983824,0.41529062,0.0000023131,0.0014359255,0.024519665],"study_design_scores_gemma":[0.050329812,0.0014575204,0.3014522,0.00009643786,0.00016619462,0.000004117789,0.000026925156,0.0019350608,0.63579667,0.000016534706,0.008362802,0.0003557395],"about_ca_topic_score_codex":0.0003984019,"about_ca_topic_score_gemma":0.00012858605,"teacher_disagreement_score":0.25121215,"about_ca_system_score_codex":0.00031638905,"about_ca_system_score_gemma":0.00022103648,"threshold_uncertainty_score":0.9964661},"labels":[],"label_agreement":null},{"id":"W2986277146","doi":"10.1007/s00280-019-03989-x","title":"Characterization and outcomes of patients enrolled to multiple phase I cancer trials","year":2019,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Adverse effect; Cancer; Demographics; Phases of clinical research; Demography","score_opus":0.2538180196436872,"score_gpt":0.5874401460463614,"score_spread":0.3336221264026742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986277146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077207,0.0003380099,0.00006328724,0.0068275896,0.00055615354,0.0012563564,0.00012722165,0.000010621001,0.000048706475],"genre_scores_gemma":[0.9783634,0.008797098,0.00007006522,0.010736112,0.0001596744,0.00015369628,0.000019371328,0.00001776987,0.0016828477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988616,0.000116652176,0.0004044852,0.00025811506,0.00019044225,0.00016870977],"domain_scores_gemma":[0.99726224,0.002097319,0.00015307647,0.00010250359,0.0002289204,0.00015591164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092099496,0.00010744293,0.00064757786,0.00007553971,0.0000271311,0.0000052972255,0.00006039599,0.0001666324,0.0028167625],"category_scores_gemma":[0.0004984907,0.00008165958,0.00005300185,0.00010016298,0.00009248724,0.000037589,0.000034144152,0.00027536976,0.0000034552472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040572085,0.00023811529,0.3968102,0.00020051605,0.00021734528,4.6539236e-7,0.00047895935,8.034055e-7,0.5602678,0.000021385811,0.00015354714,0.037553653],"study_design_scores_gemma":[0.05674606,0.0013254831,0.34559155,0.0001025695,0.0001575472,3.656568e-7,0.000027333008,0.00028288204,0.57344675,0.0001567444,0.021986471,0.00017626594],"about_ca_topic_score_codex":0.000043846667,"about_ca_topic_score_gemma":0.000016315296,"teacher_disagreement_score":0.052688852,"about_ca_system_score_codex":0.000039224633,"about_ca_system_score_gemma":0.00014916828,"threshold_uncertainty_score":0.9980948},"labels":[],"label_agreement":null},{"id":"W3006140059","doi":"10.1007/s00280-020-04038-8","title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Tolerability; Trametinib; Dosing; Medicine; Rash; Adverse effect; Internal medicine; Mucositis; Oncology; Pharmacology; Toxicity; MAPK/ERK pathway","score_opus":0.014149507990633454,"score_gpt":0.2872376165837309,"score_spread":0.27308810859309746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006140059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965128,0.00010821868,0.000038106773,0.0020449194,0.00019651781,0.0010372169,0.000023384373,0.000005137809,0.00003372861],"genre_scores_gemma":[0.9977234,0.000045950717,0.000029035931,0.0018083809,0.00020201891,0.00011750051,0.000034990313,0.00001871661,0.000019998528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903274,0.0001587118,0.0002366347,0.00026920284,0.0001195957,0.00018313996],"domain_scores_gemma":[0.9996101,0.000017448936,0.00016273519,0.00010000509,0.00005783509,0.00005186294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014254582,0.00015680554,0.00022864414,0.00002709196,0.000048946746,0.00000937748,0.00012860523,0.00010567478,0.000033275857],"category_scores_gemma":[0.000008493539,0.00009154955,0.00003480144,0.00019619931,0.00016363949,0.000010832927,0.000027987347,0.00016059855,2.2596844e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.111816056,0.0016477786,0.038073838,0.00007640244,0.0001106344,0.0000027078775,0.0017708379,0.0001495272,0.82730174,0.000022541157,0.0014390035,0.017588934],"study_design_scores_gemma":[0.15340045,0.0063198623,0.0144190565,0.00002631186,0.00003701599,8.584262e-7,0.00007982578,0.00026495373,0.8214734,0.000014393797,0.0037730557,0.00019082963],"about_ca_topic_score_codex":0.000027151696,"about_ca_topic_score_gemma":0.00009152128,"teacher_disagreement_score":0.041584387,"about_ca_system_score_codex":0.00002077759,"about_ca_system_score_gemma":0.000120734614,"threshold_uncertainty_score":0.3733282},"labels":[],"label_agreement":null},{"id":"W3014539959","doi":"10.1007/s00280-020-04063-7","title":"Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Oncology; Univariate analysis; Proportional hazards model; Cancer; Discontinuation; Prostate-specific antigen; Chemotherapy; Retrospective cohort study; Urology; Multivariate analysis","score_opus":0.02855337228452725,"score_gpt":0.34417924829541136,"score_spread":0.3156258760108841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014539959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921573,0.0008021569,0.000002256414,0.007936064,0.00021452531,0.0014762251,0.000107220134,0.00003162657,0.00021421886],"genre_scores_gemma":[0.9888428,0.0018531822,0.000020217896,0.008610724,0.00016764474,0.00019580063,0.00004040523,0.000036584184,0.00023268265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986155,0.00011636002,0.00017186433,0.0004613057,0.00021941318,0.0004155552],"domain_scores_gemma":[0.9993674,0.00008727114,0.00007249714,0.00007941195,0.00013702267,0.00025635425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010453372,0.00027160838,0.00059038674,0.00006895528,0.00006190594,0.000013839251,0.00005026638,0.000059105743,0.0004072363],"category_scores_gemma":[0.0000055440078,0.00018171364,0.000048614347,0.00021118211,0.00017490817,0.00007041117,0.000019368457,0.00037954634,0.0000061914416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15972793,0.00068207824,0.7635693,0.0007526652,0.0017569151,0.00056185044,0.0037707186,0.00016996618,0.035239846,0.000010446986,0.0025306363,0.031227652],"study_design_scores_gemma":[0.09439401,0.011512964,0.64005375,0.00026436665,0.0004751472,0.000007668994,0.000109469656,0.0005942015,0.24858122,0.000017460214,0.0034642725,0.0005254457],"about_ca_topic_score_codex":0.00026737526,"about_ca_topic_score_gemma":0.000038658458,"teacher_disagreement_score":0.21334137,"about_ca_system_score_codex":0.00020771132,"about_ca_system_score_gemma":0.00021035051,"threshold_uncertainty_score":0.7410067},"labels":[],"label_agreement":null},{"id":"W3033856706","doi":"10.1007/s00280-020-04086-0","title":"Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Gestational Trophoblastic Disease Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Methotrexate; Medicine; Gestational trophoblastic neoplasia; Internal medicine; Antimetabolite; Human chorionic gonadotropin; Oncology; Biomarker; Antifolate; Hormone","score_opus":0.021258261742797727,"score_gpt":0.2921693911466551,"score_spread":0.27091112940385736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033856706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729586,0.00004944842,0.00028606242,0.0008030342,0.000046206675,0.0006547515,0.0008520576,0.000008111644,0.000004491027],"genre_scores_gemma":[0.9980533,0.00011525573,0.0011746393,0.00037745127,0.00006821821,0.00009177934,0.000096305375,0.000012966469,0.000010070777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935544,0.00006436797,0.00021244527,0.00016044045,0.000120104945,0.00008718257],"domain_scores_gemma":[0.9993821,0.00014706631,0.00017183757,0.00004141466,0.00021104798,0.000046567984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003876993,0.00009365272,0.00020467745,0.00003903316,0.000028956307,0.0000017858188,0.000035044766,0.000033348588,0.00006786038],"category_scores_gemma":[0.00003909515,0.00006439354,0.000030160445,0.00016692195,0.00010887338,0.000050137412,0.000006051369,0.00007126722,9.10072e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009923563,0.0005049906,0.8941812,0.0003172531,0.0003746368,0.0000010066415,0.0019438023,0.0026891686,0.08626137,0.000012981821,0.00020225688,0.0035877866],"study_design_scores_gemma":[0.010088765,0.0014858703,0.93373126,0.000040993942,0.00030327006,6.632631e-7,0.00006102306,0.0031429918,0.050959963,0.0000407912,0.000093672956,0.000050749448],"about_ca_topic_score_codex":0.000030462923,"about_ca_topic_score_gemma":0.000007713638,"teacher_disagreement_score":0.039550062,"about_ca_system_score_codex":0.000027813496,"about_ca_system_score_gemma":0.000100987985,"threshold_uncertainty_score":0.26258925},"labels":[],"label_agreement":null},{"id":"W3120367735","doi":"10.1007/s00280-020-04213-x","title":"Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern Alberta Institute of Technology; University of British Columbia; University of Alberta","funders":"Novartis Pharmaceuticals Canada; Alberta Cancer Foundation; Alberta Innovates; Olav Raagholt og Gerd Meidel Raagholts stiftelse","keywords":"ERCC1; Pharmacology; DNA repair; DNA damage; Nucleotide excision repair; Medicine; DNA; Cancer research; Chemistry; Biology; Genetics","score_opus":0.005931140161619798,"score_gpt":0.26636515229225377,"score_spread":0.260434012130634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120367735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605656,0.002127309,0.00032918464,0.0007375188,0.00031996545,0.00020995927,0.0000926895,0.000017482615,0.00010934683],"genre_scores_gemma":[0.9966928,0.00074947823,0.0002479593,0.0016842171,0.00015182438,0.000054553253,0.000043307806,0.000024185489,0.00035169872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990178,0.00013476593,0.00023703065,0.0003140779,0.000099427794,0.0001969441],"domain_scores_gemma":[0.99930584,0.00008127405,0.00020289927,0.00020322853,0.00015085307,0.000055879995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025365278,0.00015303398,0.00024389295,0.000019972846,0.000049568775,0.000003641156,0.000111239926,0.00017514244,0.00019789024],"category_scores_gemma":[0.000029672925,0.00012901732,0.000117433454,0.00011910904,0.00017013175,0.000004168226,0.000048120583,0.000120427714,2.5537878e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040181327,0.00010293487,0.000198183,0.0000846584,0.00018950766,8.0181735e-7,0.00019524162,0.000005438576,0.99194896,0.000002371927,0.0031294033,0.0037406702],"study_design_scores_gemma":[0.0018756683,0.00019329818,0.000070281756,0.000013587055,0.000044413388,0.0000018887151,0.0000693062,0.00039128234,0.9768985,0.000012142081,0.020304775,0.00012489429],"about_ca_topic_score_codex":0.000050304934,"about_ca_topic_score_gemma":0.0000309297,"teacher_disagreement_score":0.01717537,"about_ca_system_score_codex":0.000020887679,"about_ca_system_score_gemma":0.00026282616,"threshold_uncertainty_score":0.5261174},"labels":[],"label_agreement":null},{"id":"W3137618571","doi":"10.1007/s00280-021-04249-7","title":"Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Prednisone; Enzalutamide; Adverse effect; Oncology; Pharmacokinetics; Urology; Discontinuation; Androgen receptor; Cancer; Androgen deprivation therapy","score_opus":0.025117111216251545,"score_gpt":0.34287421252309486,"score_spread":0.3177571013068433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137618571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98088014,0.012787798,0.0000035298017,0.0021806965,0.00013734678,0.0024822576,0.0014491396,0.000031336345,0.00004773576],"genre_scores_gemma":[0.965591,0.031652614,0.00014977832,0.0010970433,0.00011362309,0.00044721595,0.00055628933,0.00004908701,0.00034333026],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978651,0.00021287016,0.00040002388,0.00074913964,0.00032384362,0.00044902827],"domain_scores_gemma":[0.9990008,0.00011607371,0.00016261818,0.00017586736,0.00028842597,0.00025623958],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001630799,0.00035651855,0.000617534,0.00011273086,0.00015238345,0.00003761382,0.00007235835,0.000062536936,0.0010066532],"category_scores_gemma":[0.0000046929363,0.00024446798,0.00003131036,0.00046449134,0.00023604666,0.00013731979,0.000024450575,0.00031680238,9.3101403e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31841272,0.0077573303,0.45042485,0.00017103738,0.004268403,0.0005860746,0.013643585,0.00005623534,0.084066965,0.0000014418895,0.00101205,0.11959931],"study_design_scores_gemma":[0.57178324,0.013038598,0.19998193,0.00029752674,0.0008977877,0.000016920745,0.0015915651,0.0002890063,0.1951334,0.000015071799,0.01619798,0.00075695966],"about_ca_topic_score_codex":0.0009479666,"about_ca_topic_score_gemma":0.0004699596,"teacher_disagreement_score":0.25337052,"about_ca_system_score_codex":0.00020465888,"about_ca_system_score_gemma":0.0006235766,"threshold_uncertainty_score":0.99990654},"labels":[],"label_agreement":null},{"id":"W3183250534","doi":"10.1007/s00280-021-04339-6","title":"Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Fonds de Recherche du Québec - Santé; Cancer Research Society","keywords":"Decitabine; Cancer research; Azacitidine; Clonogenic assay; Rhabdomyosarcoma; Cell cycle; Demethylating agent; Biology; Paclitaxel; Chromatin immunoprecipitation; Chromatin; Epigenetics; DNA methylation; Cancer; Cell; Sarcoma; Gene expression; Medicine; Pathology; Gene; Biochemistry","score_opus":0.00957550685859864,"score_gpt":0.29500060313102366,"score_spread":0.285425096272425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183250534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283683,0.0048122704,0.00015598828,0.0012776083,0.00020533951,0.0002708232,0.0000148217405,0.000009170621,0.00041712675],"genre_scores_gemma":[0.99064124,0.005013924,0.00049313944,0.0023175084,0.00025070246,0.00013161682,0.00006213573,0.0000334632,0.0010562491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988993,0.00011940821,0.00016514995,0.00041511664,0.000120835204,0.0002802371],"domain_scores_gemma":[0.99958444,0.000021575217,0.000054101474,0.00012784358,0.00012624825,0.00008578763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015878271,0.00014498972,0.00017874288,0.000059533173,0.0000783174,0.000018839726,0.000084248735,0.00013214405,0.00012451826],"category_scores_gemma":[0.000008938459,0.00014124029,0.000031834,0.00020101237,0.0001526042,0.0000066661314,0.000046735873,0.00017692306,0.000001352209],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054530555,0.00016469375,0.001533626,0.000043175874,0.000049487142,0.00005017563,0.00015287593,0.00007015604,0.9849412,0.000007810217,0.0036688522,0.008772662],"study_design_scores_gemma":[0.0037362229,0.00019424816,0.0003772438,0.00002415448,0.0000067758965,0.000024538635,0.000032863092,0.00022756564,0.90417475,0.000011591494,0.091030315,0.00015971556],"about_ca_topic_score_codex":0.000014300922,"about_ca_topic_score_gemma":0.00007012369,"teacher_disagreement_score":0.08736146,"about_ca_system_score_codex":0.00007160615,"about_ca_system_score_gemma":0.00030332475,"threshold_uncertainty_score":0.5759612},"labels":[],"label_agreement":null},{"id":"W3214003785","doi":"10.1007/s00280-021-04369-0","title":"A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"Gilead Sciences","keywords":"Erlotinib; Medicine; Tyrosine-kinase inhibitor; Internal medicine; Lung cancer; Pharmacology; Clinical endpoint; Oncology; Epidermal growth factor receptor; Cancer; Clinical trial","score_opus":0.02987213903771854,"score_gpt":0.3992001376410065,"score_spread":0.36932799860328797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214003785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95586,0.039110232,0.000112336544,0.0016052313,0.00036795344,0.0025812075,0.00031306443,0.000010591334,0.000039370207],"genre_scores_gemma":[0.9741527,0.022327451,0.000242268,0.00081722665,0.00019807374,0.00152368,0.000031180633,0.000033789656,0.00067361863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990115,0.000048812253,0.00032062284,0.0003214323,0.00008719931,0.00021043782],"domain_scores_gemma":[0.9991039,0.00023610554,0.00019273433,0.00014018576,0.00022267232,0.00010439585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006222628,0.00021598965,0.0005406805,0.000059825496,0.000105978266,0.000007837556,0.000041994044,0.00004437623,0.00026396578],"category_scores_gemma":[0.0000029729165,0.00014492693,0.00008386523,0.00018730293,0.00012299973,0.000032613276,0.000011694621,0.00006383203,1.1622047e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009689208,0.04167982,0.029443007,0.0023072765,0.011848339,0.000143222,0.068413615,0.0002351487,0.68475336,0.000020100171,0.0044787447,0.14698817],"study_design_scores_gemma":[0.1389862,0.008379061,0.0022298484,0.00010423213,0.0074747833,0.000017170107,0.0039009184,0.0021342067,0.8261738,0.000014281164,0.010378456,0.00020707287],"about_ca_topic_score_codex":0.00066580484,"about_ca_topic_score_gemma":0.00017746552,"teacher_disagreement_score":0.1467811,"about_ca_system_score_codex":0.0001260572,"about_ca_system_score_gemma":0.00038421465,"threshold_uncertainty_score":0.59099483},"labels":[],"label_agreement":null},{"id":"W4225259757","doi":"10.1007/s00280-022-04427-1","title":"Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"Janssen Research and Development","keywords":"Placebo; Prostate cancer; Medicine; Internal medicine; Rash; Pharmacokinetics; Adverse effect; Antiandrogen; Oncology; Population; Pharmacology; Cancer; Pathology","score_opus":0.036061982547969766,"score_gpt":0.3577691898577706,"score_spread":0.32170720730980085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225259757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912217,0.0017875897,0.0000022432855,0.003518858,0.00007841861,0.0023384122,0.0010284267,0.000009318212,0.000015014618],"genre_scores_gemma":[0.9978383,0.0010405543,0.000026737329,0.0004202361,0.000035045425,0.0003689827,0.00010887845,0.000017053228,0.00014416673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983904,0.0006351967,0.0002827454,0.00029890705,0.00021014504,0.00018263729],"domain_scores_gemma":[0.998853,0.0007314143,0.00013571547,0.00011674289,0.00008982743,0.00007325536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005148646,0.00013860535,0.00028753548,0.000075702985,0.00023646378,0.0000074755426,0.000050849056,0.000021203703,0.00016754748],"category_scores_gemma":[0.000022014963,0.0000918585,0.000017040295,0.00027014472,0.00019054062,0.000052733023,0.000030063022,0.00032982652,1.927798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3961925,0.0020774342,0.534747,0.000029993253,0.00096653553,0.000068221285,0.0361782,0.00032075812,0.009983614,0.0000036029364,0.0003142841,0.019117897],"study_design_scores_gemma":[0.113558695,0.0042629037,0.873493,0.00003710023,0.0002691893,0.0000029809305,0.0027364166,0.00012880415,0.0045522396,0.0000147908395,0.00082880334,0.000115080795],"about_ca_topic_score_codex":0.00063776044,"about_ca_topic_score_gemma":0.00025422126,"teacher_disagreement_score":0.338746,"about_ca_system_score_codex":0.00018958423,"about_ca_system_score_gemma":0.0003050267,"threshold_uncertainty_score":0.37458807},"labels":[],"label_agreement":null},{"id":"W4242644534","doi":"10.1007/bf02665359","title":"Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Etoposide; Pharmacokinetics; Dexrazoxane; Pharmacology; Medicine; Toxicity; Chemotherapy; Cancer; Internal medicine; Breast cancer","score_opus":0.018015198205579865,"score_gpt":0.35429900040109963,"score_spread":0.3362838021955198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242644534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871398,0.006988019,0.000004350547,0.004334137,0.00009186822,0.0011929892,0.00004790372,0.00002868639,0.00017223536],"genre_scores_gemma":[0.9608284,0.03497353,0.00015095455,0.0032018982,0.00013195223,0.0003974891,0.000011174994,0.00004782579,0.00025676648],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984842,0.00005786155,0.0002798243,0.0004582216,0.0002739062,0.00044599595],"domain_scores_gemma":[0.9992819,0.000057286306,0.00011256805,0.00013024223,0.00020008693,0.00021794882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000956723,0.00029707773,0.00058018434,0.00016968943,0.00006955545,0.000009082842,0.00008649522,0.00009214877,0.00029808446],"category_scores_gemma":[0.000005768838,0.0002100233,0.000028583465,0.00037121194,0.0005093074,0.00007486994,0.000043474167,0.00031978008,7.881355e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030287065,0.0012641241,0.6024142,0.0011650202,0.0020109979,0.00033246411,0.0043954994,0.0006977391,0.33970806,0.000043433913,0.0012859771,0.016395407],"study_design_scores_gemma":[0.054191727,0.003939911,0.22489665,0.00056192616,0.0004963488,0.000041943124,0.000100698635,0.000041411822,0.71210605,0.000050735216,0.0032248457,0.00034777255],"about_ca_topic_score_codex":0.0065851547,"about_ca_topic_score_gemma":0.0013721179,"teacher_disagreement_score":0.37751755,"about_ca_system_score_codex":0.00039799872,"about_ca_system_score_gemma":0.00040367644,"threshold_uncertainty_score":0.9954828},"labels":[],"label_agreement":null},{"id":"W4295679167","doi":"10.1007/s00280-022-04471-x","title":"Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Dosing; Pharmacokinetics; Medicine; Population; Body surface area; Cancer; Internal medicine; Pharmacology; Oncology","score_opus":0.035151670659454175,"score_gpt":0.43091332078514066,"score_spread":0.3957616501256865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295679167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562675,0.0018232105,0.000015844298,0.0007570333,0.00036922135,0.0011403738,0.00020838717,0.000022854643,0.000036352027],"genre_scores_gemma":[0.9926193,0.0040062238,0.00026371353,0.002256364,0.00010706772,0.00040579648,0.00014722664,0.00004860949,0.00014570884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833703,0.00018849668,0.0003391076,0.00040758812,0.00036368956,0.00036405819],"domain_scores_gemma":[0.9993444,0.000053445587,0.00016454683,0.00018021953,0.00011480573,0.00014255873],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000201416,0.00019795769,0.000515098,0.00020936738,0.000090319,0.00000677188,0.00015684387,0.000040784522,0.0070447605],"category_scores_gemma":[0.000004528067,0.00016207567,0.000029327946,0.0005906221,0.0001258724,0.00012104441,0.000054287313,0.0003726584,5.1959967e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008387147,0.00093195547,0.8444846,0.00047730506,0.00025197474,0.00003416666,0.0007417893,0.0015162954,0.076067396,0.000008515529,0.0007094312,0.06638942],"study_design_scores_gemma":[0.036239434,0.0041049854,0.8556602,0.00012042033,0.00028855767,0.000014424231,0.00018089994,0.00242734,0.07057238,0.00002581352,0.029933065,0.0004324522],"about_ca_topic_score_codex":0.00069802656,"about_ca_topic_score_gemma":0.00010696693,"teacher_disagreement_score":0.065956965,"about_ca_system_score_codex":0.0002467742,"about_ca_system_score_gemma":0.00033524964,"threshold_uncertainty_score":0.9938629},"labels":[],"label_agreement":null},{"id":"W4308775132","doi":"10.1007/s00280-022-04491-7","title":"Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; London Health Sciences Centre; Western University","funders":"Ontario Ministry of Research and Innovation; Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"DPYD; Dihydropyrimidine dehydrogenase; Capecitabine; Toxicity; Haplotype; Internal medicine; Medicine; Pharmacogenetics; Linkage disequilibrium; Dosing; Fluorouracil; Genotyping; Pharmacology; Genotype; Thymidylate synthase; Oncology; Chemotherapy; Biology; Cancer; Genetics; Colorectal cancer","score_opus":0.02145409028837106,"score_gpt":0.3395445616480425,"score_spread":0.3180904713596714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308775132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710111,0.025630789,0.0000025550466,0.0018094998,0.0002907212,0.00047492274,0.00019761709,0.00003610298,0.0005467043],"genre_scores_gemma":[0.9744318,0.023133783,0.00002868314,0.0015718428,0.000124849,0.00014052652,0.000015493464,0.000029168124,0.00052381994],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988441,0.0000888302,0.00023683124,0.00037219672,0.00014738907,0.0003106834],"domain_scores_gemma":[0.9994357,0.00009768773,0.00014401424,0.000093566836,0.00007689368,0.0001521083],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001694262,0.00024522195,0.00061592343,0.00008619975,0.00025652332,0.000007874335,0.000057473564,0.00008052956,0.0020431527],"category_scores_gemma":[0.0000110695455,0.00020223545,0.000085255044,0.00020123122,0.0002248098,0.000052008283,0.00010585322,0.00020646965,3.9343846e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010453438,0.0014597195,0.18813312,0.0002473521,0.0053940923,0.000105575855,0.0051307213,0.000024591327,0.6737688,0.00006361436,0.023465296,0.09175365],"study_design_scores_gemma":[0.028889036,0.008480694,0.8924464,0.000061108505,0.0012308668,0.00016665942,0.000229423,0.0011993587,0.04726728,0.00036979694,0.019054076,0.0006052748],"about_ca_topic_score_codex":0.000383656,"about_ca_topic_score_gemma":0.00006250282,"teacher_disagreement_score":0.70431334,"about_ca_system_score_codex":0.00028888573,"about_ca_system_score_gemma":0.00016827438,"threshold_uncertainty_score":0.9988691},"labels":[],"label_agreement":null},{"id":"W432292542","doi":"10.1007/s00280-015-2776-x","title":"Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Ottawa; Ottawa Hospital","funders":"Teva Pharmaceutical Industries","keywords":"Bendamustine; Medicine; Mantle cell lymphoma; Rituximab; Internal medicine; Regimen; Clinical endpoint; Population; QT interval; Lymphoma; Gastroenterology; Clinical trial","score_opus":0.010804804229402656,"score_gpt":0.32865101746843267,"score_spread":0.31784621323903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W432292542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998384,0.00012382702,0.00004559523,0.0002257518,0.00007943986,0.0009840365,0.0000059628287,0.000008844289,0.00014255363],"genre_scores_gemma":[0.99897116,0.0001577861,0.000112311034,0.00045776856,0.000038770224,0.00014767921,0.000019708916,0.00002371739,0.00007111883],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990091,0.00010808578,0.00020765257,0.00022996716,0.00020280857,0.00024239569],"domain_scores_gemma":[0.99950063,0.000121874175,0.000098580975,0.00009120422,0.000091276794,0.00009640977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002858511,0.00014858994,0.00034903528,0.00015817204,0.000013570103,0.0000039242677,0.00006103974,0.00008087236,0.00008677282],"category_scores_gemma":[0.000013036616,0.000099098565,0.000014362505,0.00024221967,0.00009692236,0.00006509262,0.00001579492,0.00013516795,0.0000012831924],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49718913,0.0070664007,0.21289538,0.002436194,0.00022451991,0.00039281626,0.0067659807,0.0011463813,0.03032203,0.0000069731423,0.00061773777,0.24093646],"study_design_scores_gemma":[0.45752215,0.01738371,0.026526289,0.000392809,0.00004675335,0.000024339677,0.00006175711,0.0067117224,0.49091074,0.0000038557814,0.0002653693,0.00015050432],"about_ca_topic_score_codex":0.00019902602,"about_ca_topic_score_gemma":0.00013080983,"teacher_disagreement_score":0.4605887,"about_ca_system_score_codex":0.0035831134,"about_ca_system_score_gemma":0.0013528302,"threshold_uncertainty_score":0.9369717},"labels":[],"label_agreement":null},{"id":"W4323652772","doi":"10.1007/s00280-023-04516-9","title":"A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Dosing; Calicheamicin; Refractory (planetary science); Pharmacokinetics; CD33; Myeloid leukemia; Internal medicine; Oncology; Pharmacology; CD34; Stem cell","score_opus":0.024792431537484075,"score_gpt":0.386802173481273,"score_spread":0.36200974194378893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323652772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963706,0.00058075826,0.000033551023,0.00056896417,0.00036016907,0.0018798872,0.00006446756,0.00006561801,0.00007598141],"genre_scores_gemma":[0.9961354,0.0021026295,0.0001397609,0.0010190632,0.00016070054,0.00012364105,0.00008155621,0.00006981162,0.00016741818],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977604,0.00028273594,0.000513109,0.0005817287,0.00038661633,0.00047542213],"domain_scores_gemma":[0.99888474,0.0003437168,0.00022505442,0.00015621725,0.00021900247,0.00017127255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063699525,0.00031014744,0.0006783137,0.00042616113,0.00014337574,0.000015266318,0.00011845898,0.0001407865,0.0002694082],"category_scores_gemma":[0.00003013619,0.00027242143,0.00006515681,0.000722391,0.00020606806,0.00019912545,0.00009702694,0.0007431939,0.000002522408],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052382592,0.002061114,0.1709447,0.00029304784,0.003832646,0.00029119718,0.011139558,0.00020328995,0.60627866,0.0000014959206,0.0018148732,0.15075684],"study_design_scores_gemma":[0.39898053,0.021283878,0.387436,0.0008903982,0.0024414018,0.000041153904,0.0027407457,0.030470768,0.15284063,0.000026476087,0.0018372088,0.0010107873],"about_ca_topic_score_codex":0.0002537337,"about_ca_topic_score_gemma":0.00001614028,"teacher_disagreement_score":0.453438,"about_ca_system_score_codex":0.0010402659,"about_ca_system_score_gemma":0.0005006518,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4385968528","doi":"10.1007/s00280-023-04575-y","title":"Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations","year":2023,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"College of Physicians and Surgeons of Ontario; Hospital for Sick Children","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Internal medicine; Fallopian tube; Cancer; Chemotherapy; Carboplatin; Monoclonal antibody; Pharmacology; Gynecology; Antibody; Cisplatin; Immunology","score_opus":0.20744257282584447,"score_gpt":0.48335285051586097,"score_spread":0.2759102776900165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385968528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015455195,0.98123527,0.000002039174,0.01273167,0.002417879,0.0027999938,0.00028015464,0.000108490254,0.0002699749],"genre_scores_gemma":[0.00019388417,0.9769572,0.000054860044,0.014906542,0.0020739525,0.0052480283,0.00012487182,0.00014396627,0.00029666466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972378,0.00028230235,0.0007159093,0.0009882216,0.00020508538,0.0005706569],"domain_scores_gemma":[0.998649,0.00051240594,0.00027305537,0.00022663357,0.00007241187,0.00026651908],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021427576,0.000722027,0.0022309122,0.00036726164,0.00014042853,0.00003567795,0.00011700872,0.0005743435,0.0074309567],"category_scores_gemma":[0.000008920116,0.00054071005,0.0003399921,0.0004935655,0.00018869103,0.00005408364,0.000036537655,0.0007772098,0.000038120255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006255909,0.0011258402,0.0000710606,0.0017043863,0.0026169769,0.00028256013,0.0003456916,0.000006055586,0.00025443383,0.00015237181,0.06179673,0.9310183],"study_design_scores_gemma":[0.010939265,0.00051041413,0.00013701343,0.003955697,0.00042314484,0.00005322131,0.00000952293,0.000020478352,0.000801687,0.00008278603,0.9825881,0.00047867143],"about_ca_topic_score_codex":0.00033209397,"about_ca_topic_score_gemma":0.000046020232,"teacher_disagreement_score":0.9305396,"about_ca_system_score_codex":0.0007170043,"about_ca_system_score_gemma":0.0010433947,"threshold_uncertainty_score":0.9997044},"labels":[],"label_agreement":null},{"id":"W4386727291","doi":"10.1007/s00280-023-04583-y","title":"Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective","year":2023,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ginseng Biological Effects and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Prostate cancer; Pharmacology; Pharmacokinetics; Pharmacodynamics; Drug; Cancer; Chemistry; Medicine; Internal medicine","score_opus":0.03110023869443257,"score_gpt":0.41201521549504094,"score_spread":0.3809149768006084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386727291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0907088,0.9073138,0.000006086227,0.00042583913,0.0002163325,0.0009890656,0.0002897345,0.000015831898,0.000034477245],"genre_scores_gemma":[0.0130142085,0.9852808,0.00003172951,0.00038695242,0.00026399683,0.0007155054,0.000063541265,0.00004744782,0.00019582189],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863535,0.0001474562,0.00034074215,0.0005819468,0.000050297902,0.0002441922],"domain_scores_gemma":[0.9993814,0.000110778084,0.0002579902,0.00009368127,0.00006265369,0.00009348681],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015658866,0.00033880948,0.0007285549,0.00011153105,0.00005784359,0.000014699927,0.0001107418,0.00018965152,0.000033298627],"category_scores_gemma":[0.000007859405,0.0002818831,0.000080967766,0.00019395948,0.0003085728,0.00000553504,0.00010326585,0.00031262968,4.9139686e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031032853,0.00014377071,0.00021790202,0.007713517,0.00079181953,0.000007739948,0.00054309715,0.000033380013,0.08902423,0.00008785382,0.0017574691,0.8993689],"study_design_scores_gemma":[0.0020322518,0.00019217479,0.000073377254,0.0010420891,0.00055427756,0.000029843077,0.00015592534,0.00039726956,0.011177814,0.000120148325,0.98371065,0.00051420275],"about_ca_topic_score_codex":0.00024336374,"about_ca_topic_score_gemma":0.000074023155,"teacher_disagreement_score":0.98195314,"about_ca_system_score_codex":0.000055080396,"about_ca_system_score_gemma":0.00011658154,"threshold_uncertainty_score":0.99996334},"labels":[],"label_agreement":null},{"id":"W4391033120","doi":"10.1007/s00280-023-04636-2","title":"Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity","year":2024,"lang":"en","type":"erratum","venue":"Cancer Chemotherapy and Pharmacology","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Pantoprazole; Mechanism (biology); Pharmacology; Autophagy; Drug; Drug resistance; Chemotherapy; Sensitivity (control systems); Medicine; Chemistry; Biology; Internal medicine; Biochemistry; Genetics","score_opus":0.00926900909796378,"score_gpt":0.30537013380570016,"score_spread":0.29610112470773636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94060713,0.012418826,0.00038015994,0.025514413,0.015143496,0.0028423788,0.0020014204,0.00014192975,0.00095024146],"genre_scores_gemma":[0.72043407,0.013037989,0.00018895205,0.07246628,0.0017450722,0.0003811128,0.00034749,0.00022043615,0.19117858],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978154,0.0001359335,0.00052899675,0.00081028783,0.0003263164,0.00038307314],"domain_scores_gemma":[0.99852365,0.00012015395,0.00026718617,0.0002968462,0.00030433323,0.00048784915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031620704,0.00049953425,0.0010781225,0.00037707848,0.00008235969,0.000017163686,0.000098168755,0.00036871654,0.00087397447],"category_scores_gemma":[0.000022432621,0.0004965589,0.00012858519,0.0006722847,0.00013015946,0.000050346447,0.00005683095,0.00050342066,0.0000027532385],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027539167,0.00010287185,0.000019250629,0.00054215686,0.00042099858,0.000010088698,0.003687658,0.0000021024218,0.407484,0.000019340376,0.57788736,0.0070702913],"study_design_scores_gemma":[0.0024587822,0.00035194578,0.000559545,0.0006529364,0.00032988712,0.000013852597,0.000090314694,0.0003487235,0.7124607,0.0001513024,0.28224066,0.00034133205],"about_ca_topic_score_codex":0.0011496329,"about_ca_topic_score_gemma":0.0003814124,"teacher_disagreement_score":0.3049767,"about_ca_system_score_codex":0.00023185485,"about_ca_system_score_gemma":0.00052992936,"threshold_uncertainty_score":0.9997486},"labels":[],"label_agreement":null},{"id":"W4400076077","doi":"10.1007/s00280-024-04690-4","title":"Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Fulvestrant; Metastatic breast cancer; Medicine; Estrogen; Oncology; Internal medicine; Estrogen receptor; Cancer; Cancer research; Endocrinology; Breast cancer","score_opus":0.006909258984809279,"score_gpt":0.27614848791007296,"score_spread":0.2692392289252637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400076077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972882,0.0004901038,0.00014087428,0.00031764965,0.00028027053,0.0009833329,0.0004896585,0.0000066562184,0.0000032405637],"genre_scores_gemma":[0.99816716,0.0009291602,0.00011618067,0.00033390732,0.000046779624,0.00029243683,0.000058779806,0.000037586404,0.000018022527],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987349,0.00018935693,0.0002886,0.0004066011,0.00017014891,0.00021039517],"domain_scores_gemma":[0.9993332,0.00012334248,0.00023216328,0.00009683948,0.00017002561,0.000044454446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101744256,0.00024067852,0.00033910573,0.00010230627,0.000034708744,0.000009487161,0.00011553872,0.00006425764,0.00006945697],"category_scores_gemma":[0.000015929347,0.00014851642,0.000034154444,0.00046686872,0.00029388495,0.00003052517,0.000020130792,0.0001620975,1.5007512e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028821975,0.0005375866,0.0698396,0.00071651087,0.00035661526,0.0000181509,0.0004836403,0.00018728533,0.89597476,0.000027909336,0.000038209975,0.002997777],"study_design_scores_gemma":[0.008102057,0.003315906,0.116254546,0.0009873068,0.00007692868,0.00000565572,0.000029405894,0.00014086299,0.8708446,0.000010455799,0.00004081663,0.00019143845],"about_ca_topic_score_codex":0.00015415807,"about_ca_topic_score_gemma":0.00018595904,"teacher_disagreement_score":0.04641495,"about_ca_system_score_codex":0.00011196643,"about_ca_system_score_gemma":0.00032750744,"threshold_uncertainty_score":0.6056324},"labels":[],"label_agreement":null},{"id":"W4417035889","doi":"10.1007/s00280-025-04839-9","title":"Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity","year":2025,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Ontario Institute for Cancer Research","keywords":"DPYD; Dihydropyrimidine dehydrogenase; Genetic variants; Clinical significance; Toxicity; Pharmacogenetics; Cancer; Malignancy","score_opus":0.03134569304228882,"score_gpt":0.3589229152347624,"score_spread":0.32757722219247354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417035889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98866165,0.008974312,0.0000860994,0.0006109704,0.00062019966,0.00084664574,0.00008752782,0.0000229588,0.000089657246],"genre_scores_gemma":[0.98985845,0.007547829,0.00030939735,0.0017446252,0.00018545942,0.00011015876,0.000014268452,0.000028994915,0.00020080167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982596,0.00009806761,0.00056995696,0.0005379775,0.00017179776,0.0003625693],"domain_scores_gemma":[0.99924105,0.000076466145,0.00021845795,0.0001575927,0.000190957,0.000115496216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012511374,0.00028535243,0.00077075855,0.00014268467,0.000115477815,0.000009965166,0.00010024727,0.00014624078,0.00035617416],"category_scores_gemma":[0.0000140511975,0.00023067741,0.000092987626,0.0003943365,0.0002497932,0.00009140249,0.000064611755,0.00024803774,4.4538544e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01137298,0.0008193186,0.64140785,0.00058881624,0.0018254557,0.00014509512,0.00066249364,0.0017939433,0.30771583,0.0000043806467,0.0006418878,0.033021934],"study_design_scores_gemma":[0.04165739,0.0017586746,0.69619656,0.0010177499,0.0018326099,0.000034441808,0.00015363337,0.011712332,0.2432069,0.000121058474,0.0016304088,0.0006782538],"about_ca_topic_score_codex":0.00069855974,"about_ca_topic_score_gemma":0.0002984779,"teacher_disagreement_score":0.064508945,"about_ca_system_score_codex":0.0005601999,"about_ca_system_score_gemma":0.00056690717,"threshold_uncertainty_score":0.9406752},"labels":[],"label_agreement":null}]}